Novel heterocyclic compounds
Patent Information
- Application Number
- MYPI2025004290
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-01-20
- Filing Date
- 2024-01-02
- Publication Date
- 2024-07-20
AI Technical Summary
Current 15-PGDH inhibitors lack a novel structure with excellent inhibitory activity, limiting their effectiveness in treating various 15-PGDH-related diseases.
Development of a heterocyclic compound with a specific two-ring fused structure, represented by Formula 1, which includes various substituents and functional groups, acting as a 15-PGDH inhibitor.
The novel heterocyclic compound exhibits excellent 15-PGDH inhibitory activity, providing a potential solution for preventing or treating 15-PGDH-related diseases.
Abstract
Description
Novel heterocyclic compounds This application claims priority to Korean Patent Application No. 10-2023-0009009, filed January 20, 2023, the entire disclosure of which is incorporated herein by reference. The present invention relates to novel heterocyclic compounds as 15-PGDH inhibitors. Prostaglandins are physiologically active substances synthesized within the body. They are widely distributed in organs and body fluids, exerting physiological effects in extremely small amounts. Prostaglandins are 20-carbon fatty acid derivatives based on the skeleton of prostanic acid, a five-membered ring at the center of the molecule. They are classified into groups A through J based on the number of double bonds in the five-membered ring, and into series 1 through 3 based on the number of double bonds in the two side chains. They are widely present in animal tissues and are known to be rapidly metabolized after being synthesized from polyunsaturated fatty acids. Depending on their form, prostaglandins can stimulate smooth muscle contraction. In some animals, they can lower or increase blood pressure, and in some animals, they can also decrease or increase blood coagulation. They are also known to promote ion transport across membranes, stimulate inflammation, and suppress cardiovascular disease and viral infections. 15-PGDH (15-hydroxyprostaglandin dehydrogenase) uses active prostaglandins such as PGD2, PGE1, PGE2, PGF2α, and PGI2 as substrates, and is involved in the inactivation of these, for example, the conversion of PGE2 to 15-keto-PGE2, which catalyzes the oxidation reaction of the hydroxyl group at position 15 of PGE2. Receptors corresponding to 15-PGDH substrates are widely distributed throughout the body, with different expression sites, and are known to be involved in various physiological functions within the body. For example, 15-PGDH substrates include those with antifibrotic, anti-inflammatory, blood circulation-enhancing, proliferation-promoting, stem cell growth-promoting, smooth muscle contraction / relaxation, immunosuppressive, and bone metabolism effects.Therefore, 15-PGDH inhibitors are indicated for the treatment of fibrosis [pulmonary fibrosis (e.g., idiopathic pulmonary fibrosis), liver fibrosis, renal fibrosis, myocardial fibrosis, scleroderma, myelofibrosis, etc.], inflammatory diseases [chronic obstructive pulmonary disease (COPD), acute lung injury, sepsis, exacerbation of asthma and lung disease, inflammatory bowel disease (e.g., ulcerative colitis, Crohn's disease), peptic ulcer (e.g., NSAID-induced ulcer), autoinflammatory diseases (e.g., Behcet's disease), vasculitic syndrome, acute liver injury, acute kidney injury, nonalcoholic fatty liver disease (NASH), atopic dermatitis, psoriasis, interstitial cystitis, prostatitis syndrome (e.g., chronic prostatitis / chronic pelvic pain syndrome), etc.], circulatory diseases [pulmonary hypertension, angina pectoris, myocardial infarction, heart failure, ischemic heart disease]. [cardiac damage, chronic kidney disease, renal failure, stroke, peripheral circulatory disorder, etc.], wounds [acute mucosal injury of acute mucosal injury diseases including diabetic ulcers, lacerations, bedsores, Stevens-Johnson syndrome, anticancer chemotherapy, immunotherapy or radiation, mucosal injury (mucositis or stomatitis) related to graft-versus-host disease, etc.], autoimmune diseases [multiple sclerosis, rheumatoid arthritis, etc.], graft-versus-host disease (GVHD), hair loss, osteoporosis, ear diseases [hearing loss, tinnitus, vertigo, balance disorder, etc.], eye diseases [glaucoma, dry eye, etc.], diabetes, underactive bladder, neutropenia, promotion of engraftment in stem cell and bone marrow transplantation or organ transplantation, neurogenesis and nerve cell death [psychiatric disorders, nerve injury, neurotoxic disorder, neuropathic pain, neurodegeneration It can be effective in the treatment or prevention of diseases such as], muscle regeneration [muscular dystrophy, muscle damage], and cervical ripening. The problem to be solved by the present invention is to provide a novel 15-PGDH inhibitory compound having a structure that exhibits excellent 15-PGDH inhibitory activity. In addition, the problem to be solved by the present invention is to provide a pharmaceutical composition for preventing or treating a 15-PGDH-related disease, which comprises a 15-PGDH inhibitory compound having the novel structure. In addition, the problem of the present invention is to provide a method for preventing or treating a 15-PGDH-related disease, which comprises administering a therapeutically effective amount of a 15-PGDH inhibitory compound having the novel structure to a subject in need thereof. In addition, the problem to be solved by the present invention is to provide a use of the novel 15-PGDH inhibitory compound as an effective ingredient in the manufacture of a medicine for preventing or treating a 15-PGDH-related disease. The problems to be solved by the present invention are not limited to the problems mentioned above, and other technical problems not mentioned can be clearly understood by a person having ordinary skill in the technical field to which the present invention belongs from the description below. In order to solve the above problem, according to one aspect of the present invention, a heterocyclic compound represented by the following chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof is provided. <Chemical Formula 1> In the above formula, A fused ring is formed by the fusion of ring A and ring B, X1, Y1, Y2, Y3 and Y4 are independently CH or N, X2 is CH, N or NH, Z1 and Z2 are C or N, At least one of X1, X2, Y1, Y2, Y3, Y4, Z1 and Z2 is N or NH, R a is H, R a-1 C replaced by 1-6 Straight or branched chain alkyl, or C(O)R a-1 And, The above R a-1 is C 1-6 Straight or branched chain alkyl, C 3-8 Cycloalkyl, hydroxy, R s , or R u and the above R a-1 is a singular or plural independent R a-2 Is replaced or not replaced, The above R a-2 is C 1-6 Straight or branched chain alkyl, halogen, C 1-4 It is haloalkyl, The above X1 is R b Is substituted or not substituted with, and the above R b is amino, or C(O)R s And, The above Y1 is R 1 Is substituted or not substituted with, and the above R 1 Silver R f And, The above Y2 is R 2 Is replaced or not replaced, The above R 2 is C 1-6 Straight or branched chain alkyl, halogen, C 5-12 Aryl of one or two rings, R u , or R f and the above R 2 is a singular or plural independent R 2-1 Is replaced or not replaced, The above R 2-1 is C 1-4 alkoxy, halogen or hydroxy, The above Y3 is R 3 Is replaced or not replaced, The above R 3 is C 5-7 Aryl, R u , or R f and the above R 3 is a singular or plural independent R 3-1 Is replaced or not replaced, The above R 3-1 Silver C1-4 alkoxy, halogen, hydroxy or cyano, The above Y4 is R 4 or -LR 4 Is replaced or not replaced, The above L is -NH(CH2) m -, -NHC(O)-, -NHSO2- or -S-, and m is an integer from 0 to 3, The above R 4 is C 5-12 Aryl of one or two rings, R u , R s , or R f and the above R 4 is replaced or not replaced by a singular or plural independent Q, The above Q is C 1-6 Straight or branched chain alkyl, halogen, hydroxy, C 1-4 Haloalkyl, C 1-4 Alkoxy, nitro, cyano, amino, carboxylate, carboxylic acid, CHR 5 , CH2R 5 , NR 5 R 6 , C(O)R 5 , C(O)OR 5 , C(O)NR 5 R 6 , NHC(O)(CH2) p R 5 , NHC(O)CH2OR 5 , NHC(O)CH2NR 5 R 6 , NHCH2CH2R 5 , NR 5 C(O)R 6 , R u , or R s , and the above p is an integer from 0 to 3, and the above Q is a single or multiple independent R 7 Is not replaced or substituted with, The above R 5 and R 6 is independently H, C 1-6 Straight or branched chain alkyl, C3-8 Cycloalkyl, C 1-4 Alkoxy, amino, sulfonyl, C 5-7 Aryl, arylalkyl, R u , or R s And, The above R 7 Silver C 1-6 Straight or branched chain alkyl, C 3-8 Cycloalkyl, halogen, C 1-4 Haloalkyl, hydroxy, C 1-4 Alkoxy, hydroxyalkyl, cyano, amino, alkylamino, C 1-6 Alkyl carboxylate, nitro, R u , R u C replaced by 1-4 Alkyl, or R s and the above Q and R 7 The bond between the two is either a single bond or a double bond, The above R s is a saturated heterocycloalkyl ring of 1 or 2 rings of 4 to 10 members containing 1 to 3 heteroatoms selected from N, O and S, The above R u is a 5- to 7-membered unsaturated heterocycloalkyl ring containing 1 to 4 heteroatoms selected from N, O and S, The above R f is a fused ring of two rings in which a 5- to 7-membered saturated or unsaturated heterocycloalkyl ring containing 1 to 2 heteroatoms selected from N, O and S and an aryl ring or a 5- to 7-membered heteroaryl ring containing 1 to 2 N are fused, The above R s , R u and R f is independently substituted or unsubstituted with one or two oxo(O) or thioxo(S). According to another aspect of the present invention, a pharmaceutical composition for preventing or treating a 15-PGDH-related disease is provided, comprising a heterocyclic compound represented by the above chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. According to another aspect of the present invention, a method for preventing or treating a 15-PGDH-related disease is provided, comprising administering to a subject in need thereof a therapeutically effective amount of a heterocyclic compound represented by the above chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. According to another aspect of the present invention, there is provided a use of a heterocyclic compound represented by the above chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient in the manufacture of a medicament for preventing or treating a 15-PGDH-related disease. According to another aspect of the present invention, a pharmaceutical composition is provided comprising a heterocyclic compound represented by the above chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. It was confirmed that the novel heterocyclic compound of the present invention exhibits excellent 15-PGDH inhibitory activity, and thus it was found that it can be used for the prevention or treatment of 15-PGDH-related diseases. Therefore, the novel heterocyclic compound of the present invention can be usefully used in the fields of medicine and pharmacy for the prevention or treatment of 15-PGDH-related diseases. The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the composition of the invention described in the description or claims of the present invention. The present invention provides a heterocyclic compound represented by the following chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. <Chemical Formula 1> In the above formula, A fused ring is formed by the fusion of ring A and ring B, X1, Y1, Y2, Y3 and Y4 are independently CH or N, X2 is CH, N or NH, Z1 and Z2 are C or N, At least one of X1, X2, Y1, Y2, Y3, Y4, Z1 and Z2 is N or NH, R a is H, R a-1 C replaced by 1-6 Straight or branched chain alkyl, or C(O)R a-1 And, The above R a-1 is C 1-6 Straight or branched chain alkyl, C 3-8 Cycloalkyl, hydroxy, R s , or R u and the above R a-1 is a singular or plural independent R a-2 Is replaced or not replaced, The above R a-2 is C 1-6 Straight or branched chain alkyl, halogen, C 1-4 It is haloalkyl, The above X1 is R b Is substituted or not substituted with, and the above R b is amino, or C(O)R s And, The above Y1 is R 1 Is substituted or not substituted with, and the above R 1 Silver R f And, The above Y2 is R 2 Is replaced or not replaced, The above R 2 is C 1-6 Straight or branched chain alkyl, halogen, C 5-12 Aryl of one or two rings, Ru , or R f and the above R 2 is a singular or plural independent R 2-1 Is replaced or not replaced, The above R 2-1 is C 1-4 alkoxy, halogen or hydroxy, The above Y3 is R 3 Is replaced or not replaced, The above R 3 is C 5-7 Aryl, R u , or R f and the above R 3 is a singular or plural independent R 3-1 Is replaced or not replaced, The above R 3-1 Silver C 1-4 alkoxy, halogen, hydroxy or cyano, The above Y4 is R 4 or -LR 4 Is replaced or not replaced, The above L is -NH(CH2) m -, -NHC(O)-, -NHSO2- or -S-, and m is an integer from 0 to 3, The above R 4 is C 5-12 Aryl of one or two rings, R u , R s , or R f and the above R 4 is replaced or not replaced by a singular or plural independent Q, The above Q is C 1-6 Straight or branched chain alkyl, halogen, hydroxy, C 1-4 Haloalkyl, C 1-4 Alkoxy, nitro, cyano, amino, carboxylate, carboxylic acid, CHR 5 , CH2R 5 , NR 5 R 6 , C(O)R 5 , C(O)OR 5, C(O)NR 5 R 6 , NHC(O)(CH2) p R 5 , NHC(O)CH2OR 5 , NHC(O)CH2NR 5 R 6 , NHCH2CH2R 5 , NR 5 C(O)R 6 , R u , or R s , and the above p is an integer from 0 to 3, and the above Q is a single or multiple independent R 7 Is not replaced or substituted with, The above R 5 and R 6 is independently H, C 1-6 Straight or branched chain alkyl, C 3-8 Cycloalkyl, C 1-4 Alkoxy, amino, sulfonyl, C 5-7 Aryl, arylalkyl, R u , or R s And, The above R 7 Silver C 1-6 Straight or branched chain alkyl, C 3-8 Cycloalkyl, halogen, C 1-4 Haloalkyl, hydroxy, C 1-4 Alkoxy, hydroxyalkyl, cyano, amino, alkylamino, C 1-6 Alkyl carboxylate, nitro, R u , R u C replaced by 1-4 Alkyl, or R s and the above Q and R 7 The bond between the two is either a single bond or a double bond, The above R s is a saturated heterocycloalkyl ring of 1 or 2 rings of 4 to 10 members containing 1 to 3 heteroatoms selected from N, O and S, The above R uis a 5- to 7-membered unsaturated heterocycloalkyl ring containing 1 to 4 heteroatoms selected from N, O and S, The above R f is a fused ring of two rings in which a 5- to 7-membered saturated or unsaturated heterocycloalkyl ring containing 1 to 2 heteroatoms selected from N, O and S and an aryl ring or a 5- to 7-membered heteroaryl ring containing 1 to 2 N are fused, The above R s , R u and R f is independently substituted or unsubstituted with one or two oxo(O) or thioxo(S). In one embodiment, the A ring can be pyrrole, pyrazole, imidazole, or triazole, and the B ring can be benzene, pyridine, pyrimidine, or triazine. In one embodiment, the fused ring of the two rings in which the A ring and the B ring are fused may be indole, indazole, pyrrolopyridine, pyrrolopyrimidine, pyrrolotriazine, pyrazolopyridine, imidazopyridine, or triazolopyridine. More specifically, the fused ring of the two rings in which the A ring and the B ring are fused may be any one selected from the group consisting of the following chemical formulas. , , , , , , , , , , and . In one embodiment, the R ais H, profile, C(O)R a-1 and the above R a-1 is methyl, butyl, cyclohexyl, hydroxy, piperidinyl, azaspiroheptanyl, azaspiroctanyl, azaspirononanyl, azabicycloheptanyl, azabicyclooctanyl, azabicyclononanyl or tetrahydropyridinyl, and R a-2 may be methyl, ethyl, propyl, isopropyl, fluoro, or trifluoromethyl. In one embodiment, the R b may be amino or piperidinyl-carbonyl. In one embodiment, the R 1 It may be benzodioxolyl. In one embodiment, the R 2 is methyl, fluoro, phenyl, naphthyl (naphthalenyl), furanyl, pyridinyl, isoindolinone, benzodioxolyl, dihydrobenzodioxinyl, benzofuranyl or indazolyl, and R 2-1 may be methoxy, chloro, fluoro or hydroxy. In one embodiment, the R 3 is phenyl, pyridinyl or benzodioxolyl, and R 3-1 can be methoxy, chloro, hydroxy or cyano. In one embodiment, L can be -NH-, -NHCH2-, -NH(CH2)2-, -NHC(O)-, -NHSO2-, or -S-. In one embodiment, the R 4 It can be phenyl, naphthyl(naphthalenyl), furanyl, pyrazolyl, dihydropyridinyl, pyridinyl, pyrimidinyl, pyridinone, pyrimidinone, isoxazolyl, piperidinyl, benzodioxolyl, isoindolinone, dihydroisoquinolinone, benzofuranyl, benzothiophenyl, indolyl, indazolyl, quinolinyl, quinolinone, isoquinolinone, dihydropyrrolopyridinone, benzoisoxazolone, dihydronaphthyridinone, benzoxazolyl, benzoisoxazolyl, triazolopyridinone, phthalazinone, quinazolinone, or pyridopyrimidinone. In one embodiment, Q is methyl, propyl, isopropyl, fluoro, chloro, bromo, hydroxy, trifluoromethyl, methoxy, nitro, cyano, amino, carboxylate, carboxylic acid, CHR 5 , CH2R 5 , NR 5 R 6 , C(O)R 5 , C(O)OR 5 , C(O)NR 5 R 6 , NHC(O)R 5 , NHC(O)CH2R 5 , NHC(O)(CH2)2R 5 , NHC(O)CH2OR 5 , NHC(O)CH2NR 5 R 6 , NHCH2CH2R 5 , NR 5 C(O)R 6 , tetrazolyl, oxadiazolyl, oxadiazolone, furyl, thienyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, oxo-thiadiazolyl, thioxo-oxadiazolyl, pyridinyl, pyrimidinyl, azetidinyl, oxazolidinone, piperidinyl, piperazinyl, morpholino, azaspiroheptanyl, azaspiroctanyl, azaspirononanyl, azabicycloheptanyl, or azabicyclooctanyl, wherein R 5 is H, methyl, ethyl, butyl, cyclopropyl, cyclohexane, methoxy, amino, phenyl, benzyl, imidazolyl, oxadiazolyl, oxadiazolone, pyridinyl, pyrimidinyl, azetidinyl, piperidinyl, piperidinone, piperazinyl, morpholino, thiazolidinedione, piperazinone, piperazine-dione, azaspiroheptanyl, or azaspirononanyl, and wherein R 6 may be H, methyl, ethyl, propyl, isopropyl, sulfonyl, pyrazolyl, pyridinyl, pyridazinyl, azetidinyl or piperidinyl. In one embodiment, the R 7It can be methyl, propyl, isopropyl, cyclopropyl, fluoro, chloro, difluoromethyl, trifluoromethyl, hydroxy, methoxy, hydroxymethyl, cyano, amino, dimethylamino, methylcarboxylate, tert-butylcarboxylate, nitro, isoxazolyl, thiazolyl, pyridinyl, or oxadiazolylmethyl. In defining the compound of formula 1 throughout this specification, the following definitions apply unless otherwise stated. The term "alkyl" refers to a straight-chain or branched-chain saturated hydrocarbon, C 1-10 Alkyl is preferred. For example, the alkyl includes, but is not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, n-pentyl, iso-pentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl. The term "cycloalkyl" refers to a partially or fully saturated single or fused ring hydrocarbon, C 3-10 Cycloalkyl is preferred. Examples include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexynyl. The term "hydroxy" or "hydroxyl" is defined as -OH, and the term "alkoxy", unless otherwise defined, means alkyloxy, a radical in which the hydrogen atoms of the hydroxyl group are replaced by 1 to 10 alkyl groups. The term "halogen" or "halo" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I). The terms “haloalkyl” and “haloalkoxy” mean alkyl or alkoxy substituted with one or more halogen atoms. The term "heteroatom" means N, O or S. The term "aryl" means an aromatic hydrocarbon, including polycyclic aromatic ring systems in which a carbocyclic aromatic ring or a heteroaryl ring is fused with one or more other rings. Preferably C 5-12 Aryl, more preferably C 5-10 Aryl. Examples of aryl include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, etc. Also, there are groups in which a heteroaryl ring is fused to a cycloalkyl or non-aromatic heterocyclic ring, such as indanyl or tetrahydrobenzopyranyl. The term "heteroaryl" or "aromatic heterocycle" refers to a heterocycle comprising one or more heteroatoms selected from N, O and S as a reducing agent, and benzo or C 3-8 It refers to a 3 to 12 membered, more preferably 5 to 10 membered aromatic hydrocarbon group forming a single or fused ring that can be fused with a cycloalkyl. For example, the heteroaryl includes, but is not limited to, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, triazinyl, oxadiazolyl, isoxadiazolyl, tetrazolyl, indolyl, indazolyl, isoxazolyl, oxazolyl, thiazolyl, isothiazolyl, furanyl, benzofuranyl, thiophenyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, quinolinyl, isoquinolinyl, and the like. Specific examples of heterocyclic compounds according to the present invention are as follows: [1] 7-phenylpyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [2] (7-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [3] Methyl 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoate, [4] (7-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [5] (7-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [6] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [7] (7-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [8] (7-(2-chloropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [9] (7-(5-aminopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0010] 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoic acid,
[0011] Methyl 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoate,
[0012] (7-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0013] (7-(4-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0014] (7-(4-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0015] 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile,
[0016] (7-(6-nitropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0017] (7-(6-aminopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0018] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinonitrile,
[0019] (7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0020] (7-(4-methoxy-3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0021] (7-(3-chloro-4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0022] 2-fluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile,
[0023] 2-(dimethylamino)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile,
[0024] (7-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0025] (7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0026] (7-(3-(morpholine-4-carbonyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0027] N-methyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0028] N-isopropyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0029] Azetidin-1-yl(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone,
[0030] N-(2-methoxyethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0031] N-(2-(dimethylamino)ethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0032] N-(cyclopropylmethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0033] N-(1-methylpiperidin-4-yl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0034] Piperazin-1-yl(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone,
[0035] tert-butyl 4-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoyl)piperazine-1-carboxylate,
[0036] N-(2-cyanoethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0037] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)benzamide,
[0038] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)benzamide,
[0039] (7-(5-(morpholine-4-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0040] N-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide,
[0041] Azetidin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone,
[0042] (3-hydroxyazetidin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone,
[0043] (7-(5-(2-azaspiro[3.3]heptane-2-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0044] (3,3-difluoroazetidin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone,
[0045] N-(2-methoxyethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide,
[0046] N-(cyclopropylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide,
[0047] N-(1-methylpiperidin-4-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide,
[0048] Piperazin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone,
[0049] (4-methylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone,
[0050] (4-isopropylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone,
[0051] N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide,
[0052] N-(cyanomethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide,
[0053] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)nicotinamide,
[0054] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)nicotinamide,
[0055] N-(isoxazol-3-ylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide,
[0056] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridazin-4-yl)nicotinamide,
[0057] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(thiazol-5-ylmethyl)nicotinamide,
[0058] N-methyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0059] N,N-dimethyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0060] N-isopropyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0061] azetidin-1-yl(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone,
[0062] N-(2-methoxyethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0063] N-(2-(dimethylamino)ethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0064] N-(cyclopropylmethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0065] N-(1-methylpiperidin-4-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0066] Piperazin-1-yl(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone,
[0067] (4-methylpiperazin-1-yl)(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone,
[0068] (4-isopropylpiperazin-1-yl)(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone,
[0069] N-(2-cyanoethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0070] N-(cyanomethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0071] 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)benzamide,
[0072] 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)benzamide,
[0073] N-(isoxazol-3-ylmethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide,
[0074] (7-(6-(morpholine-4-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0075] N-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide,
[0076] N-isopropyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide,
[0077] Azetidin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone,
[0078] N-(2-methoxyethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide,
[0079] N-(2-(dimethylamino)ethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide,
[0080] N-(cyclopropylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide,
[0081] N-(1-methylpiperidin-4-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide,
[0082] Piperazin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone,
[0083] (4-methylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone,
[0084] (4-isopropylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone,
[0085] N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide,
[0086] N-(cyanomethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide,
[0087] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)picolinamide,
[0088] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)picolinamide,
[0089] N-(isoxazol-3-ylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide,
[0090] N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)furan-2-carboxamide,
[0091] 3-methoxy-N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)propanamide,
[0092] 1-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)urea,
[0093] 1-Methyl-N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)piperidine-4-carboxamide,
[0094] N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclopropanecarboxamide,
[0095] N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide,
[0096] N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclohexanecarboxamide,
[0097] N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)acetamide,
[0098] 3-methoxy-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)propanamide,
[0099] 1-methyl-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)piperidine-4-carboxamide,
[0100] N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclopropanecarboxamide,
[0101] N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide,
[0102] N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclohexanecarboxamide,
[0103] 3-methoxy-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)propanamide,
[0104] 2-(Dimethylamino)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)acetamide,
[0105] 2-oxo-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)piperidine-4-carboxamide,
[0106] N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide,
[0107] (7-(6-((3-methoxypropyl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0108] (7-(6-morpholinopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0109] (7-(6-(isopropylamino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0110] Piperidin-1-yl(7-(6-(piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone,
[0111] (7-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0112] N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanesulfonamide,
[0113] (7-(3-(1H-tetrazol-5-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0114] (7-(4-(1H-tetrazol-5-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0115] 3-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one,
[0116] 3-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one,
[0117] 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-1,2,4-oxadiazol-5(4H)-one,
[0118] (7-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0119] (Z)-5-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzylidene)thiazolidine-2,4-dione,
[0120] tert-Butyl 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate,
[0121] (7-(benzo[d][1,3]dioxol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0122] (7-(benzofuran-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0123] (7-(benzofuran-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0124] (7-(benzo[b]thiophen-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0125] (7-(1H-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0126] (7-(1H-Indol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0127] (7-(benzofuran-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0128] (7-(naphthalen-1-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0129] (7-(naphthalen-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0130] Piperidin-1-yl(7-(quinolin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone,
[0131] 7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one,
[0132] 2-Methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one,
[0133] 2-Isopropyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one,
[0134] 7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one,
[0135] 2-methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one,
[0136] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one,
[0137] 2-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one,
[0138] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one,
[0139] 2-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one,
[0140] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0141] 2-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0142] 2-Isopropyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0143] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0144] 2-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0145] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinolin-2(1H)-one,
[0146] 4-((3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)amino)benzonitrile,
[0147] 3-((3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)amino)pyridin-2(1H)-one,
[0148] Piperidin-1-yl(7-((pyrimidin-2-ylmethyl)amino)pyrazolo[1,5-a]pyridin-3-yl)methanone,
[0149] Piperidin-1-yl(7-((2-(pyridin-4-yl)ethyl)amino)pyrazolo[1,5-a]pyridin-3-yl)methanone,
[0150] (7-((1-methylpiperidin-4-yl)amino)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0151] 1-(7-(quinolin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)pentan-1-one,
[0152] 4-(3-acetylpyrazolo[1,5-a]pyridin-7-yl)benzonitrile,
[0153] 4-(3-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile,
[0154] 7-(3-(4-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one,
[0155] 6-(3-(4-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0156] 4-(3-(4-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile,
[0157] (4-fluoropiperidin-1-yl)(7-(4-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)methanone,
[0158] Cyclohexyl(7-phenylpyrazolo[1,5-a]pyridin-3-yl)methanone,
[0159] 7-(2-amino-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one,
[0160] 7-(2-amino-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one,
[0161] (7-(3-chlorophenyl)-1H-indazol-3-yl)(piperidin-1-yl)methanone,
[0162] (8-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0163] (8-(4-nitrophenyl)imidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0164] (8-(4-aminophenyl)imidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0165] (8-(3-chlorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0166] (8-(2-chloropyridin-4-yl)-6-methylimidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0167] (8-(3-chlorophenyl)-6-fluoroimidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0168] (7-(4-methoxyphenyl)-[1,2,3]triazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0169] (7-(3-chlorophenyl)-1H-indol-3-yl)(piperidin-1-yl)methanone,
[0170] (6-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0171] (6-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0172] (6-(Benzo[d][1,3]dioxol-5-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0173] (5-(Benzo[d][1,3]dioxol-5-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0174] (4-(Benzo[d][1,3]dioxol-5-yl)-1H-pyrrolo[3,2-c]pyridin-2-yl)(piperidin-1-yl)methanone,
[0175] (4-(Benzo[d][1,3]dioxol-5-yl)-1H-pyrrolo[2,3-c]pyridin-2-yl)(piperidin-1-yl)methanone,
[0176] (4-(benzo[d][1,3]dioxol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)(piperidin-1-yl)methanone,
[0177] (4-(benzo[d][1,3]dioxol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone,
[0178] (5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0179] (5-(4-methoxyphenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0180] (5-(4-chlorophenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0181] (5-(3,4-dimethoxyphenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0182] (5-(4-fluorophenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0183] (5-(furan-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0184] Piperidin-1-yl(5-(pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)methanone,
[0185] (5-(3-chlorophenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0186] (5-(3-chloro-4-hydroxyphenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0187] (2-(Benzo[d][1,3]dioxol-5-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl)(piperidin-1-yl)methanone,
[0188] (5-(benzofuran-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0189] (5-(naphthalen-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0190] (5-(1H-indazol-6-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone,
[0191] 2-(2-(piperidine-1-carbonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl)isoindolin-1-one,
[0192] (3-fluoroacetidine-1-yl)(5-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone,
[0193] N-(1-methyl-1H-pyrazol-3-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide,
[0194] (7-((3-methoxyphenyl)thio)(pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0195] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-7,8-dihydro-1,6-naphthyridin-5-(6H)-one,
[0196] 2-(dimethylamino)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide,
[0197] 3-methoxy-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)propenamide,
[0198] 2-oxo-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)piperidine-4-carboxamide,
[0199] 6-methyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-7,8-dihydro-1,6-naphthyridin-5-(6H)-one,
[0200] N-(azetidin-3-yl)-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]nicotinamide,
[0201] N-methylsulfonyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide,
[0202] N-(1-methylazetidin-3-yl)-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide,
[0203] 4-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carbonyl]piperazin-2-one,
[0204] 4-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carbonyl]piperazine-2,6-dione,
[0205] 3-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carbonitrile,
[0206] (7-(6-(azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0207] 3-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrimidin-4(3H)-one,
[0208] (7-(6-(3-fluoroazetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0209] (7-(6-(3,3-difluoroazetiin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0210] (7-(6-(3-hydroxyazetiin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0211] 7-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino-3,4-dihydro-2H-isoquinolin-1-one,
[0212] 6-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]isoindolin-1-one,
[0213] (3-Fluorazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone,
[0214] 2-Azaspiro[3,3]heptan-2-yl-[5-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone,
[0215] (7-(6-(2-azabicyclo[2.2.1]heptan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0216] (7-(6-(2-azabicyclo[2.2.2]octan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0217] (7-(6-(7-azabicyclo[2.2.1]heptan-7-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0218] (7-(6-(3-(dimethylamino)azetidin-1-yl)(pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0219] Methyl 1-(5-(3-(piperidine-1-carbonyl)(pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)azetidine-3-carboxylate,
[0220] (7-(6-(2-azaspiro[3.3]heptan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0221] (7-(6-(3-(hydroxymethyl)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0222] (7-(6-(7-azaspiro[3.5]nonan-7-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0223] (7-(6-(6-azaspiro[3.4]octan-6-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0224] 7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phthalazin-1-(2H)-one,
[0225] (6-Hydroxy-2-azaspiro[3.3]heptan-2-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone,
[0226] 2-Oxa-7-azaspiro[3.5]nonan-7-yl-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone,
[0227] (2-azabicyclo[2.2.1]heptan-2-yl)(7-phenylpyrazolo[1,5-a]pyridin-3-yl)methanone,
[0228] (2-azabicyclo[2.2.2]octan-2-yl)(7-phenylpyrazolo[1,5-a]pyridin-3-yl)methanone,
[0229] (7-azabicyclo[2.2.1]heptan-7-yl)(7-phenylpyrazolo[1,5-a]pyridin-3-yl)methanone,
[0230] (3-hydroxyiminoazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone,
[0231] 6-(3-(4-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-2-methylisoindolin-1-one,
[0232] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one,
[0233] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phthalazin-1(2H)-one,
[0234] 6-(3-(4,4-difluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0235] 4-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]-1H-pyrimidin-6-one,
[0236] 3-methyl-6-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]pyrimidin-4-one,
[0237] (3,3-difluoroazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone,
[0238] [7-[(4-chlorophenyl)methylamino]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0239] 4-chloro-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzamide,
[0240] 1,3,5-Trimethyl-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrazolo-4-sulfonamide,
[0241] 5-Fluoro-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide,
[0242] [7-[2-(4-chlorophenyl)ethylamino]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0243] 3-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylic acid,
[0244] Methyl 3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylate,
[0245] 3-methyl-6-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinazolin-4(3H)-one,
[0246] 2-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one,
[0247] 3-[3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]2-pyridyl]-4H-1,2,4-oxadiazol-5-one,
[0248] [7-[6-(azetidine-1-carbonyl)-5-fluoro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0249] [7-[5-fluoro-6-(morpholine-4-carbonyl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0250] 3-Fluoro-N-methyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxamide,
[0251] 3-methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinazolin-4(3H)-one,
[0252] 2-Methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one,
[0253] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzaldehyde oxime,
[0254] 2-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzonitrile,
[0255] 3-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrido[2,3-d]pyrimidin-4(3H)-one,
[0256] 3-Methyl-7-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrido[3,2-d]pyrimidin-4(3H)-one,
[0257] (7-(2-(3-fluoroazetidin-1-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0258] 3-chloro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylic acid,
[0259] [7-(3-amino-1,2-benzoxazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0260] [7-(3-amino-1H-indazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0261] [7-(3-amino-1-methyl-indazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0262] 3-chloro-N-methyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxamide,
[0263] [7-[5-fluoro-6-(5-methyl-1,2,4-oxadiazol-3-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0264] (7-(2-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0265] (7-(5-bromo-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0266] (7-(2,6-difluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0267] (7-(2-chloropyrimidin-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0268] 2-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzo[d]isoxazol-3(2H)-one,
[0269] (7-(3-methoxybenzo[d]isoxazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0270] 2-(dimethylamino)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinonitrile,
[0271] (7-(6-fluoropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0272] (7-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0273] (7-(2,6-difluoropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0274] N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-2-(pyridin-3-yl)acetamide,
[0275] 3-[2-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one,
[0276] [7-[4-fluoro-3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0277] [7-[2-(azetidine-1-carbonyl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0278] N-(2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-2-(pyridin-3-yl)acetamide,
[0279] (7-(3-chloro-5-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0280] 5,6-dimethyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one,
[0281] (7-(6-chloro-5-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0282] (7-(2,6-dichloropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0283] (7-(5-chloro-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0284] (7-(5-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0285] 3-fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzonitrile,
[0286] [7-[6-(azetidine-1-carbonyl)-5-chloro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0287] N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)nicotinamide,
[0288] (7-(5,6-difluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl](piperidin-1-yl)methanone,
[0289] (7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0290] 2,6-Difluoro-4-(3-(piperidine-1-carbonyl(pyrazolo[1,5-a]pyridin-7-yl)benzonitrile,
[0291] 3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile,
[0292] (7-(4-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0293] 5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrimidine-2-carbonitrile,
[0294] [7-(2-hydroxypyrimidin-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0295] 3-[3-fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one,
[0296] [7-[2-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0297] 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-1,2,4-oxadiazol-5-(4H)-one,
[0298] (7-(5-chloro-2-fluoropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0299] 3-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one,
[0300] [7-[4-(2-methylpyrazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0301] N-(3-chloro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)nicotinamide,
[0302] [7-[4-(3-furyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone],
[0303] [7-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0304] 3-[2-fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one,
[0305] 5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]pyrimidine-2-carbonitrile,
[0306] [7-[4-(2-hydroxypyrimidin-5-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0307] 5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]pyrimidine-2-carboxamide,
[0308] 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrimidin-2-yl)oxazolidin-2-one,
[0309] 7-(3-amino-1H-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0310] [7-(3-amino-1-methyl-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0311] N-(3-chloro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide,
[0312] 3-nitro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile,
[0313] (7-(6-bromopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0314] (7-(6-chloropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0315] (7-(6-chloro-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0316] 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0317] [7-[2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0318] (7-(5-nitropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0319] (7-(5-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0320] [7-(3-amino-1,2-benzoxazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0321] 3-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrimidin-2-yl]-4H-1,2,4-oxadiazol-5-one,
[0322] (7-(3-fluoro-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0323] 3-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0324] [7-[4-(3,5-dimethylisoxazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0325] (7-(2-fluoro-5-(1-methyl-1H-pyrazol-5-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0326] N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)nicotinamide,
[0327] N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(pyridin-3-yl)acetamide,
[0328] (7-(3,5-difluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0329] 3-(3-nitro-5-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one,
[0330] (7-(3-(5-methyl-1,2,4-oxadiazol-3-yl)-5-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0331] 3-(2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one,
[0332] Piperidin-1-yl(7-(6-((2-pyridin-3-yl)ethyl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone,
[0333] 1,2-Dimethyl-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-1H-imidazole-5-carboxamide,
[0334] N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)pyrimidine-5-carboxamide,
[0335] 5-Fluoro-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)nicotinamide,
[0336] (7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(3-methylpiperidin-1-yl)methanone,
[0337] (3-ethylpiperidin-1-yl)(7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone,
[0338] (7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(3-(trifluoromethyl)piperidin-1-yl)methanone,
[0339] 3-(5-(3-(3-(trifluoromethyl)piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0340] N-(2-nitrobenzyl)-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide,
[0341] (7-(3-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0342] (7-(3-nitro-5-(1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0343] (7-(3-amino-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0344] (7-(6-(4-amino-1H-pyrazol-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0345] (7-(3-(3-hydroxyazetidin-1-yl)-5-(isoxazol-4-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0346] 1-piperidyl-[7-[4-(1H-pyrazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]methanone,
[0347] 1-piperidyl-[7-[4-(3-thienyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]methanone,
[0348] [7-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0349] 5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-3H-1,3,4-oxadiazol-2-one,
[0350] [7-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0351] [7-[4-(5-methylthiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0352] [7-[4-(1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0353] 3-(5-(3-(3-methylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0354] 3-(5-(3-(3-ethylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0355] (7-(6-(4-nitro-1H-pyrazol-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0356] (7-(2-(4-amino-1H-pyrazol-1-yl)-6-bromopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0357] (7-(2-(3-hydroxyazetidin-1-yl)-6-(1-methyl-1H-pyrazol-5-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0358] [7-[4-(1,2-dimethylimidazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0359] [7-[4-(5-amino-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0360] 5-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-3H-1,3,4-oxadiazol-2-one,
[0361] 1-piperidyl-[7-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]pyrazolo[1,5-a]pyridin-3-yl]methanone,
[0362] N-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide,
[0363] (7-(5-bromo-2-(3-(hydroxymethyl)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0364] [7-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0365] 1-Piperidyl-[7-[6-(2-thioxo-3H-1,3,4-oxadiazol-5-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]methanone,
[0366] (7-(2-(isoxazol-4-yl)-6-morpholinopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0367] 3-(6-(1-methyl-1H-pyrazol-5-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0368] 3-(6-(3,5-dimethylisoxazol-4-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0369] (7-(2-(1-methyl-1H-pyrazol-5-yl)-6-morpholinopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0370] 3-(5'-fluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[2,3'-bipyridin]-6-yl)oxazolidin-2-one,
[0371] (7-(2-(3,5-dimethylisoxazol-4-yl)-6-morpholinopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0372] 3-(6-(2-methylpyrimidin-5-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0373] 5-[3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-3H-1,3,4-oxadiazol-2-one,
[0374] (7-(5-(1,2,4-oxadiazol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0375] (7-(6-(3-(dimethylamino)azetidin-1-yl)-5'-fluoro-[2,3'-bipyridin]-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0376] (7-(5'-fluoro-6-morpholino-[2,3'-bipyridin]-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0377] (7-(2-(2-methylpyrimidin-5-yl)-6-morpholinopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0378] 6-(3-(3-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0379] [7-[5-fluoro-6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0380] [7-[5-fluoro-6-(1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0381] [7-[6-(3,5-dimethylisoxazol-4-yl)-5-fluoro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0382] 6-(3-(3,3-difluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0383] 3-(5-(3-(3-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0384] 3-(5-(3-(3,3,-difluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one,
[0385] (R)-6-(3-(3-methylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0386] (S)-6-(3-(3-methylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0387] 6-(3-(3-methylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0388] N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(6-(trifluoromethyl)pyridin-3-yl)acetamide,
[0389] 2-phenyl-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide,
[0390] 6-(3-(2-azaspiro[3.3]heptane-2-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0391] 6-(3-(6-azaspiro[3.4]octane-6-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0392] 6-(3-(7-azaspiro[3.5]nonane-7-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0393] 6-(3-(3-ethylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0394] [7-[5-fluoro-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0395] (7-(1-((1,2,4-oxadiazol-3-yl)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0396] 3-((4-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-1H-pyrazol-1-yl)methyl)-1,2,4-oxadiazol-5(4H)-one,
[0397] (7-(2-(1-((1,2,4-oxadiazol-3-yl)methyl)-1H-pyrazol-4-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone,
[0398] 6-(3-(3-(trifluoromethyl)piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0399] [7-[2-(3,5-dimethylisoxazol-4-yl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone,
[0400] 6-(3-(3-isopropylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0401] 6-(3-(1,2,3,6-tetrahydropyridine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0402] 2-(5-fluoropyridin-3-yl)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide,
[0403] N-(5-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(pyrimidin-5-yl)acetamide,
[0404] [7-[2-[5-(difluoromethyl)-1-oxo-1,3,4-thiadiazol-2-yl]pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone],
[0405] 6-(3-(6-azaspiro[3.5]nonane-6-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0406] 2-(4-chlorophenoxy)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide,
[0407] N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl-2-pyrimidin-5-yl-acetamide,
[0408] N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-2-[6-(trifluoromethyl)-3-pyridyl]acetamide,
[0409] 2-(5-fluoropyridin-3-yl)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)acetamide,
[0410] 2-(4-chlorophenoxy)-N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]acetamide,
[0411] 6-(3-(6-fluoro-2-azaspiro[3.3]heptane-2-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one,
[0412] 6-(3-(6,6-difluoro-2-azaspiro[3.3]heptane-2-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, and
[0413] 3-Hydro-5-[2-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-6-yl]pyridine-2-carbonitrile. The compound represented by the above chemical formula 1 according to the present invention can be prepared and used in the form of a prodrug, a hydrate, a solvate, and a pharmaceutically acceptable salt to promote absorption in the body or increase solubility, and therefore the above prodrug, hydrate, solvate, and pharmaceutically acceptable salt also fall within the scope of the present invention. The term "prodrug" refers to a substance that is transformed into the parent drug in vivo. Prodrugs are often used because, in some cases, they are easier to administer than the parent drug. For example, they may be bioactive by oral administration, whereas the parent drug may not be. Prodrugs may also have improved solubility in pharmaceutical compositions compared to the parent drug. For example, prodrugs may be biohydrolyzable esters of compounds according to the present invention and pharmaceutically acceptable salts thereof. Another example of a prodrug may be a short peptide (polyamino acid) linked to an acid group that is metabolized to reveal the active site of the peptide. The term "hydrate" means a compound of the present invention or a salt thereof containing a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces. The term "solvate" refers to a compound of the present invention or a salt thereof that contains a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents include those that are volatile, non-toxic, and / or suitable for human administration. The term "isomer" refers to a compound of the present invention or a salt thereof that has the same chemical formula or molecular formula but is structurally or sterically different. Such isomers include structural isomers such as tautomers, stereoisomers such as R or S isomers with an asymmetric carbon center, and geometric isomers (trans, cis). All of these isomers and mixtures thereof are also included within the scope of the present invention. The term "pharmaceutically acceptable salt" means a salt form of a compound that does not cause serious irritation to the organism to which the compound is administered and does not impair the biological activity and physical properties of the compound. The pharmaceutical salts include acid addition salts formed by acids that form non-toxic acid addition salts containing pharmaceutically acceptable anions, for example, inorganic acids such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, hydrobromic acid, hydroiodic acid, etc.; organic carboxylic acids such as tartaric acid, formic acid, citric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid, gluconic acid, benzoic acid, lactic acid, fumaric acid, maleic acid, salicylic acid, etc.; sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc. For example, pharmaceutically acceptable carboxylic acid salts include metal salts or alkaline earth metal salts formed by lithium, sodium, potassium, calcium, magnesium, etc.; amino acid salts such as lysine, arginine, guanidine, etc.; organic salts such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, diethanolamine, choline, and triethylamine, etc. The compound of formula 1 according to the present invention can be converted into its salt by a conventional method. In addition, the present invention provides a method for producing a compound of the above chemical formula 1. Reaction Schemes 1 to 55 are exemplified as methods for preparing compounds of chemical formula 1 of the present invention, and the methods of reaction schemes 1 to 55 do not limit the method for preparing compounds of chemical formula 1 according to the present invention. The methods of reaction schemes 1 to 55 are merely examples, and it is obvious that they can be easily modified by those skilled in the art depending on specific substituents. The present invention also provides a pharmaceutical composition for preventing or treating a 15-PGDH-related disease, comprising a heterocyclic compound represented by the above chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also provides a method for preventing or treating a 15-PGDH-related disease, comprising administering to a subject in need thereof a therapeutically effective amount of a heterocyclic compound represented by the above chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. The present invention also provides the use of a heterocyclic compound represented by the above chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient in the manufacture of a medicament for preventing or treating a disease related to 15-PGDH. In one embodiment, the 15-PGDH-related disease is an inflammatory disease (inflammatory bowel disease (ulcerative colitis, Crohn's disease, etc.), chronic obstructive pulmonary disease (COPD), Behcet's disease, acute liver injury, acute kidney injury, acute lung injury, sepsis, worsening of asthma and lung disease, peptic ulcer (ulcer caused by NSAIDs, etc.), vasculitis syndrome, non-alcoholic fatty liver disease (NASH), atopic dermatitis, psoriasis, interstitial cystitis, prostatitis syndrome, etc.), fibrosis (pulmonary fibrosis (idiopathic pulmonary fibrosis, etc.), renal fibrosis (glomerulosclerosis, etc.), cardiac fibrosis (myocardial fibrosis, etc.), oral fibrosis, triangular fibrosis, liver fibrosis, myelofibrosis, scleroderma, etc.), autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, severe combined immunodeficiency syndrome (SCID), etc.), Ophthalmic diseases (dry eye, conjunctivitis, keratitis, etc.), thrombocytopenia (drug-induced thrombocytopenia, autoimmune thrombocytopenia, idiopathic thrombocytopenia, thrombocytopenia due to viral infection, etc.), myopathy (muscular dystrophy, muscle damage, muscular dystrophy, etc.), anemia (aplastic anemia, anemia of chronic disease, Fanconi anemia, beta-thalassemia or anemia of unknown cause, etc.), circulatory diseases (heart disease (angina pectoris, heart failure, myocardial infarction, etc.), kidney disease (chronic kidney disease, renal failure, etc.), stroke, pulmonary hypertension, peripheral circulatory disorder, etc.), nerve cell death (psychiatric disorders, neurodegenerative diseases, nerve injuries, etc.), cytopenia (immune cytopenia, neutropenia, lymphopenia, etc.), osteoporosis, fracture, leukemia (acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), etc.), lymphoma (Hodgkin's lymphoma, non-Hodgkin's lymphoma, etc.), toxicity due to radiation exposure, 15-PGDH expressing cancer, multiple myeloma, paroxysmal nocturnal hemoglobinuria (PNH), pure red cell aplasia, megakaryocytosis, Wiskott-Aldrich syndrome, sickle cell disease, Hurler syndrome, adrenoleukodystrophy, metachromatic leukodystrophy, myelodysplasia, Duchenne muscular dystrophy, solid tumors, chronic granulomatous disease, systemic sclerosis, scars, wounds, otological disorders (vertigo, tinnitus, balance disorders, etc.), hair loss,It could be skin aging, periodontal disease, diabetes, stem cell and bone marrow transplants or organ transplants, cervical ripening, Alzheimer's, or Parkinson's disease. As a result of measuring the 15-PGDH inhibitory activity of the heterocyclic compound of the present invention, it was confirmed that it exhibited excellent 15-PGDH inhibitory activity. The present invention also provides a pharmaceutical composition comprising a heterocyclic compound represented by the above chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. The above additives may include pharmaceutically acceptable carriers or diluents, and may be formulated in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. The pharmaceutically acceptable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, diluents or excipients such as fillers, bulking agents, binders, wetting agents, disintegrating agents, and surfactants are included. Oral solid preparations include tablets, pills, powders, granules, capsules, etc., and these solid preparations may contain at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc., and may contain lubricants, such as magnesium stearate, talc, etc. Oral liquid preparations include suspensions, oral solutions, emulsions, syrups, etc., and may contain diluents, such as water or liquid paraffin, wetting agents, sweeteners, flavoring agents, preservatives, etc. Parenteral preparations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, creams, lyophilized preparations, suppositories, and non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils, such as olive oil, and injectable esters, such as ethyl oleate. Suppository bases that can be used include witepsol, macrogol, tween 61, cocoa butter, laurin butter, and glycerogelatin. The dosage of the active ingredient contained in the pharmaceutical composition of the present invention varies depending on the patient's condition and weight, the degree of the disease, the form of the active ingredient, the route and period of administration, and can be appropriately adjusted depending on the patient. For example, the active ingredient may be administered at a dosage of 0.0001 to 1000 mg / kg per day, preferably 0.001 to 100 mg / kg, and the administration may be administered once a day or divided into several times. In addition, the pharmaceutical composition of the present invention may contain the active ingredient at a weight percentage of 0.001 to 90% based on the total weight of the composition. The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, and humans by various routes, for example, orally, cutaneously, intraperitoneally, rectally, or by intravenous, intramuscular, subcutaneous, intrauterine, or intracerebroventricular injection. Hereinafter, the present invention will be described in more detail through examples and experimental examples. However, the following examples and experimental examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention. Example 1. 7-phenylpyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [7-phenylpyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Scheme 1> Step 1-1: Pyrazolo[1,5-a]pyridine-3-carboxylic acid (1.0 g, 6.18 mmol) was dissolved in tetrahydrofuran (20 mL), and the temperature was lowered to -20 °C. Lithium bis(trimethylsilyl)amide (18.5 mL, 18.5 mmol) dissolved in 1 M tetrahydrofuran was slowly added, and the mixture was stirred for 30 minutes. Iodine (1.878 g, 7.4 mmol) dissolved in tetrahydrofuran (5 mL) was added to the reaction solution, and the mixture was stirred for 30 minutes. After the reaction was completed, a saturated aqueous solution of sodium bicarbonate (50 mL) was added, and dichloromethane (50 mL x 3) was used for extraction. The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. After solidifying with a small amount of dichloromethane, the residue was filtered and air-dried to obtain the target compound 1-1 (1.86 g, 94%). Step 1-2: Compound 1-1 (1.7 g, 5.9 mmol) was dissolved in N,N-dimethylformamide (30 mL), and HATU (2.69 g, 7.1 mmol) and DIPEA (3.1 mL, 17.7 mmol) were added. The mixture was stirred at room temperature for 10 minutes. Piperidine (0.7 mL, 7.1 mmol) was added to the reaction solution and stirred for 4 hours. After completion of the reaction, the reaction solution was concentrated, diluted with ethyl acetate (100 mL), and washed sequentially with water (50 mL), saturated ammonium chloride aqueous solution (50 mL), saturated sodium bicarbonate aqueous solution (50 mL), and brine (50 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. After solidification with diethyl ether / ethyl acetate (10:1) solution (20 mL), filtration and air drying were performed to obtain target compound 1-2 (1.51 g, 72%). [HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate, Hexafluorophosphate Azabenzotriazole Tetramethyl Uronium), DIPEA (N,N-Diisopropylethylamine)] Step 1-3: Compound 1-2 (70 mg, 0.19 mmol) was dissolved in 1,4-dioxin (7 mL), benzeneboronic acid (24 mg, 0.19 mmol), tetrakis(triphenylphosphine)palladium (57 mg, 0.04 mmol), and 2 M potassium carbonate aqueous solution (0.19 mL, 0.39 mmol) were added, and nitrogen was flowed for 10 minutes, and the mixture was stirred at 100 ℃ for 12 hours. After completion of the reaction, the reaction solution was concentrated and diluted with dichloromethane (10 mL). The remaining palladium was filtered off using diatomaceous earth (Celite), and the filtrate was washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 1 (42.3 mg, 70%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.23 (s, 1H), 7.90 (ddd,J= 16.6, 8.4, 2.0 Hz, 3H), 7.60-7.45 (m, 4H), 7.16 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (s, 2H), 1.60-1.43 (m, 4H). MS (ESI, LR) Calc. for C 19 H 20 N3O [M+H] + : 306.2, found: 306.2 Example 2. (7-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 3. Methyl 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoate [methyl 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoate] Example 4. (7-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 5. (7-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 6. 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile [3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile] Example 8. (7-(2-chloropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(2-chloropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 10. 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoic acid Example 11. Methyl 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoate [methyl 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoate] Example 12. (7-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 13. (7-(4-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone ([7-(4-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 15. 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile [4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile] Example 16. (7-(6-nitropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-nitropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 18. 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinonitrile [5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinonitrile] Example 19. (7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 20. (7-(4-methoxy-3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(4-methoxy-3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 21. (7-(3-chloro-4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-chloro-4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 22. 2-fluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile [2-fluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile] Example 23. 2-(dimethylamino)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile [2-(dimethylamino)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile] Example 24. (7-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 25. (7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 120. tert-Butyl 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate [tert-butyl 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate] Example 121. (7-(benzo[d][1,3]dioxol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(benzo[d][1,3]dioxol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 122. (7-(benzofuran-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(benzofuran-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 123. (7-(benzofuran-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(benzofuran-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 124. (7-(Benzo[b]thiophen-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(benzo[b]thiophen-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 125. (7-(1H-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(1H-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 126. (7-(1H-indol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(1H-indol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 127. (7-(benzofuran-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(benzofuran-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 128. (7-(naphthalen-1-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(naphthalen-1-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 129. (7-(naphthalen-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(naphthalen-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 130. Piperidin-1-yl(7-(quinolin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone [piperidin-1-yl(7-(quinolin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone] Example 131. 7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one [7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one] Example 134. 7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one [7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one] Example 136. 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one [6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one] Example 138. 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one [6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one] Example 140. 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one [6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one] Example 143. 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one [5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one] Example 145. 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinolin-2(1H)-one [6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinolin-2(1H)-one] Example 195. 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-7,8-dihydro-1,6-naphthyridin-5-(6H)-one [3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one] Example 205. 3-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carbonitrile [3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carbonitrile] Example 207. 3-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrimidin-4(3H)-one [3-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrimidin-4(3H)-one] Example 224. 7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phthalazin-1-(2H)-one [7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phthalazin-1(2H)-one] Example 232. 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one [3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one] Example 233. 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phthalazin-1(2H)-one [6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phthalazin-1(2H)-one] Example 244. Methyl 3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylate [methyl 3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylate] Example 245. 3-methyl-6-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinazolin-4(3H)-one [3-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinazolin-4(3H)-one] Example 246. 2-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one [2-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one] Example 251. 3-methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinazolin-4(3H)-one [3-methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinazolin-4(3H)-one] Example 252. 2-Methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one [2-methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one] Example 254. 2-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzonitrile [2-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzonitrile] Example 255. 3-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrido[2,3-d]pyrimidin-4(3H)-one [3-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrido[2,3-d]pyrimidin-4(3H)-one] Example 256. 3-methyl-7-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrido[3,2-d]pyrimidin-4(3H)-one [3-methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrido[3,2-d]pyrimidin-4(3H)-one] Example 264. (7-(2-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(2-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 265. (7-(5-bromo-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-bromo-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 266. (7-(2,6-difluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(2,6-difluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 267. (7-(2-chloropyrimidin-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(2-chloropyrimidin-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 268. 2-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzo[d]isoxazol-3(2H)-one [2-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzo[d]isoxazol-3(2H)-one] Example 269. (7-(3-methoxybenzo[d]isoxazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-methoxybenzo[d]isoxazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 270. 2-(dimethylamino)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinonitrile [2-(dimethylamino)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinonitrile] Example 271. (7-(6-fluoropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-fluoropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 272. (7-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 273. (7-(2,6-difluoropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(2,6-difluoropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 279. (7-(3-chloro-5-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-chloro-5-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 280. 5,6-dimethyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one [5,6-dimethyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one] Example 281. (7-(6-chloro-5-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-chloro-5-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 282. (7-(2,6-dichloropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(2,6-dichloropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 283. (7-(5-chloro-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-chloro-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 284. (7-(5-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 285. 3-fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzonitrile Example 288. (7-(5,6-difluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl](piperidin-1-yl)methanone [(7-(5,6-difluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 289. (7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 290. 2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile [2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile] Example 291. 3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile [3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile] Example 292. (7-(4-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(4-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone Example 293. 5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrimidine-2-carbonitrile [5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrimidine-2-carbonitrile Example 294. [7-(2-hydroxypyrimidin-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-(2-hydroxypyrimidin-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 298. (7-(5-chloro-2-fluoropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-chloro-2-fluoropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 312. 3-nitro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile [3-nitro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile] Example 313. (7-(6-bromopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-bromopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 314. (7-(6-chloropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-chloropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 315. (7-(6-chloro-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-chloro-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 318. (7-(5-nitropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-nitropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Examples 2, 3, 4, 5, 6, 8, 10, 11, 12, 13, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 134, 136, 138, 140, 143, 145, 195, 205, 207, 224, 232, 233, 244, 245, 246, 251, 252, 254, 255, 256, 264, For compounds 265, 266, 267, 268, 269, 270, 271, 272, 273, 279, 280, 281, 282, 283, 284, 285, 288, 289, 290, 291, 292, 293, 294, 298, 312, 313, 314, 315, and 318, the compounds were obtained by the same synthetic method as steps 1-3 in Example 1 using compounds 1-2 and the corresponding compounds. The structural and spectral data are shown in Table 1 below. Example structure 1 H NMRMS2 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.05 (d,J= 2.1 Hz, 1H), 7.93-7.84 (m, 2H), 7.64-7.56 (m, 2H), 7.52 (dd,J= 8.9, 7.0 Hz, 1H), 7.24 (dd,J= 7.1, 1.3 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 6.5 Hz, 2H), 1.57 (d,J= 8.4 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 19 ClN3O [M+H] + : 340.1, found: 340.1.3 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.53 (t,J= 1.8 Hz, 1H), 8.27 (s, 1H), 8.18 (dt,J= 7.8, 1.5 Hz, 1H), 8.12 (dt,J= 7.8, 1.4 Hz, 1H), 7.92 (dd,J= 8.9, 1.4 Hz, 1H), 7.73 (t,J= 7.8 Hz, 1H), 7.53 (dd,J= 8.9, 7.1 Hz, 1H), 7.25 (dd,J= 7.0, 1.4 Hz, 1H), 3.90 (s, 3H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.57 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 22 N3O3[M+H] + : 364.2, found: 364.2.4 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.23 (s, 1H), 7.88 (dd,J= 8.9, 1.4 Hz, 1H), 7.53-7.45 (m, 4H), 7.18 (dd,J= 7.0, 1.4 Hz, 1H), 7.14-7.08 (m, 1H), 3.83 (s, 3H), 3.62 (t,J= 5.4 Hz, 4H), 1.69-1.61 (m, 2H), 1.61-1.51 (m, 4H).MS (ESI, LR) Calc. for C 20 H 22 N3O2[M+H] + : 336.2, found: 336.1.5 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.87 (t,J= 2.0 Hz, 1H), 8.42-8.35 (m, 2H), 8.29 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.87 (t,J= 8.0 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.1, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.7 Hz, 2H), 1.57 (d,J= 7.6 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 19 N4O3[M+H] + : 351.1, found: 351.1.6 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.21 (s, 1H), 7.83 (dd,J= 8.9, 1.4 Hz, 1H), 7.47 (dd,J= 8.9, 7.0 Hz, 1H), 7.17 (d,J= 7.8 Hz, 1H), 7.09 (t,J= 2.0 Hz, 1H), 7.05 (dd,J= 7.1, 1.4 Hz, 1H), 6.99-6.94 (m, 1H), 6.75-6.68 (m, 1H), 5.27 (s, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.2 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 20 H 19 N4O [M+H] + : 331.2, found: 331.2.8 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.62 (d,J= 5.2 Hz, 1H), 8.30 (s, 1H), 8.17 (d,J= 1.5 Hz, 1H), 8.03-7.94 (m, 2H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.43 (dd,J= 7.1, 1.3 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.62-1.52 (m, 4H).MS (ESI, LR) Calc. for C 18 H 18 ClN4O [M+H] + : 341.1, found: 341.0.10 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (s, 1H), 8.08 (q,J= 8.5 Hz, 4H), 7.91 (dd,J= 8.9, 1.4 Hz, 1H), 7.53 (dd,J= 8.9, 7.1 Hz, 1H), 7.25 (dd,J= 7.0, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.72-1.61 (m, 2H), 1.58-1.54 (m, 4H).MS (ESI, LR) Calc. for C 20 H 20 N3O3[M+H] + : 350.1, found: 350.2.11 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.18 - 8.06 (m, 4H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.27 (dd,J= 7.0, 1.4 Hz, 1H), 3.92 (s, 3H), 3.62 (t, J = 5.4 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 21 H 22 N3O3[M+H] + : 364.2, found: 364.2.12 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (s, 1H), 8.02-7.93 (m, 2H), 7.89 (dd,J= 8.9, 1.3 Hz, 1H), 7.68-7.58 (m, 2H), 7.51 (dd,J= 8.9, 7.1 Hz, 1H), 7.20 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 8.2 Hz, 2H), 1.57 (d,J= 7.7 Hz, 4H).MS (ESI, LR) Calc. for C19 H 19 ClN3O [M+H] + : 340.1, found: 340.0.13 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.46-8.36 (m, 2H), 8.32-8.20 (m, 3H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.1 Hz, 1H), 7.33 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.2 Hz, 2H), 1.62-1.45 (m, 4H).MS (ESI, LR) Calc. for C 19 H 19 N4O3[M+H] + : 351.1, found: 351.1.15 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.20-8.11 (m, 2H), 8.09-7.99 (m, 2H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.28 (dd,J= 7.0, 1.3 Hz, 1H), 3.62 (t,J= 5.5 Hz, 4H), 1.71-1.62 (m, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 20 H 19 N4O [M+H] + : 331.2, found: 331.2.16 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.21 (d,J= 2.2 Hz, 1H), 8.87 (dd,J= 8.5, 2.3 Hz, 1H), 8.51 (d,J= 8.4 Hz, 1H), 8.29 (s, 1H), 8.00 (dd,J= 8.9, 1.3 Hz, 1H), 7.67-7.64 (m, 1H), 7.46 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.4 Hz, 2H), 1.57 (d,J= 7.1 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 18 N5O3[M+H] + : 352.1, found: 352.1.18 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.30 (d,J= 2.2 Hz, 1H), 8.68 (dd,J= 8.2, 2.2 Hz, 1H), 8.30-8.24 (m, 2H), 7.98 (dd,J= 8.9, 1.3 Hz, 1H), 7.65 (t,J= 1.3 Hz, 1H), 7.44-7.39 (m, 1H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 7.9 Hz, 2H), 1.56 (s, 4H).MS (ESI, LR) Calc. for C 19 H 18 N5O [M+H] + : 332.1, found: 332.1.19 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.77 (d,J= 2.5 Hz, 1H), 8.60 (td,J= 8.3, 2.5 Hz, 1H), 8.25 (d,J= 5.6 Hz, 1H), 7.93 (d,J= 8.9 Hz, 1H), 7.65 (s, 1H), 7.41 (dd,J= 8.6, 2.8 Hz, 1H), 7.30 (d,J= 7.1 Hz, 1H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 6.0 Hz, 2H), 1.56 (s, 4H).MS (ESI, LR) Calc. for C 18 H 18 FN4O [M+H] + : 325.1, found: 325.1.20 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.27 (d,J= 2.7 Hz, 2H), 8.20 (dd,J= 8.8, 2.3 Hz, 1H), 7.88 (dd,J= 8.8, 1.3 Hz, 1H), 7.55-7.43 (m, 2H), 7.24 (dd,J= 7.1, 1.4 Hz, 1H), 4.00 (s, 3H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.4 Hz, 2H), 1.61-1.49 (m, 4H).MS (ESI, LR) Calc. for C 21 H 21 F3N3O2[M+H] + : 404.2, found: 404.1.21 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (s, 1H), 8.04 (d,J= 2.2 Hz, 1H), 7.83 (dd,J= 8.9, 1.3 Hz, 1H), 7.74 (dd,J= 8.5, 2.3 Hz, 1H), 7.48 (dd,J= 8.9, 7.1 Hz, 1H), 7.15 (dd,J= 7.1, 1.4 Hz, 1H), 7.12 (d,J= 8.6 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.0 Hz, 2H), 1.57 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 19 ClN3O2[M+H] + : 356.1, found: 356.1.22 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.28 (s, 1H), 8.20 (dd,J= 10.8, 1.5 Hz, 1H), 8.13 (dd,J= 8.2, 6.9 Hz, 1H), 8.02 (dd,J= 8.2, 1.6 Hz, 1H), 7.96 (dd,J= 8.9, 1.4 Hz, 1H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.36 (dd,J= 7.1, 1.3 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 8.2 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 20 H 18 FN4O [M+H] + : 349.1, found: 349.1.23 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (s, 1H), 7.92 (dd,J= 9.0, 1.4 Hz, 1H), 7.76 (d,J= 8.1 Hz, 1H), 7.55-7.49 (m, 2H), 7.43 (dd,J= 8.1, 1.5 Hz, 1H), 7.27 (dd,J= 7.1, 1.3 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 3.06 (s, 6H), 1.65 (d,J= 7.4 Hz, 2H), 1.62-1.53 (m, 4H).MS (ESI, LR) Calc. for C 22 H 24 N5O [M+H] + : 374.2, found: 374.2.24 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (s, 1H), 7.84 (dd,J= 8.9, 1.3 Hz, 1H), 7.64-7.61 (m, 2H), 7.49 (dd,J= 8.9, 7.0 Hz, 1H), 7.17 (dd,J= 7.0, 1.4 Hz, 1H), 7.13 (d,J= 8.3 Hz, 1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 6.9 Hz, 2H), 1.57 (d,J= 8.4 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 24 N3O3[M+H] + : 366.2, found: 366.1.25 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 7.97 (dd,J= 9.0, 1.4 Hz, 1H), 7.61 (d,J= 1.9 Hz, 1H), 7.52 (dd,J= 8.9, 7.0 Hz, 1H), 7.22 (dd,J= 7.0, 1.3 Hz, 1H), 6.69 (d,J= 1.9 Hz, 1H), 3.74 (s, 3H), 3.62 (t,J= 5.5 Hz, 4H), 1.70-1.61 (m, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 17 H 20 N5O [M+H] + : 310.2, found: 310.1.120 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (d,J= 5.2 Hz, 1H), 7.82 (dd,J= 15.5, 8.7 Hz, 1H), 7.43 (dt,J= 8.9, 6.3 Hz, 1H), 7.02 (dd,J= 23.5, 7.1 Hz, 1H), 6.51 (d,J= 27.0 Hz, 1H), 4.10 (s, 2H), 3.60 (t,J= 5.3 Hz, 6H), 2.68 (s, 2H), 1.64 (s, 2H), 1.56 (s, 4H), 1.46 (d,J= 4.8 Hz, 9H).MS (ESI, LR) Calc. for C 23 H 31 N4O3[M+H] + : 411.2, found: 411.2.121 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.23 (s, 1H), 7.84 (dd,J= 8.9, 1.3 Hz, 1H), 7.53 (d,J= 1.7 Hz, 1H), 7.48 (dd,J= 8.9, 7.1 Hz, 1H), 7.43 (dd,J= 8.1, 1.8 Hz, 1H), 7.13 (dd,J= 7.1, 1.4 Hz, 1H), 7.10 (d,J= 8.1 Hz, 1H), 6.14 (s, 2H), 3.62 (t,J= 5.3 Hz, 4H), 1.65 (s, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 20 H 20 N3O3[M+H] + : 350.1, found: 350.1.122 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.16 (s, 1H), 8.36 (s, 1H), 8.03 (d,J= 7.8 Hz, 1H), 7.93 (dd,J= 8.8, 1.4 Hz, 1H), 7.79 (d,J= 8.1 Hz, 1H), 7.68 (dd,J= 7.2, 1.4 Hz, 1H), 7.60 (dd,J= 8.8, 7.1 Hz, 1H), 7.53-7.46 (m, 1H), 7.46-7.40 (m, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.5 Hz, 2H), 1.58 (d,J= 7.6 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 20 N3O2[M+H] + : 346.2, found: 346.1.123 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.47 (d,J= 1.6 Hz, 2H), 7.97 (dd,J= 8.8, 1.3 Hz, 1H), 7.91-7.82 (m, 2H), 7.74 (d,J= 8.3 Hz, 1H), 7.63 (dd,J= 8.8, 7.3 Hz, 1H), 7.48 (td,J= 7.8, 1.3 Hz, 1H), 7.37 (t,J= 7.5 Hz, 1H), 3.65 (t,J= 5.4 Hz, 4H), 1.67 (d,J= 6.2 Hz, 2H), 1.59 (s, 4H).MS (ESI, LR) Calc. for C 21 H 20 N3O2[M+H] + : 346.2, found: 346.1.124 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.33 (s, 1H), 8.19 (s, 1H), 8.13 (d,J= 8.0 Hz, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.60-7.34 (m, 4H), 7.26 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.64 (dd,J= 7.8, 3.6 Hz, 2H), 1.57 (td,J= 6.6, 3.4 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 20 N3OS [M+H] + : 362.1, found: 362.1.125 1H NMR (400 MHz, DMSO-d6) δ(ppm): 13.32 (s, 1H), 8.25 (s, 1H), 8.18 (d,J= 3.9 Hz, 2H), 7.97-7.83 (m, 2H), 7.62-7.49 (m, 2H), 7.26 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 7.2 Hz, 2H), 1.57 (d,J= 6.9 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 20 N5O [M+H] + : 346.2, found: 346.1.126 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.34 (s, 1H), 8.23 (s, 1H), 8.19-8.12 (m, 1H), 7.83 (dd,J= 8.8, 1.3 Hz, 1H), 7.64 (dd,J= 8.5, 1.7 Hz, 1H), 7.57-7.42 (m, 3H), 7.14 (dd,J= 7.1, 1.4 Hz, 1H), 6.56 (t,J= 2.6 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 7.6 Hz, 2H), 1.57 (d, J = 6.9 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 21 N4O [M+H] + : 345.2, found: 345.1.127 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (d,J= 2.1 Hz, 2H), 8.12 (d,J= 2.2 Hz, 1H), 7.86 (ddd,J= 15.3, 8.8, 1.6 Hz, 2H), 7.77 (d,J= 8.6 Hz, 1H), 7.52 (dd,J= 8.9, 7.0 Hz, 1H), 7.19 (dd,J= 7.0, 1.4 Hz, 1H), 7.09 (d,J= 2.2 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.69-1.62 (m, 2H), 1.57 (q,J= 5.8 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 20 N3O2[M+H] + : 346.2, found: 346.1.128 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.17-8.11 (m, 1H), 8.06 (d,J= 6.4 Hz, 2H), 8.00 (dd,J= 9.0, 1.4 Hz, 1H), 7.71 - 7.66 (m, 2H), 7.62-7.53 (m, 2H), 7.42 (ddd,J= 8.3, 6.8, 1.3 Hz, 1H), 7.22-7.14 (m, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.3 Hz, 2H), 1.57 (d,J= 7.6 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 22 N3O [M+H] + : 356.2, found: 356.1.129 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.51 (d,J= 1.6 Hz, 1H), 8.27 (s, 1H), 8.12-7.99 (m, 4H), 7.93 (dd,J= 8.8, 1.4 Hz, 1H), 7.69-7.49 (m, 3H), 7.31 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.6 Hz, 2H), 1.58 (d,J= 7.1 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 22 N3O [M+H] + : 356.2, found: 356.1.130 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.39 (d,J= 2.2 Hz, 1H), 8.98 (d,J= 2.2 Hz, 1H), 8.30 (s, 1H), 8.13 (d,J= 8.3 Hz, 2H), 7.97 (dd,J= 8.9, 1.3 Hz, 1H), 7.94-7.84 (m, 1H), 7.78-7.67 (m, 1H), 7.60 (dd,J= 8.9, 7.0 Hz, 1H), 7.43 (dd,J= 7.0, 1.3 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 6.2 Hz, 2H), 1.58 (d,J= 7.7 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 21 N4O [M+H] + : 357.2, found: 357.1.131 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.40 (d,J= 2.0 Hz, 1H), 8.24 (s, 1H), 8.07 (s, 1H), 8.00 (dd,J= 7.9, 2.0 Hz, 1H), 7.89 (dd,J= 8.9, 1.4 Hz, 1H), 7.51 (dd,J= 9.3, 7.3 Hz, 2H), 7.19 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.45 (td,J= 6.5, 2.7 Hz, 2H), 3.01 (t,J= 6.5 Hz, 2H), 1.68-1.62 (m, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 23 N4O2[M+H] + : 375.2, found: 375.1.134 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.42 (d,J= 5.6 Hz, 1H), 8.78 (d,J= 2.0 Hz, 1H), 8.32-8.18 (m, 2H), 7.95-7.77 (m, 2H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.35-7.24 (m, 2H), 6.66 (d,J= 7.1 Hz, 1H), 3.64 (t,J= 5.5 Hz, 4H), 1.66 (s, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 21 N4O2[M+H] + : 373.2, found: 373.1.136 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.06 (s, 1H), 7.99 (d,J= 8.6 Hz, 1H), 7.95-7.84 (m, 3H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.22 (dd,J= 7.1, 1.3 Hz, 1H), 3.62 (t,J= 5.6 Hz, 4H), 3.49-3.41 (m, 2H), 3.00 (t,J= 6.6 Hz, 2H), 1.65 (d,J= 5.4 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 23 N4O2[M+H] + : 375.2, found: 375.2.138 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.38 (s, 1H), 8.31 (d,J= 8.4 Hz, 1H), 8.27 (s, 1H), 8.22 (d,J= 1.8 Hz, 1H), 7.99 (dd,J= 8.3, 1.7 Hz, 1H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.8, 7.0 Hz, 1H), 7.34-7.19 (m, 2H), 6.65 (d,J= 7.1 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (s, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 21 N4O2[M+H] + : 373.2, found: 373.2.140 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.71 (s, 1H), 8.25 (d,J= 3.2 Hz, 2H), 8.12 (dd,J= 7.9, 1.7 Hz, 1H), 7.91 (dd,J= 8.9, 1.4 Hz, 1H), 7.76 (d,J= 7.8 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.26 (dd,J= 7.1, 1.4 Hz, 1H), 4.50 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.73-1.50 (m, 6H).MS (ESI, LR) Calc. for C 21 H 21 N4O2[M+H] + : 361.2, found: 361.1.143 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.72 (s, 1H), 8.25 (s, 1H), 8.14 (s, 1H), 8.00 (d,J= 8.0 Hz, 1H), 7.94-7.89 (m, 1H), 7.83 (d,J= 7.9 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.23 (d,J= 7.0 Hz, 1H), 4.48 (s, 2H), 3.63 (t,J= 5.5 Hz, 4H), 1.65 (s, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 21 H 21 N4O2[M+H] + : 361.2, found: 361.2.145 1H NMR (400 MHz, DMSO-d6) δ(ppm): 11.97 (s, 1H), 8.33-8.20 (m, 2H), 8.06 (dd,J= 8.6, 2.0 Hz, 1H), 8.01 (d,J= 9.6 Hz, 1H), 7.88 (dd,J= 8.9, 1.3 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.45 (d,J= 8.6 Hz, 1H), 7.21 (dd,J= 7.0, 1.4 Hz, 1H), 6.58 (d,J= 9.5 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 6.0 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 21 N4O2[M+H] + : 373.2, found: 373.1.195 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.10 (d,J= 2.3 Hz, 1H), 8.77 (d,J= 2.3 Hz, 1H), 8.27 (s, 2H), 7.93 (dd,J= 8.9, 1.4 Hz, 1H), 7.54 (dd,J= 8.9, 7.1 Hz, 1H), 7.34 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.55 (td,J= 6.7, 2.8 Hz, 2H), 3.16 (t,J= 6.7 Hz, 2H), 1.65 (d,J= 5.3 Hz, 2H), 1.57 (d,J= 7.1 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 22 N5O2[M+H] + : 376.1, found: 376.1.205 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.23 (t, J = 1.6 Hz, 1H), 8.80 (dd, J = 10.3, 1.7 Hz, 1H), 8.31 (s, 1H), 8.01 (dd, J = 8.8, 1.4 Hz, 1H), 7.58 (dd, J = 8.9, 7.1 Hz, 1H), 7.49 (dd, J = 7.2, 1.4 Hz, 1H), 3.62 (t, J = 5.5 Hz, 4H), 1.65 (d, J = 6.8 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 19 H 17 FN5O [M+H] + : 350.1, found: 350.1.207 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.64 (s, 1H), 8.40 (s, 1H), 8.25 (s, 1H), 8.04 (d,J= 8.0 Hz, 2H), 7.59 (t,J= 8.0 Hz, 1H), 3.62 (dt,J= 10.9, 5.2 Hz, 4H), 3.49 (s, 3H), 1.65 (d,J= 5.9 Hz, 2H), 1.56 (p,J= 5.6 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 20 N5O2[M+H] + : 338.2, found: 338.1.224 1H NMR (400 MHz, DMSO-d6) δ(ppm): 12.80 (s, 1H), 8.83 (d,J= 1.8 Hz, 1H), 8.46 (dd,J= 8.2, 1.4 Hz, 2H), 8.29 (s, 1H), 8.11 (d,J= 8.3 Hz, 1H), 7.96 (dd,J= 8.9, 1.4 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.3 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 6.2 Hz, 2H), 1.58 (s, 4H).MS (ESI, LR) Calc. for C 21 H 20 N5O2[M+H] + : 374.2, found: 374.1.232 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.24 (d,J= 2.1 Hz, 1H), 8.94 (s, 1H), 8.67 (d,J= 2.1 Hz, 1H), 8.27 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.38 (dd,J= 7.1, 1.4 Hz, 1H), 4.56 (s, 2H), 3.62 (dt,J= 10.9, 5.4 Hz, 6H), 1.71-1.53 (m, 8H).MS (ESI, LR) Calc. for C 20 H 20 N5O2[M+H] + : 362.2, found: 362.1.233 1H NMR (400 MHz, DMSO-d6) δ(ppm): 12.78 (s, 1H), 8.52 (t,J= 1.2 Hz, 1H), 8.46 (s, 1H), 8.37 (d,J= 1.3 Hz, 2H), 8.29 (s, 1H), 7.97 (dd,J= 8.9, 1.4 Hz, 1H), 7.58 (dd,J= 8.9, 7.0 Hz, 1H), 7.35 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.7 Hz, 2H), 1.58 (d,J= 6.3 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 20 N5O2[M+H] + : 374.2, found: 374.1.244 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.12 (t,J= 1.5 Hz, 1H), 8.63 (dd,J= 11.6, 1.7 Hz, 1H), 8.31 (s, 1H), 7.99 (dd,J= 8.9, 1.4 Hz, 1H), 7.58 (dd,J= 8.9, 7.1 Hz, 1H), 7.48 (dd,J= 7.1, 1.4 Hz, 1H), 3.96 (s, 3H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.2 Hz, 2H), 1.57 (d,J= 7.3 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 20 FN4O3[M+H] + : 383.1, found: 383.1.245 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.76 (d,J= 2.1 Hz, 1H), 8.48 (s, 1H), 8.36 (dd,J= 8.6, 2.2 Hz, 1H), 8.28 (s, 1H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.83 (d,J= 8.5 Hz, 1H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.32 (dd,J= 7.0, 1.3 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 3.55 (s, 3H), 1.66 (d,J= 5.5 Hz, 2H), 1.57 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 22 N5O2[M+H] + : 388.2, found: 388.1.246 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.82 (t,J= 1.4 Hz, 1H), 8.33 (s, 1H), 7.92 (dd,J= 8.8, 1.4 Hz, 1H), 7.77 (dd,J= 9.8, 1.8 Hz, 1H), 7.53 (dd,J= 8.8, 7.1 Hz, 1H), 7.44-7.35 (m, 2H), 3.61 (d,J= 13.8 Hz, 7H), 1.66 (q,J= 5.9 Hz, 2H), 1.58 (q,J= 5.6 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 21 N6O2[M+H] + : 377.2, found: 377.1.251 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.46 (s, 1H), 8.32-8.24 (m, 3H), 8.07 (dd,J= 8.3, 1.8 Hz, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.34 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.55 (s, 3H), 1.66 (d,J= 5.4 Hz, 2H), 1.57 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 22 N5O2[M+H] + : 388.2, found: 388.1.252 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.30 (s, 1H), 8.00-7.92 (m, 3H), 7.54 (dd,J= 8.9, 7.1 Hz, 1H), 7.39 (dd,J= 7.1, 1.4 Hz, 1H), 7.15-7.10 (m, 1H), 3.62 (d,J= 8.7 Hz, 7H), 1.69-1.63 (m, 2H), 1.57 (d,J= 5.8 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 21 N6O2[M+H] + : 377.2, found: 377.1.254 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.54 (dd,J= 6.3, 2.4 Hz, 1H), 8.38 (ddd,J= 8.9, 5.3, 2.4 Hz, 1H), 8.27 (s, 1H), 7.93 (dd,J= 8.9, 1.4 Hz, 1H), 7.74 (t,J= 9.1 Hz, 1H), 7.54 (dd,J= 8.9, 7.1 Hz, 1H), 7.29 (dd,J= 7.1, 1.3 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.2 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 18 FN4O [M+H] + : 349.1, found: 349.1.255 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.46 (d,J= 2.5 Hz, 1H), 9.21 (d,J= 2.5 Hz, 1H), 8.69 (s, 1H), 8.31 (s, 1H), 7.96 (dd,J= 8.9, 1.4 Hz, 1H), 7.60-7.55 (m, 1H), 7.47 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.5 Hz, 4H), 3.56 (s, 3H), 1.66 (d,J= 5.9 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 21 H 21 N6O2[M+H] + : 389.2, found: 389.2.256 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.31 (d,J= 2.1 Hz, 1H), 8.73 (d,J= 2.1 Hz, 1H), 8.55 (s, 1H), 8.31 (s, 1H), 8.00 (dd,J= 8.8, 1.4 Hz, 1H), 7.59 (dd,J= 8.9, 7.0 Hz, 1H), 7.49 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.5 Hz, 4H), 3.59 (s, 3H), 1.66 (d,J= 5.7 Hz, 2H), 1.58 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 21 N6O2[M+H] + : 389.2, found: 389.1.264 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.16 (s, 1H), 7.95 (dd,J= 9.0, 1.4 Hz, 1H), 7.66 (dd,J= 8.4, 1.5 Hz, 1H), 7.63-7.56 (m, 2H), 7.53 (ddd,J= 9.1, 6.6, 2.5 Hz, 2H), 7.08 (dd,J= 6.9, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.74 1.60 (m, 2H), 1.57 (q,J= 5.8 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 19 ClN3O [M+H] + : 340.1, found: 340.1.265 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.63 (d,J= 7.3 Hz, 2H), 8.24 (s, 1H), 7.99 (dd,J= 9.0, 1.3 Hz, 1H), 7.55 (dd,J= 9.0, 7.0 Hz, 1H), 7.34-7.29 (m, 1H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 6.0 Hz, 2H), 1.57 (d,J= 6.6 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 17 BrFN4O [M+H] + : 403, found: 403.266 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.54 (dt,J= 9.3, 7.9 Hz, 1H), 8.23 (s, 1H), 7.98 (dd,J= 9.0, 1.4 Hz, 1H), 7.55 (dd,J= 9.0, 7.0 Hz, 1H), 7.43 (dd,J= 8.1, 2.4 Hz, 1H), 7.27 (dd,J= 7.1, 1.3 Hz, 1H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (q,J= 4.8 Hz, 2H), 1.56 (h,J= 4.4 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 17 F2N4O [M+H] + : 343.1, found: 343.1.267 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.39 (s, 2H), 8.31 (s, 1H), 7.98 (dd,J= 8.9, 1.4 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.45 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 8.2 Hz, 2H), 1.57 (d,J= 5.7 Hz, 4H).MS (ESI, LR) Calc. for C 17 H 17 ClN5O [M+H] + : 342.1, found: 342.1.268 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.39 (d,J= 1.9 Hz, 1H), 8.30-8.24 (m, 2H), 7.91 (dd,J= 8.9, 1.3 Hz, 1H), 7.69 (d,J= 8.8 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.28 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (d,J= 9.0 Hz, 7H), 1.66 (d,J= 5.6 Hz, 2H), 1.57 (d,J= 7.6 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 21 N4O3[M+H] + : 377.2, found: 377.1.269 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.35 (d,J= 1.8 Hz, 1H), 8.26 (s, 1H), 8.20 (dd,J= 8.8, 1.8 Hz, 1H), 7.91 (dd,J= 8.9, 1.4 Hz, 1H), 7.82 (d,J= 8.8 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.27 (dd,J= 7.1, 1.4 Hz, 1H), 4.17 (s, 3H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.7 Hz, 2H), 1.57 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 21 N4O3[M+H] + : 377.2, found: 377.1.270 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.91 (d,J= 2.4 Hz, 1H), 8.67 (d,J= 2.5 Hz, 1H), 8.27 (s, 1H), 7.85 (dd,J= 8.9, 1.3 Hz, 1H), 7.50 (dd,J= 8.9, 7.1 Hz, 1H), 7.29 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 3.34 (s, 6H), 1.65 (d,J= 5.5 Hz, 2H), 1.57 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 23 N6O [M+H] + : 375.2, found: 375.1.271 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.77 (dd,J= 7.6, 2.7 Hz, 1H), 8.35 (s, 1H), 8.25 (q,J= 8.1 Hz, 1H), 8.00 (dd,J= 8.8, 1.5 Hz, 1H), 7.72 (dd,J= 7.2, 1.5 Hz, 1H), 7.59 (dd,J= 8.8, 7.1 Hz, 1H), 7.37 (dd,J= 8.2, 2.7 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.71-1.63 (m, 2H), 1.63-1.54 (m, 4H).MS (ESI, LR) Calc. for C 18 H 18 FN4O [M+H] + : 325.1, found: 325.1.272 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.47 (d,J= 7.8 Hz, 1H), 8.21 (d,J= 7.7 Hz, 2H), 8.02 (dd,J= 9.0, 1.4 Hz, 1H), 7.59 (dd,J= 9.0, 7.0 Hz, 1H), 7.28 (dd,J= 7.0, 1.3 Hz, 1H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 7.0 Hz, 2H), 1.57 (d,J= 7.6 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 17 ClF3N4O [M+H] + : 409.1, found: 409.1.273 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.33 (s, 1H), 8.02 (dd,J= 8.8, 1.4 Hz, 1H), 7.88 (s, 2H), 7.57 (dd,J= 8.8, 7.1 Hz, 1H), 7.51 (dd,J= 7.1, 1.5 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.0 Hz, 2H), 1.57 (d,J= 7.8 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 17 F2N4O [M+H] + : 343.1, found: 343.1.279 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.28 (s, 1H), 7.96-7.90 (m, 2H), 7.88-7.82 (m, 1H), 7.64 (dt,J= 8.7, 2.2 Hz, 1H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.31 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.69-1.61 (m, 2H), 1.57 (q,J= 5.9 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 18 ClFN3O [M+H] + : 358.1, found: 358.1.280 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.19 (d,J= 2.0 Hz, 1H), 8.69 (d,J= 1.9 Hz, 1H), 8.29 (s, 1H), 7.97 (dd,J= 8.8, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.39-7.34 (m, 1H), 4.74 (q,J= 6.8 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.11 (s, 3H), 1.66 (d,J= 5.5 Hz, 2H), 1.57 (s, 4H), 1.52 (d,J= 6.7 Hz, 2H).MS (ESI, LR) Calc. for C 22 H 24 N5O2[M+H] + : 390.2, found: 390.1.281 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.88 (d,J= 1.9 Hz, 1H), 8.64 (dd,J= 9.8, 2.0 Hz, 1H), 8.30 (s, 1H), 7.97 (dd,J= 8.9, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.41 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 4.5 Hz, 2H), 1.57 (d,J= 6.1 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 17 ClFN4O [M+H] + : 359.1, found: 359.1.282 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.33 (s, 1H), 8.23 (s, 2H), 8.00 (dd,J= 8.7, 1.6 Hz, 1H), 7.58-7.49 (m, 2H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 7.6 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 18 H 17 Cl2N4O [M+H] + : 375.1, found: 375.283 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.57-8.52 (m, 2H), 8.24 (s, 1H), 7.99 (dd,J= 9.0, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.32 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.2 Hz, 2H), 1.57 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 17 ClFN4O [M+H] + : 359.1, found: 359.1.284 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.99 (t,J= 1.8 Hz, 1H), 8.76 (d,J= 2.8 Hz, 1H), 8.40 (ddd,J= 10.1, 2.8, 1.7 Hz, 1H), 8.28 (s, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (q,J= 5.8 Hz, 2H), 1.57 (h,J= 5.9 Hz, 4H).MS (ESI, LR) Calc. for C18 H 18 FN4O [M+H] + : 325.1, found: 325.1.285 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.21 (s, 1H), 8.14-8.06 (m, 1H), 7.99 (dd,J= 8.9, 1.3 Hz, 1H), 7.94 (d,J= 5.8 Hz, 2H), 7.55 (dd,J= 9.0, 7.0 Hz, 1H), 7.24 (dd,J= 7.0, 1.3 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.4 Hz, 2H), 1.61-1.46 (m, 4H).MS (ESI, LR) Calc. for C 20 H 18 FN4O [M+H] + : 349.1, found: 349.1.288 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.72 (ddd,J= 11.1, 9.3, 2.0 Hz, 1H), 8.63 (t,J= 1.8 Hz, 1H), 8.28 (s, 1H), 7.96 (dd,J= 8.9, 1.4 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.5 Hz, 4H), 1.72-1.62 (m, 2H), 1.57 (d,J= 4.4 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 17 F2N4O [M+H] + : 343.1, found: 343.1.289 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.86 (dd,J= 8.9, 2.2 Hz, 1H), 8.76-8.72 (m, 1H), 8.29 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.69-1.63 (m, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 18 H 17 ClFN4O [M+H] + : 359.1, found: 359.1.290 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.31 (s, 1H), 8.14 (d,J= 9.9 Hz, 2H), 7.99 (dd,J= 8.9, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.1 Hz, 1H), 7.42 (d,J= 7.1 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.4 Hz, 2H), 1.58 (d,J= 7.9 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 17 F2N4O [M+H] + : 367.1, found: 367.1.291 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.33 (t,J= 1.5 Hz, 1H), 8.30-8.23 (m, 2H), 8.08-8.03 (m, 1H), 7.96 (dd,J= 8.9, 1.4 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.5 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 18 FN4O [M+H] + : 349.1, found: 349.1.292 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (s, 1H), 7.93-7.86 (m, 3H), 7.80-7.73 (m, 2H), 7.51 (dd,J= 8.9, 7.1 Hz, 1H), 7.20 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.69-1.61 (m, 2H), 1.57 (td,J= 6.8, 3.4 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 19 BrN3O [M+H] + : 384.1, found: 384.293 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.65 (s, 2H), 8.32 (s, 1H), 8.02 (dd,J= 8.8, 1.5 Hz, 1H), 7.60 (dd,J= 8.8, 7.0 Hz, 1H), 7.54 (dd,J= 7.1, 1.5 Hz, 1H), 3.63 (dd,J= 7.0, 4.1 Hz, 4H), 1.68-1.62 (m, 2H), 1.61-1.55 (m, 4H).MS (ESI, LR) Calc. for C 18H 17 N6O [M+H] + : 333.1, found: 333.1.294 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.66 (s, 2H), 8.20 (s, 1H), 7.64 (dd,J= 8.8, 1.3 Hz, 1H), 7.39 (dd,J= 8.8, 7.2 Hz, 1H), 6.99 (dd,J= 7.2, 1.4 Hz, 1H), 3.61 (t,J= 5.4 Hz, 4H), 1.72-1.61 (m, 2H), 1.56 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 17 H 18 N5O2[M+H] + : 324.1, found: 324.1298 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.58 (s, 1H), 8.22 (s, 1H), 8.02 (dd,J= 8.9, 1.3 Hz, 1H), 7.70 (d,J= 2.6 Hz, 1H), 7.57 (dd,J= 9.0, 6.9 Hz, 1H), 7.26-7.22 (m, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 7.8 Hz, 2H), 1.61-1.55 (m, 4H).MS (ESI, LR) Calc. for C 18 H 17 ClFN4O [M+H] + : 359.1, found: 359.1312 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.18 (t,J= 1.9 Hz, 1H), 8.90 (dt,J= 7.0, 1.6 Hz, 2H), 8.33 (s, 1H), 7.99 (dd,J= 8.8, 1.4 Hz, 1H), 7.58 (dd,J= 8.9, 7.1 Hz, 1H), 7.48 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.7 Hz, 2H), 1.58 (s, 4H).MS (ESI, LR) Calc. for C 20 H 18 N5O3[M+H] + : 376.1, found: 376.1313 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.92 (d,J= 2.5 Hz, 1H), 8.37 (dd,J= 8.3, 2.6 Hz, 1H), 8.26 (s, 1H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.87 (d,J= 8.4 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.32 (dd,J= 7.1, 1.3 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.69-1.61 (m, 2H), 1.61-1.53 (m, 4H).MS (ESI, LR) Calc. for C 18 H 18 BrN4O [M+H] + : 385.1, found: 385314 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.95 (d,J= 2.5 Hz, 1H), 8.48 (dd,J= 8.4, 2.5 Hz, 1H), 8.26 (s, 1H), 7.94 (dd,J= 8.9, 1.4 Hz, 1H), 7.74 (d,J= 8.4 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.33 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.5 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 18 H 18 ClN4O [M+H] + : 341.1, found: 341.1315 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.41 (dd,J= 9.2, 7.8 Hz, 1H), 8.23 (s, 1H), 7.98 (dd,J= 8.9, 1.4 Hz, 1H), 7.76 (dd,J= 7.9, 1.1 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.28 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (q,J= 5.0 Hz, 2H), 1.57 (q,J= 6.0 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 17 ClFN4O [M+H] + : 359.1, found: 359.0318 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.50 (dd,J= 6.2, 2.2 Hz, 2H), 9.27 (t,J= 2.3 Hz, 1H), 8.32 (s, 1H), 8.00 (dd,J= 8.9, 1.4 Hz, 1H), 7.58 (dd,J= 8.9, 7.1 Hz, 1H), 7.50 (dd,J= 7.0, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.82-1.62 (m, 2H), 1.57 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 18 N5O3[M+H] + : 352.1, found: 352.1 Example 7. (7-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 2> Compound 5 (0.331 g, 0.94 mmol) was dissolved in methanol (16.5 mL), and palladium / carbon (0.025 g, 0.24 mmol) was added. The reaction solution was filled with hydrogen gas and stirred for 12 hours. After completion of the reaction, the remaining palladium was removed using diatomaceous earth (Celite), and the filtrate was concentrated. Dichloromethane (30 mL) was added, and the mixture was washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 7 (0.297 g, 95%). 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.21 (s, 1H), 7.83 (dd,J= 8.9, 1.4 Hz, 1H), 7.47 (dd,J= 8.9, 7.0 Hz, 1H), 7.17 (d,J= 7.8 Hz, 1H), 7.09 (t,J= 2.0 Hz, 1H), 7.05 (dd,J= 7.1, 1.4 Hz, 1H), 6.99-6.94 (m, 1H), 6.75-6.68 (m, 1H), 5.27 (s, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.2 Hz, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 19 H 21 N4O [M+H] + : 321.2, found: 321.2. Example 9. (7-(5-aminopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-aminopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 14. (7-(4-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(4-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 17. (7-(6-aminopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-aminopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] For Examples 9, 14, and 17, the compounds corresponding to Compound 1-2 were obtained by sequentially using the synthetic method of Steps 1-3 in Example 1 and the synthetic method of Example 7. The structural and spectral data are shown in Table 2 below. Example structure1 H NMRMS9 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.23 (s, 1H), 8.16 (d,J= 1.9 Hz, 1H), 8.06 (d,J= 2.7 Hz, 1H), 7.87 (dd,J= 8.9, 1.3 Hz, 1H), 7.53-7.46 (m, 2H), 7.15 (dd,J= 7.0, 1.4 Hz, 1H), 5.54 (s, 2H), 3.61 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.2 Hz, 2H), 1.56 (d,J= 7.7 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 20 N5O [M+H] + : 322.2, found: 322.1.14 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.21 (s, 1H), 7.75-7.68 (m, 3H), 7.43 (dd,J= 8.8, 7.1 Hz, 1H), 7.03 (dd,J= 7.2, 1.4 Hz, 1H), 6.68 (d,J= 8.6 Hz, 2H), 5.59 (s, 2H), 3.61 (t, J = 5.4 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.56 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 21 N4O [M+H] + : 321.2, found: 321.2.17 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.51 (d,J= 2.4 Hz, 1H), 8.22 (s, 1H), 8.02 (dd,J= 8.7, 2.5 Hz, 1H), 7.78 (dd,J= 8.8, 1.3 Hz, 1H), 7.46 (dd,J= 8.8, 7.1 Hz, 1H), 7.11 (dd,J= 7.1, 1.4 Hz, 1H), 6.57 (d,J= 8.7 Hz, 1H), 6.43 (s, 2H), 3.61 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.56 (d,J= 6.5 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 20 N5O [M+H] + : 322.2, found: 322.1. Example 26. (7-(3-(morpholine-4-carbonyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-(morpholine-4-carbonyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 3> Step 26-1 [Step 26-1]: The target compound 26-1 was obtained using the same synthetic method as step 1-3 in Example 1 using compound 1-2 and 3-boronobenzoic acid. Step 26-2 [Step 26-2]: The target compound 26 was obtained using the same synthetic method as step 1-2 in Example 1 using compound 26-1 and morpholine. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.03-7.92 (m, 3H), 7.65-7.54 (m, 2H), 7.38 (dd,J= 8.9, 7.0 Hz, 1H), 6.98 (dd,J= 7.0, 1.4 Hz, 1H), 3.78-3.60 (m, 12H), 1.74-1.66 (m, 6H). MS (ESI, LR) Calc. for C 24 H 27 N4O3[M+H] + : 419.2, found: 419.2. Example 27. N-methyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-methyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 28. N-isopropyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-isopropyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 29. Azetidin-1-yl(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone [azetidin-1-yl(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone] Example 30. N-(2-methoxyethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(2-methoxyethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 31. N-(2-(dimethylamino)ethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(2-(dimethylamino)ethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 32. N-(cyclopropylmethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(cyclopropylmethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 33. N-(1-methylpiperidin-4-yl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(1-methylpiperidin-4-yl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 35. tert-Butyl 4-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoyl)piperazine-1-carboxylate [tert-butyl 4-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoyl)piperazine-1-carboxylate] Example 36. N-(2-cyanoethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(2-cyanoethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 37. 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)benzamide [3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)benzamide] Example 38. 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)benzamide [3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)benzamide] For Examples 27, 28, 29, 30, 31, 32, 33, 35, 36, 37, and 38, the compounds corresponding to compound 26-1 were obtained using the same synthetic method as steps 1-2 of Example 1. The structural and spectral data are shown in Table 3 below. Example structure 1 H NMRMS27 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (t,J= 1.8 Hz, 1H), 8.06 (s, 1H), 7.98 (ddd,J= 8.9, 6.9, 1.4 Hz, 2H), 7.89 (dt,J= 7.7, 1.5 Hz, 1H), 7.60 (t,J= 7.8 Hz, 1H), 7.38 (dd,J= 8.9, 7.0 Hz, 1H), 6.98 (dd,J= 7.0, 1.4 Hz, 1H), 6.33 (s, 1H), 3.04 (d,J= 4.9 Hz, 3H), 1.70 (d, J = 27.1 Hz, 10H).MS (ESI, LR) Calc. for C 21 H 23 N4O2[M+H] + : 363.2, found: 363.2.28 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.21 (t,J= 1.8 Hz, 1H), 8.06 (s, 1H), 8.02-7.93 (m, 2H), 7.87 (dt,J= 7.8, 1.5 Hz, 1H), 7.60 (t,J= 7.8 Hz, 1H), 7.39 (dd,J= 8.9, 7.0 Hz, 1H), 6.98 (dd,J= 6.9, 1.4 Hz, 1H), 6.01 (d,J= 7.7 Hz, 1H), 4.31 (dq,J= 13.4, 6.7 Hz, 1H), 3.72 (t,J= 5.4 Hz, 4H), 1.73-1.72 (m, 2H), 1.59 (s, 4H), 1.28 (d,J= 6.6 Hz, 6H).MS (ESI, LR) Calc. for C 23 H 27 N4O2[M+H] + : 391.2, found: 391.2.29 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.16 (t,J= 1.8 Hz, 1H), 8.06 (s, 1H), 8.02-7.93 (m, 2H), 7.77 (dt,J= 7.7, 1.5 Hz, 1H), 7.58 (t,J= 7.8 Hz, 1H), 7.38 (dd,J= 8.9, 7.0 Hz, 1H), 6.98 (dd,J= 7.0, 1.4 Hz, 1H), 4.40 (t,J= 7.8 Hz, 2H), 4.26 (t,J= 7.9 Hz, 2H), 3.72 (t,J= 5.4 Hz, 4H), 2.43-2.32 (m, 2H), 1.78-1.70 (m, 2H), 1.70-1.64 (m, 4H).MS (ESI, LR) Calc. for C 23 H 25 N4O2[M+H] + : 389.2, found: 389.2.30 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.06 (s, 1H), 8.03-7.96 (m, 2H), 7.91 (dt,J= 7.9, 1.5 Hz, 1H), 7.61 (t,J= 7.8 Hz, 1H), 7.39 (dd,J= 8.9, 7.0 Hz, 1H), 6.98 (dd,J= 7.0, 1.4 Hz, 1H), 6.64 (s, 1H), 3.72 (t,J= 5.4 Hz, 4H), 3.68 (t,J= 5.2 Hz, 2H), 3.58 (t,J= 5.0 Hz, 2H), 3.39 (s, 3H), 1.72 (t,J= 4.7 Hz, 2H), 1.67 (s, 4H).MS (ESI, LR) Calc. for C 23 H 27 N4O3[M+H] + : 407.2, found: 407.2.31 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (t,J= 1.8 Hz, 1H), 8.04 (s, 1H), 8.00 (dt,J= 7.8, 1.4 Hz, 1H), 7.98-7.88 (m, 2H), 7.59 (t,J= 7.8 Hz, 1H), 7.38 (dd,J= 8.9, 7.0 Hz, 1H), 6.99 (dd,J= 7.0, 1.4 Hz, 1H), 3.69 (t,J= 5.3 Hz, 4H), 3.60 (q,J= 5.5 Hz, 2H), 2.76 (t,J= 5.7 Hz, 2H), 2.45 (s, 6H), 1.80-1.57 (m, 6H).MS (ESI, LR) Calc. for C 24 H 30 N5O2[M+H] + : 420.2, found: 420.2.32 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (t,J= 1.9 Hz, 1H), 8.06 (s, 1H), 8.04-7.95 (m, 2H), 7.91 (dt,J= 8.0, 1.4 Hz, 1H), 7.61 (t,J= 7.8 Hz, 1H), 7.39 (dd,J= 8.9, 7.0 Hz, 1H), 6.99 (dd,J= 7.0, 1.4 Hz, 1H), 6.32 (s, 1H), 3.72 (t,J= 5.3 Hz, 4H), 3.34 (dd,J= 7.2, 5.4 Hz, 2H), 1.74-1.67 (m, 6H), 1.06 (dt,J= 7.7, 4.4 Hz, 1H), 0.62-0.50 (m, 2H), 0.31-0.26 (m,J= 5.0 Hz, 2H).MS (ESI, LR) Calc. for C 24 H 27 N4O2[M+H] + : 403.2, found: 403.2.33 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.44 (d,J= 7.5 Hz, 1H), 8.33 (d,J= 2.0 Hz, 1H), 8.25 (s, 1H), 8.07 (d,J= 7.7 Hz, 1H), 8.01 (d,J= 7.8 Hz, 1H), 7.92 (d,J= 8.9 Hz, 1H), 7.66 (t,J= 7.8 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.23 (d,J= 7.0 Hz, 1H), 3.91 (s, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.36-3.31 (m, 2H), 3.12 (d,J= 23.3 Hz, 2H), 2.46 (s, 3H), 1.98-1.85 (m, 2H), 1.77-1.61 (m, 4H), 1.58 (q,J= 5.7 Hz, 4H).MS (ESI, LR) Calc. for C 26 H 32 N5O2[M+H] +: 446.3, found: 446.2.35 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.03-7.92 (m, 3H), 7.66-7.52 (m, 2H), 7.43-7.34 (m, 1H), 7.28-7.26 (m, 1H), 6.98 (d,J= 7.0 Hz, 1H), 3.72 (t,J= 5.3 Hz, 6H), 3.51 (s, 6H), 1.73-1.67 (m, 6H), 1.48 (s, 9H).MS (ESI, LR) Calc. for C 29 H 36 N5O4[M+H] + : 518.3, found: 518.2.36 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.97 (t,J= 5.6 Hz, 1H), 8.37 (d,J= 1.8 Hz, 1H), 8.26 (s, 1H), 8.11 (d,J= 7.8 Hz, 1H), 8.02 (d,J= 7.8 Hz, 1H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.69 (t,J= 7.8 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.24 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.54 (q,J= 6.2 Hz, 2H), 2.81 (t,J= 6.5 Hz, 2H), 1.66 (d,J= 5.7 Hz, 2H), 1.57 (d,J= 6.8 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 24 N5O2[M+H] + : 402.2, found: 402.2.37 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.55 (s, 1H), 8.94 (d,J= 2.6 Hz, 1H), 8.51 (t,J= 1.7 Hz, 1H), 8.34 (dd,J= 4.7, 1.5 Hz, 1H), 8.27 (s, 1H), 8.24-8.09 (m, 3H), 7.93 (dd,J= 8.9, 1.3 Hz, 1H), 7.75 (t,J= 7.8 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.42 (dd,J= 8.3, 4.7 Hz, 1H), 7.30 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 6.4 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 25 H 24 N5O2[M+H] + : 426.2, found: 426.1.38 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.00 (s, 1H), 8.52 (d,J= 5.5 Hz, 2H), 8.39 (t,J= 1.8 Hz, 1H), 8.11-7.89 (m, 4H), 7.72-7.58 (m, 3H), 7.35 (dd,J= 8.9, 7.0 Hz, 1H), 6.96 (dd,J= 7.1, 1.4 Hz, 1H), 3.69 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.7 Hz, 6H).MS (ESI, LR) Calc. for C 25 H 24 N5O2[M+H] + : 426.2, found: 426.2. Example 34. Piperazin-1-yl(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone [piperazin-1-yl(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone] <Reaction Formula 4> Compound 35 (0.1 g, 0.19 mmol) was dissolved in dichloromethane (1 mL) and stirred at 0 °C for 10 minutes. 4 N hydrochloric acid dissolved in 1,4-dioxin (0.48 mL) was added and stirred at room temperature for 16 hours. After completion of the reaction, the reaction solution was concentrated and separated using column chromatography to obtain the target compound 34 (36 mg, 44%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (s, 1H), 8.07 (d,J= 1.7 Hz, 1H), 8.01 (dt,J= 7.5, 1.7 Hz, 1H), 7.91 (dd,J= 8.9, 1.4 Hz, 1H), 7.71-7.60 (m, 2H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.23 (dd,J= 7.0, 1.4 Hz, 1H), 3.76 (s, 4H), 3.62 (t,J= 5.5 Hz, 4H), 3.20 (t,J= 5.1 Hz, 4H), 1.66 (d,J= 5.2 Hz, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 24 H 28 N5O2[M+H] + : 418.2, found: 418.2. Example 39. (7-(5-(morpholine-4-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-(morpholine-4-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 5> Step 39-1 [Step 39-1]: Using compound 1-2 and methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-3-carboxylate, the target chemical compound 39-1 was obtained using the same synthetic method as step 1-3 in Example 1. Step 39-2 [Step 39-2]: The target compound 39 was obtained using the same synthetic method as Step 1-2 in Example 1 using compound 39-1 and morpholine. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.15 (d,J= 2.2 Hz, 1H), 8.77 (d,J= 2.0 Hz, 1H), 8.48 (t,J= 2.1 Hz, 1H), 8.27 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.1, 1.4 Hz, 1H), 3.67 (s, 4H), 3.63 (t,J= 5.4 Hz, 6H), 3.47 (s, 2H), 1.66 (d,J= 5.7 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H). MS (ESI, LR) Calc. for C 23 H 26 N5O3[M+H] + : 420.2, found: 420.2. Example 40. N-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide [N-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide] Example 41. Azetidin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone [azetidin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone] Example 42. (3-hydroxyazetidin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone [(3-hydroxyazetidin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone] Example 43. (7-(5-(2-azaspiro[3.3]heptane-2-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-(2-azaspiro[3.3]heptane-2-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 44. (3,3-difluoroazetidin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone [(3,3-difluoroazetidin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone] Example 45. N-(2-methoxyethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide [N-(2-methoxyethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide] Example 46. N-(cyclopropylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide [N-(cyclopropylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide] Example 47. N-(1-methylpiperidin-4-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide [N-(1-methylpiperidin-4-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide] Example 51. N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide [N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide] Example 52. N-(cyanomethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide [N-(cyanomethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide] Example 53. 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)nicotinamide [5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)nicotinamide] Example 54. 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)nicotinamide [5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)nicotinamide] Example 55. N-(isoxazol-3-ylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide [N-(isoxazol-3-ylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide] Example 56. 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridazin-4-yl)nicotinamide [5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridazin-4-yl)nicotinamide] Example 57. 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(thiazol-5-ylmethyl)nicotinamide [5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(thiazol-5-ylmethyl)nicotinamide] Example 192. (3-fluoroazetidin-1-yl)(5-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone [(3-fluoroazetidin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone] Example 193. N-(1-methyl-1H-pyrazol-3-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide [N-(1-methyl-1H-pyrazol-3-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide] Example 201. N-methylsulfonyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide [N-methylsulfonyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide] Example 203. 4-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carbonyl]piperazin-2-one [4-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carbonyl]piperazin-2-one] Example 204. 4-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carbonyl]piperazine-2,6-dione [4-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carbonyl]piperazine-2,6-dione] Example 225. (6-Hydroxy-2-azaspiro[3.3]heptan-2-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone [(6-hydroxy-2-azaspiro[3.3]heptan-2-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone] Example 226. 2-Oxa-7-azaspiro[3.5]nonan-7-yl-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone [2-oxa-7-azaspiro[3.5]nonan-7-yl-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone] For Examples 40, 41, 42, 43, 44, 45, 46, 47, 51, 52, 53, 54, 55, 56, 57, 192, 193, 201, 203, 204, 225, and 226, the compounds corresponding to compound 39-1 were obtained by the same synthetic method as steps 1-2 of Example 1. The structural and spectral data are shown in Table 4 below. Example structure 1H NMRMS40 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.15 (d,J= 2.2 Hz, 1H), 8.90 (d,J= 5.1 Hz, 1H), 8.58 (dd,J= 8.2, 2.2 Hz, 1H), 8.28 (s, 1H), 8.20 (d,J= 8.2 Hz, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.87 (d,J= 4.8 Hz, 3H), 1.65 (d,J= 6.1 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 22 N5O2[M+H] + : 364.2, found: 364.2.41 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.17 (d,J= 2.2 Hz, 1H), 8.92 (d,J= 2.1 Hz, 1H), 8.62 (t,J= 2.2 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.0, 1.4 Hz, 1H), 4.42 (t,J= 7.7 Hz, 2H), 4.11 (t,J= 7.8 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 2.30 (p,J= 7.7 Hz, 2H), 1.66 (q,J= 5.9 Hz, 2H), 1.57 (q,J= 5.7 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 24 N5O2[M+H] + : 390.2, found: 390.2.42 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.18 (d,J= 2.2 Hz, 1H), 8.92 (d,J= 2.0 Hz, 1H), 8.62 (t,J= 2.1 Hz, 1H), 8.27 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.0, 1.4 Hz, 1H), 5.82 (s, 1H), 4.57 (d,J= 8.4 Hz, 2H), 4.31 (dd,J= 10.1, 6.4 Hz, 1H), 4.21-4.11 (m, 1H), 3.85 (dd,J= 11.0, 3.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (q,J= 5.8 Hz, 2H), 1.58 (t,J= 6.8 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 24 N5O3[M+H] + : 406.2, found: 406.2.43 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.18 (d,J= 2.2 Hz, 1H), 8.92 (d,J= 2.1 Hz, 1H), 8.59 (t,J= 2.1 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 9.0, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.1, 1.4 Hz, 1H), 4.39 (s, 2H), 4.08 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 2.18 (t,J= 7.6 Hz, 4H), 1.78 (td,J= 7.9, 5.9 Hz, 2H), 1.71-1.61 (m, 2H), 1.58 (q,J= 5.7 Hz, 4H).MS (ESI, LR) Calc. for C 25 H 28 N5O2[M+H] + : 430.2, found: 430.2.44 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.23 (d,J= 2.1 Hz, 1H), 8.99 (d,J= 2.1 Hz, 1H), 8.67 (t,J= 2.2 Hz, 1H), 8.29 (s, 1H), 7.96 (dd,J= 8.9, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 4.93 (s, 2H), 4.56 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.8 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 22 F2N5O2[M+H] + : 426.2, found: 426.1.45 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.16 (d,J= 2.2 Hz, 1H), 8.82 (s, 1H), 8.60 (dd,J= 8.2, 2.2 Hz, 1H), 8.28 (s, 1H), 8.21 (d,J= 8.2 Hz, 1H), 7.96 (dd,J= 8.8, 1.4 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.52 (d,J= 2.7 Hz, 4H), 3.30 (s, 3H), 1.66 (d,J= 5.6 Hz, 2H), 1.57 (d,J= 6.6 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 26 N5O3[M+H] + : 408.2, found: 408.1.46 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.97 (d,J= 2.1 Hz, 1H), 8.88 (d,J= 2.1 Hz, 1H), 8.63 (t,J= 5.6 Hz, 1H), 8.51 (t,J= 2.2 Hz, 1H), 8.04 (s, 1H), 7.70 (dd,J= 8.9, 1.4 Hz, 1H), 7.32 (dd,J= 8.9, 7.0 Hz, 1H), 7.12 (dd,J= 7.1, 1.4 Hz, 1H), 3.38 (t,J= 5.4 Hz, 4H), 2.95 (t,J= 6.2 Hz, 2H), 1.40 (d,J= 5.5 Hz, 2H), 1.32 (s, 4H), 0.87-0.75 (m, 1H), 0.29 - 0.17 (m, 2H), 0.01 (dd,J= 4.8, 1.6 Hz, 2H).MS (ESI, LR) Calc. for C 23 H 26 N5O2[M+H] + : 404.2, found: 404.1.47 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.21 (d,J= 2.1 Hz, 1H), 9.11 (d,J= 2.1 Hz, 1H), 8.73 (t,J= 2.1 Hz, 1H), 8.56 (d,J= 7.6 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 9.0, 7.0 Hz, 1H), 7.36 (dd,J= 7.1, 1.3 Hz, 1H), 3.87-3.73 (m, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.79 (d,J= 11.0 Hz, 2H), 2.19 (d,J= 4.9 Hz, 3H), 2.06 - 1.93 (m, 2H), 1.88-1.77 (m, 2H), 1.65 (dd,J= 7.9, 4.3 Hz, 2H), 1.57 (q,J= 7.6 Hz, 6H).MS (ESI, LR) Calc. for C 25 H 31N6O2[M+H] + : 447.2, found: 447.2.51 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.25 (d,J= 2.2 Hz, 1H), 9.22-9.12 (m, 2H), 8.78 (t,J= 2.1 Hz, 1H), 8.29 (s, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.0, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.57 (q,J= 6.3 Hz, 2H), 2.82 (t,J= 6.5 Hz, 2H), 1.66 (d,J= 5.3 Hz, 2H), 1.57 (d,J= 7.6 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 23 N6O2[M+H] + : 403.2, found: 403.1.52 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.55 (s, 1H), 9.28 (d,J= 2.1 Hz, 1H), 9.14 (d,J= 2.1 Hz, 1H), 8.82 (t,J= 2.2 Hz, 1H), 8.29 (s, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.39 (dd,J= 7.1, 1.4 Hz, 1H), 4.41 (d,J= 4.3 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.7 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 21 N6O2[M+H] + : 389.2, found: 389.1.53 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.73 (s, 1H), 9.32 (d,J= 2.1 Hz, 1H), 9.26 (d,J= 2.1 Hz, 1H), 8.95 (d,J= 2.5 Hz, 1H), 8.90 (t,J= 2.2 Hz, 1H), 8.36 (dd,J= 4.7, 1.5 Hz, 1H), 8.30 (s, 1H), 8.21 (dt,J= 8.4, 1.9 Hz, 1H), 7.97 (dd,J= 8.9, 1.3 Hz, 1H), 7.59 (dd,J= 8.9, 7.0 Hz, 1H), 7.48-7.39 (m, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 4.9 Hz, 2H), 1.58 (q, J = 5.8 Hz, 4H).MS (ESI, LR) Calc. for C 24 H 23 N6O2[M+H] + : 427.2, found: 427.1.54 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.17 (s, 1H), 9.15 (d,J= 2.1 Hz, 1H), 8.64 - 8.57 (m, 2H), 8.53 (dd,J= 8.2, 2.1 Hz, 1H), 8.46 (d,J= 8.2 Hz, 1H), 8.12-8.05 (m, 2H), 7.77-7.71 (m, 2H), 7.43 (dd,J= 9.0, 7.0 Hz, 1H), 7.07 (dd,J= 7.0, 1.4 Hz, 1H), 3.73 (t,J= 5.3 Hz, 4H), 1.79-1.72 (m, 2H), 1.69 (s, 4H).MS (ESI, LR) Calc. for C 24 H 23 N6O2[M+H] + : 427.2, found: 427.1.55 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.41 (t,J= 5.9 Hz, 1H), 9.26 (d,J= 2.1 Hz, 1H), 9.16 (d,J= 2.1 Hz, 1H), 8.87 (d,J= 1.7 Hz, 1H), 8.80 (t,J= 2.1 Hz, 1H), 8.29 (s, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 6.62-6.55 (m, 1H), 4.62 (d,J= 5.8 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.6 Hz, 2H), 1.58 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 23 N6O3[M+H] + : 431.2, found: 431.1.56 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.10 (s, 1H), 9.52 (d,J= 2.7 Hz, 1H), 9.35 (d,J= 2.1 Hz, 1H), 9.27 (d,J= 2.1 Hz, 1H), 9.14 (d,J= 5.9 Hz, 1H), 8.91 (t,J= 2.1 Hz, 1H), 8.30 (s, 1H), 8.12 (dd,J= 5.9, 2.7 Hz, 1H), 7.98 (dd,J= 8.9, 1.3 Hz, 1H), 7.59 (dd,J= 8.9, 7.0 Hz, 1H), 7.42 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.73-1.63 (m, 2H), 1.58 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 22 N7O2[M+H] + : 428.2, found: 428.1.57 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.49 (t,J= 5.7 Hz, 1H), 9.24 (d,J= 2.1 Hz, 1H), 9.14 (d,J= 2.1 Hz, 1H), 9.00 (s, 1H), 8.78 (t,J= 2.2 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.87 (s, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.1, 1.4 Hz, 1H), 4.75 (d,J= 5.7 Hz, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.71-1.61 (m, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 23 H 23 N6O2S [M+H] + : 447.2, found: 447.1.192 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.20 (d,J= 2.2 Hz, 1H), 8.95 (d,J= 2.1 Hz, 1H), 8.64 (t,J= 2.1 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.4 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.0, 1.4 Hz, 1H), 5.48 (ddt,J= 57.6, 6.1, 2.9 Hz, 1H), 4.72-4.42 (m, 3H), 4.16 (dd,J= 24.6, 11.8 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.57 (d,J= 7.7 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 23 FN5O2[M+H] + : 408.1, found: 408.1.193 1H NMR (400 MHz, DMSO-d6) δ(ppm): 11.22 (s, 1H), 9.31 (d,J= 2.1 Hz, 1H), 9.22 (d,J= 2.1 Hz, 1H), 8.92 (t,J= 2.2 Hz, 1H), 8.29 (s, 1H), 7.96 (dd,J= 9.0, 1.4 Hz, 1H), 7.65 (d,J= 2.2 Hz, 1H), 7.58 (dd,J= 8.9, 7.0 Hz, 1H), 7.42 (dd,J= 7.1, 1.3 Hz, 1H), 6.64 (d,J= 2.2 Hz, 1H), 3.80 (s, 3H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 6.9 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 24 N7O2[M+H] + : 430.1, found: 430.1.201 1H NMR (400 MHz, DMSO-d6) δ(ppm): 12.49 (s, 1H), 9.36 (d,J= 2.1 Hz, 1H), 9.18 (d,J= 2.1 Hz, 1H), 8.88 (t,J= 2.1 Hz, 1H), 8.30 (s, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.58 (dd,J= 8.9, 7.0 Hz, 1H), 7.40 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.41 (s, 3H), 1.70-1.62 (m, 2H), 1.57 (t,J= 6.1 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 22 N5O4S[M+H] + : 428.1, found: 428.1.203 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.11 (d,J= 2.2 Hz, 1H), 8.84 (d,J= 2.1 Hz, 1H), 8.52 (t,J= 2.1 Hz, 1H), 8.11-7.98 (m, 2H), 7.41 (dd,J= 9.0, 7.0 Hz, 1H), 7.06 (dd,J= 7.0, 1.4 Hz, 1H), 6.34 (s, 1H), 4.38 (s, 2H), 3.90 (s, 2H), 3.72 (t,J= 5.3 Hz, 4H), 3.54 (s, 2H), 1.74 (s, 2H), 1.67 (d,J= 6.5 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 25 N6O3[M+H] + : 433.2, found: 433.2.204 1H NMR (400 MHz, DMSO-d6) δ(ppm): 11.48 (s, 1H), 9.19 (d,J= 2.1 Hz, 1H), 8.82 (d,J= 2.1 Hz, 1H), 8.54 (t,J= 2.1 Hz, 1H), 8.26 (s, 1H), 7.95 (dd,J= 8.9, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 4.41 (s, 4H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 6.5 Hz, 2H), 1.57 (d,J= 7.3 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 23 N6O4[M+H] + : 447.2, found: 447.1.225 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.18 (t,J= 1.6 Hz, 1H), 8.91 (t,J= 1.8 Hz, 1H), 8.58 (q,J= 2.2 Hz, 1H), 8.28 (s, 1H), 7.94 (dd,J= 9.0, 1.4 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.35 (dd,J= 7.0, 1.4 Hz, 1H), 5.04 (d,J= 6.0 Hz, 1H), 4.36 (d,J= 17.6 Hz, 2H), 4.06 (d,J= 21.1 Hz, 2H), 3.96 (dq,J= 20.5, 6.8 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.47 (td,J= 6.7, 3.4 Hz, 2H), 1.99 (s, 2H), 1.66 (d,J= 5.7 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 25 H 28 N5O3[M+H] + : 446.2, found: 446.1.226 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.14 (d,J= 2.2 Hz, 1H), 8.73 (d,J= 2.0 Hz, 1H), 8.44 (t,J= 2.1 Hz, 1H), 8.27 (s, 1H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.1, 1.4 Hz, 1H), 4.35 (d,J= 5.7 Hz, 4H), 3.73-3.51 (m, 6H), 3.36 (s, 2H), 1.86 (s, 4H), 1.65 (d,J= 6.3 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 26 H 30 N5O3[M+H] + : 460.2, found: 460.1. Example 48. Piperazin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone [piperazin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone] Example 200. N-(azetidin-3-yl)-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]nicotinamide The target compound was obtained by sequentially using the same synthetic method as steps 1-2 of Example 1 and the synthetic method of Example 34 using compound 39-1 and the corresponding compound. The structural and spectral data are shown in Table 5 below. Example structure 1 H NMRMS48 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.17 (d,J= 2.1 Hz, 1H), 8.81 (d,J= 2.0 Hz, 1H), 8.54 (t,J= 2.1 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.1, 1.3 Hz, 1H), 3.63 (t,J= 5.5 Hz, 8H), 3.20 (t,J= 5.3 Hz, 4H), 1.66 (q,J= 5.9 Hz, 2H), 1.57 (q,J= 5.8 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 28 N6O2[M+H] + : 419.2, found: 419.1.200 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.61 (d,J= 6.6 Hz, 1H), 9.27 (d,J= 2.1 Hz, 1H), 9.19 (d,J= 2.1 Hz, 1H), 9.05 (s, 2H), 8.82 (t,J= 2.1 Hz, 1H), 8.29 (s, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.39 (dd,J= 7.0, 1.4 Hz, 1H), 4.88 (h,J= 7.6 Hz, 1H), 4.26-4.09 (m, 4H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 6.8 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 25 N6O2[M+H] + : 405.2, found: 405.1. Example 49. (4-methylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone [(4-methylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone] <Reaction Formula 6> Compound 48 (50 mg, 0.12 mmol) was dissolved in ethyl alcohol (0.6 mL) and water (0.6 mL), 37% formaldehyde (17.8 μL, 0.24 mmol) was added, and the mixture was stirred at 60 °C for 1 hour. Sodium cyanoborohydride (15 mg, 0.24 mmol) and acetic acid (6.8 μL, 0.12 mmol) were added to the reaction solution, and the mixture was stirred at 60 °C for 12 hours. The reaction solution was concentrated and separated using column chromatography to obtain the target compound 49 (30 mg, 57%). 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.14 (d,J= 2.1 Hz, 1H), 8.74 (d,J= 2.0 Hz, 1H), 8.45 (t,J= 2.1 Hz, 1H), 8.27 (s, 1H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.0, 1.4 Hz, 1H), 3.64 (q,J= 8.5 Hz, 6H), 3.44 (s, 2H), 2.37 (d,J= 19.9 Hz, 4H), 2.21 (s, 3H), 1.65 (d,J= 5.5 Hz, 2H), 1.57 (d,J= 7.2 Hz, 4H). MS (ESI, LR) Calc. for C 24 H 29 N6O2[M+H] + : 433.2, found: 433.1. Example 202. N-(1-methylazetidin-3-yl)-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide [N-(1-methylazetidin-3-yl)-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide] Compound 200 and the corresponding compound were used to obtain the target compound 202 using the same synthetic method as Example 49. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.68-9.54 (m, 1H), 9.26 (t,J= 2.4 Hz, 1H), 9.18 (d,J= 5.6 Hz, 1H), 8.81 (t,J= 2.0 Hz, 1H), 7.98-7.93 (m, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.38 (dd,J= 7.1, 2.9 Hz, 1H), 4.49 (s, 1H), 4.16 (dt,J= 18.1, 8.5 Hz, 2H), 3.62 (t,J= 5.4 Hz, 4H), 2.89 (d,J= 5.5 Hz, 4H), 2.73 (s, 1H), 1.65 (q,J= 5.6 Hz, 2H), 1.60-1.51 (m, 4H). MS (ESI, LR) Calc. for C 23 H 27 N6O2[M+H] + : 419.1, found: 419.1. Example 50. (4-isopropylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone [(4-isopropylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone] The target compound 50 was obtained using the synthetic method used in Example 49 using compound 48 and acetone. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.14 (d,J= 2.2 Hz, 1H), 8.75 (d,J= 2.1 Hz, 1H), 8.45 (t,J= 2.1 Hz, 1H), 8.27 (s, 1H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.36 (dd,J= 7.0, 1.3 Hz, 1H), 3.63 (t,J= 5.5 Hz, 6H), 3.42 (s, 2H), 2.70 (p,J= 6.5 Hz, 1H), 2.49 (d,J= 12.9 Hz, 4H), 1.65 (d,J= 5.1 Hz, 2H), 1.57 (s, 4H), 0.98 (d,J= 6.5 Hz, 6H). MS (ESI, LR) Calc. for C 26 H 33 N6O2[M+H] + : 461.3, found: 461.2. Example 58. N-methyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-methyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 59. N,N-dimethyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N,N-dimethyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 60. N-isopropyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-isopropyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 61. Azetidin-1-yl(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone [azetidin-1-yl(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone] Example 62. N-(2-methoxyethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(2-methoxyethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 63. N-(2-(dimethylamino)ethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(2-(dimethylamino)ethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 64. N-(cyclopropylmethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(cyclopropylmethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 65. N-(1-methylpiperidin-4-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(1-methylpiperidin-4-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 69. N-(2-cyanoethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(2-cyanoethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 70. N-(cyanomethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(cyanomethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] Example 71. 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)benzamide [4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)benzamide] Example 72. 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)benzamide [4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)benzamide] Example 73. N-(isoxazol-3-ylmethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide [N-(isoxazol-3-ylmethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide] For Examples 58, 59, 60, 61, 62, 63, 64, 65, 69, 70, 71, 72, and 73, the compounds corresponding to compound 10 were obtained using the same synthetic method as steps 1-2 of Example 1. The structural and spectral data are shown in Table 6 below. Example structure 1 H NMRMS58 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.59 (d,J= 4.8 Hz, 1H), 8.25 (s, 1H), 8.01 (q,J= 8.6 Hz, 4H), 7.91 (dd,J= 8.9, 1.4 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.24 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.84 (d,J= 4.5 Hz, 3H), 1.71-1.61 (m, 2H), 1.57 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 23 N4O2[M+H] + : 363.2, found: 363.2.59 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (s, 1H), 8.04-7.97 (m, 2H), 7.90 (dd,J= 8.9, 1.3 Hz, 1H), 7.62-7.56 (m, 2H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.23 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.01 (d,J= 17.6 Hz, 6H), 1.65 (d,J= 5.5 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 25 N4O2[M+H] + : 377.2, found: 377.3.60 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.05 (s, 1H), 7.99 (dd,J= 8.9, 1.4 Hz, 1H), 7.96 - 7.86 (m, 4H), 7.38 (dd,J= 8.9, 7.0 Hz, 1H), 6.97 (dd,J= 7.0, 1.4 Hz, 1H), 5.98 (d,J= 7.8 Hz, 1H), 4.32 (dq,J= 13.4, 6.7 Hz, 1H), 3.72 (t,J= 5.3 Hz, 4H), 1.73-1.65 (m, 6H), 1.29 (d,J= 6.5 Hz, 6H).MS (ESI, LR) Calc. for C 23 H 27 N4O2[M+H] + : 391.2, found: 391.2.61 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (s, 1H), 8.06-7.98 (m, 2H), 7.91 (dd,J= 8.9, 1.4 Hz, 1H), 7.84-7.74 (m, 2H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.23 (dd,J= 7.1, 1.4 Hz, 1H), 4.38 (t,J= 7.7 Hz, 2H), 4.10 (t,J= 7.8 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 2.30 (p,J= 7.7 Hz, 2H), 1.72-1.61 (m, 2H), 1.57 (q,J= 6.0 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 25 N4O2[M+H] + : 389.2, found: 389.2.62 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.68 (d,J= 6.3 Hz, 1H), 8.25 (s, 1H), 8.09-7.97 (m, 4H), 7.91 (dd,J= 8.9, 1.4 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.24 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.57-3.44 (m, 4H), 3.30 (s, 3H), 1.65 (d,J= 5.4 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 27 N4O3[M+H] + : 407.2, found: 407.2.63 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.53 (s, 1H), 8.25 (s, 1H), 8.01 (q,J= 8.6 Hz, 4H), 7.91 (dd,J= 8.9, 1.3 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.23 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.5 Hz, 4H), 3.40 (q,J= 6.5 Hz, 2H), 2.44 (t,J= 6.9 Hz, 2H), 2.20 (s, 6H), 1.65 (d,J= 6.5 Hz, 2H), 1.57 (d,J= 6.9 Hz, 4H).MS (ESI, LR) Calc. for C 24 H 30 N5O2[M+H] + : 420.2, found: 420.2.64 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.06 (s, 1H), 7.99 (dd,J= 8.9, 1.4 Hz, 1H), 7.94 (s, 4H), 7.39 (dd,J= 8.9, 7.0 Hz, 1H), 6.98 (dd,J= 7.0, 1.4 Hz, 1H), 6.27 (s, 1H), 3.72 (t,J= 5.4 Hz, 4H), 3.36 (dd,J= 7.2, 5.3 Hz, 2H), 1.73-1.66 (m, 6H), 1.09 (ddd,J= 12.6, 7.8, 4.9 Hz, 1H), 0.63-0.53 (m, 2H), 0.35-0.24 (m, 2H).MS (ESI, LR) Calc. for C 24 H 27 N4O2[M+H] + : 403.2, found: 403.2.65 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.38 (d,J= 7.7 Hz, 1H), 8.25 (s, 1H), 8.06-7.96 (m, 4H), 7.91 (dd,J= 8.9, 1.3 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.22 (dd,J= 7.2, 1.4 Hz, 1H), 3.83-3.71 (m, 1H), 3.62 (t,J= 5.4 Hz, 4H), 2.79 (d,J= 11.0 Hz, 2H), 2.18 (s, 3H), 1.96 (dd,J= 12.8, 10.3 Hz, 2H), 1.79 (d,J= 12.3 Hz, 2H), 1.70 - 1.53 (m, 8H).MS (ESI, LR) Calc. for C 26 H 32 N5O2[M+H] + : 446.3, found: 446.2.69 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.00 (t,J= 5.7 Hz, 1H), 8.25 (s, 1H), 8.07 (d,J= 8.3 Hz, 2H), 8.02 (d,J= 8.5 Hz, 2H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.54 (dd,J= 8.9, 7.1 Hz, 1H), 7.25 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.55 (q,J= 6.3 Hz, 2H), 2.83 (t,J= 6.5 Hz, 2H), 1.65 (d,J= 8.1 Hz, 2H), 1.57 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 24 N5O2[M+H] + : 402.2, found: 402.1.70 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.36 (t,J= 5.4 Hz, 1H), 8.25 (s, 1H), 8.08 (d,J= 8.5 Hz, 2H), 8.03 (d,J= 8.3 Hz, 2H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.53 (dd, J = 8.9, 7.1 Hz, 1H), 7.25 (dd,J= 7.1, 1.4 Hz, 1H), 4.37 (d,J= 5.4 Hz, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.3 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 22 N5O2[M+H] + : 388.2, found: 388.1.71 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.61 (s, 1H), 8.98 (d,J= 2.5 Hz, 1H), 8.35 (dd,J= 4.7, 1.5 Hz, 1H), 8.30-8.21 (m, 2H), 8.19-8.06 (m, 4H), 7.93 (dd,J= 8.9, 1.4 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.43 (dd,J= 8.3, 4.7 Hz, 1H), 7.28 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 6.6 Hz, 2H), 1.58 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 25 H 24 N5O2[M+H] + : 426.2, found: 426.1.72 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.75 (s, 1H), 8.57-8.48 (m, 2H), 8.27 (s, 1H), 8.13 (s, 4H), 7.93 (dd,J= 8.9, 1.3 Hz, 1H), 7.88-7.79 (m, 2H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.28 (dd,J= 7.1, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.8 Hz, 2H), 1.62-1.49 (m, 4H).MS (ESI, LR) Calc. for C 25 H 24 N5O2[M+H] + : 426.2, found: 426.2.73 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.26 (t,J= 5.8 Hz, 1H), 8.87 (d,J= 1.7 Hz, 1H), 8.25 (s, 1H), 8.05 (s, 4H), 7.91 (dd,J= 8.8, 1.4 Hz, 1H), 7.53 (dd,J= 8.9, 7.1 Hz, 1H), 7.24 (dd,J= 7.1, 1.4 Hz, 1H), 6.55 (d,J= 1.7 Hz, 1H), 4.61 (d,J= 5.9 Hz, 2H), 3.63 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 24 H 24 N5O3[M+H] + : 430.2, found: 430.2. Example 66. Piperazin-1-yl(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone [piperazin-1-yl(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone] Compound 10 and 1-Boc-piperazine were used in the same manner as steps 1-2 of Example 1 and the method of synthesizing Example 34, respectively, to obtain the target compound 66. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (s, 1H), 8.03 (d,J= 8.1 Hz, 2H), 7.90 (dd,J= 8.9, 1.3 Hz, 1H), 7.65 (d,J= 8.3 Hz, 2H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.22 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 8H), 3.18 (s, 4H), 1.66 (d,J= 5.8 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H). MS (ESI, LR) Calc. for C 24 H 28 N5O2[M+H] + : 418.2, found: 418.1. Example 67. (4-methylpiperazin-1-yl)(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone [(4-methylpiperazin-1-yl)(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone] Example 68. (4-isopropylpiperazin-1-yl)(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone [(4-isopropylpiperazin-1-yl)(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone] For Examples 67 and 68, compounds corresponding to compound 66 were obtained by the synthetic method used in Example 49. The structural and spectral data are shown in Table 7 below. Example structure 1 H NMRMS67 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (s, 1H), 8.06-7.96 (m, 2H), 7.90 (dd,J= 8.9, 1.3 Hz, 1H), 7.63-7.48 (m, 3H), 7.22 (dd,J= 7.0, 1.3 Hz, 1H), 3.62 (t,J= 5.3 Hz, 8H), 2.36 (d,J= 19.6 Hz, 4H), 2.22 (s, 3H), 1.70-1.62 (m, 2H), 1.57 (d,J= 6.9 Hz, 4H).MS (ESI, LR) Calc. for C 25 H 30 N5O2[M+H] + : 432.2, found: 432.1.68 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (s, 1H), 8.05-7.96 (m, 2H), 7.90 (dd,J= 8.9, 1.3 Hz, 1H), 7.54 (dd,J= 16.2, 8.6 Hz, 3H), 7.22 (dd,J= 7.1, 1.4 Hz, 1H), 3.74-3.54 (m, 6H), 3.41 (s, 2H), 2.70 (p,J= 6.5 Hz, 1H), 2.51-2.35 (m, 4H), 1.65 (d,J= 5.8 Hz, 2H), 1.57 (d,J= 7.2 Hz, 4H), 0.99 (d,J= 6.5 Hz, 6H).MS (ESI, LR) Calc. for C 27 H 34 N5O2[M+H] + : 460.3, found: 460.2. Example 74. (7-(6-(morpholine-4-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(morpholine-4-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 7> The target compound 74 was obtained using the synthetic method used in Example 39 using compound 1-2 and methyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine-2-carboxylate. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.15 (d,J= 2.1 Hz, 1H), 8.77 (d,J= 2.0 Hz, 1H), 8.48 (t,J= 2.1 Hz, 1H), 8.27 (s, 1H), 7.95 (dd,J= 9.0, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.0, 1.4 Hz, 1H), 3.64 (q,J= 9.3 Hz, 10H), 3.46 (s, 2H), 1.72-1.61 (m, 2H), 1.58 (t,J= 6.5 Hz, 4H). MS (ESI, LR) Calc. for C 23 H 26 N5O3[M+H] + : 420.2, found: 420.1. Example 75. N-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide [N-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide] Example 76. N-isopropyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide [N-isopropyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide] Example 77. Azetidin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone [azetidin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone] Example 78. N-(2-methoxyethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide [N-(2-methoxyethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide] Example 79. N-(2-(dimethylamino)ethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide Example 80. N-(cyclopropylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide [N-(cyclopropylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide] Example 81. N-(1-methylpiperidin-4-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide [N-(1-methylpiperidin-4-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide] Example 85. N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide [N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide] Example 86. N-(cyanomethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide [N-(cyanomethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide] Example 87. 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)picolinamide [5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)picolinamide] Example 88. 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)picolinamide [5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)picolinamide] Example 89. N-(isoxazol-3-ylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide [N-(isoxazol-3-ylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide] Example 213. (3-Fluoroazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone [(3-fluoroazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone] Example 214. 2-Azaspiro[3,3]heptan-2-yl-[5-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone [2-azaspiro[3.3]heptan-2-yl-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone] Example 237. (3,3-difluoroazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone [(3,3-difluoroazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone] For Examples 75, 76, 77, 78, 79, 80, 81, 85, 86, 87, 88, 89, 213, 214, and 237, the compounds corresponding to compound 74-1 were obtained by the same synthetic method as steps 1-2 of Example 1. The structural and spectral data are shown in Table 8 below. Example structure 1 H NMRMS75 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.22 (d,J= 2.1 Hz, 1H), 9.10 (d,J= 2.1 Hz, 1H), 8.81-8.70 (m, 2H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.1, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.85 (d,J= 4.5 Hz, 3H), 1.65 (d,J= 6.2 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 20 H 22 N5O2[M+H] + : 364.2, found: 364.2.76 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.20 (d,J= 2.1 Hz, 1H), 9.11 (d,J= 2.1 Hz, 1H), 8.73 (t,J= 2.1 Hz, 1H), 8.53 (d,J= 7.6 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.0, 1.3 Hz, 1H), 4.14 (dq,J= 13.4, 6.6 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 6.5 Hz, 2H), 1.57 (s, 4H), 1.20 (d,J= 6.6 Hz, 6H).MS (ESI, LR) Calc. for C 22 H 26 N5O2[M+H] + : 392.2, found: 392.2.77 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.17 (d,J= 2.2 Hz, 1H), 8.92 (d,J= 2.1 Hz, 1H), 8.62 (t,J= 2.1 Hz, 1H), 8.27 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.36 (dd,J= 7.1, 1.4 Hz, 1H), 4.42 (t,J= 7.7 Hz, 2H), 4.11 (t,J= 7.8 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 2.30 (p,J= 7.6 Hz, 2H), 1.65 (d,J= 5.4 Hz, 2H), 1.57 (d,J= 6.4 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 24 N5O2[M+H] + : 390.2, found: 390.1.78 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.22 (d,J= 2.1 Hz, 1H), 9.12 (d,J= 2.1 Hz, 1H), 8.86 (s, 1H), 8.76 (t,J= 2.2 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.1 Hz, 1H), 7.36 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.49 (q,J= 2.8 Hz, 4H), 3.29 (s, 3H), 1.71-1.61 (m, 2H), 1.57 (d,J= 7.3 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 26 N5O3[M+H] + : 408.2, found: 408.2.79 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.22 (d,J= 2.1 Hz, 1H), 9.11 (d,J= 2.1 Hz, 1H), 8.79-8.67 (m, 2H), 8.29 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.1, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.41 (q,J= 6.5 Hz, 2H), 2.43 (t,J= 6.8 Hz, 2H), 2.19 (s, 6H), 1.66 (d,J= 6.4 Hz, 2H), 1.57 (d,J= 6.6 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 29 N6O2[M+H] + : 421.2, found: 421.2.80 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.22 (d,J= 2.1 Hz, 1H), 9.13 (d,J= 2.1 Hz, 1H), 8.88 (t,J= 5.6 Hz, 1H), 8.77 (t,J= 2.1 Hz, 1H), 8.29 (s, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.20 (t,J= 6.2 Hz, 2H), 1.66 (d,J= 5.4 Hz, 2H), 1.58 (d,J= 4.4 Hz, 4H), 1.12 - 1.00 (m, 1H), 0.51-0.42 (m, 2H), 0.30-0.21 (m, 2H).MS (ESI, LR) Calc. for C 23 H 26 N5O2[M+H] + : 404.2, found: 404.2.81 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.20 - 9.12 (m, 1H), 8.66 (d,J= 8.4 Hz, 1H), 8.58 (dd,J= 8.2, 2.2 Hz, 1H), 8.27 (s, 1H), 8.23-8.14 (m, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 7.0, 1.4 Hz, 1H), 3.80 (dd,J= 9.4, 4.9 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.76 (d,J= 11.2 Hz, 2H), 2.18 (s, 3H), 1.99 (t,J= 11.0 Hz, 2H), 1.74 (dt,J= 14.0, 10.0 Hz, 4H), 1.65 (d,J= 6.1 Hz, 2H), 1.62 - 1.51 (m, 4H).MS (ESI, LR) Calc. for C 25 H 31N6O2[M+H] + : 447.2, found: 447.3.85 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.25 (d,J= 2.1 Hz, 1H), 9.17 (t,J= 5.6 Hz, 1H), 9.14 (d,J= 2.1 Hz, 1H), 8.78 (t,J= 2.1 Hz, 1H), 8.29 (s, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.57 (q,J= 6.2 Hz, 2H), 2.82 (t,J= 6.5 Hz, 2H), 1.66 (d,J= 5.5 Hz, 2H), 1.62-1.52 (m, 4H).MS (ESI, LR) Calc. for C 22 H 23 N6O2[M+H] + : 403.2, found: 403.2.86 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.54 (s, 1H), 9.28 (d,J= 2.1 Hz, 1H), 9.14 (d,J= 2.1 Hz, 1H), 8.81 (t,J= 2.1 Hz, 1H), 8.29 (s, 1H), 7.96 (dd,J= 9.0, 1.4 Hz, 1H), 7.57 (dd,J= 8.9, 7.1 Hz, 1H), 7.38 (dd,J= 7.0, 1.4 Hz, 1H), 4.41 (d,J= 4.6 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.7 Hz, 2H), 1.57 (d,J= 6.8 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 21 N6O2[M+H] + : 389.2, found: 389.1.87 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.74 (s, 1H), 9.29 (dd,J= 22.2, 2.1 Hz, 2H), 8.99-8.87 (m, 2H), 8.37 (dd,J= 4.7, 1.5 Hz, 1H), 8.30 (s, 1H), 8.22 (dt,J= 8.5, 2.0 Hz, 1H), 7.97 (dd,J= 8.9, 1.3 Hz, 1H), 7.59 (dd,J= 8.9, 7.0 Hz, 1H), 7.44 (td,J= 8.1, 3.0 Hz, 2H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 7.1 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 24 H 23 N6O2[M+H] + : 427.2, found: 427.1.88 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.86 (s, 1H), 9.32 (d,J= 2.1 Hz, 1H), 9.24 (d,J= 2.1 Hz, 1H), 8.88 (t,J= 2.2 Hz, 1H), 8.58 - 8.48 (m, 2H), 8.30 (s, 1H), 7.97 (dd,J= 8.9, 1.4 Hz, 1H), 7.84-7.74 (m, 2H), 7.58 (dd,J= 8.9, 7.0 Hz, 1H), 7.42 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 6.0 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 24 H 23 N6O2[M+H] + : 427.2, found: 427.1.89 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.42 (t,J= 5.9 Hz, 1H), 9.26 (d,J= 2.1 Hz, 1H), 9.16 (d,J= 2.1 Hz, 1H), 8.87 (d,J= 1.7 Hz, 1H), 8.80 (t,J= 2.1 Hz, 1H), 8.29 (s, 1H), 7.95 (dd,J= 8.9, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 6.58 (d,J= 1.7 Hz, 1H), 4.62 (d,J= 5.8 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.8 Hz, 2H), 1.56 (t,J= 5.8 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 23 N6O3[M+H] + : 431.2, found: 431.1.213 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.18 (t,J= 1.6 Hz, 1H), 8.91 (t,J= 1.8 Hz, 1H), 8.58 (q,J= 2.2 Hz, 1H), 8.28 (s, 1H), 7.94 (dd,J= 9.0, 1.4 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.35 (dd,J= 7.0, 1.4 Hz, 1H), 5.04 (d,J= 6.0 Hz, 1H), 4.36 (d,J= 17.6 Hz, 2H), 4.06 (d,J= 21.1 Hz, 2H), 3.96 (dq,J= 20.5, 6.8 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.47 (td,J= 6.7, 3.4 Hz, 2H), 1.99 (s, 2H), 1.66 (d,J= 5.7 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 23 FN5O2[M+H]+ : 408.2, found: 408.1.214 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.14 (d,J= 2.2 Hz, 1H), 8.54 (dd,J= 8.2, 2.3 Hz, 1H), 8.27 (s, 1H), 8.11 (d,J= 8.2 Hz, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.35 (dd,J= 7.0, 1.4 Hz, 1H), 4.62 (s, 2H), 4.09 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 2.19 (t,J= 7.6 Hz, 4H), 1.86-1.75 (m, 2H), 1.66 (t,J= 5.7 Hz, 2H), 1.57 (d,J= 6.3 Hz, 4H).MS (ESI, LR) Calc. for C 25 H 28 N5O2[M+H] + : 430.2, found: 430.2.237 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.19 (d,J= 2.2 Hz, 1H), 8.59 (dd,J= 8.2, 2.2 Hz, 1H), 8.28 (s, 1H), 8.20 (d,J= 8.3 Hz, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.66-7.62 (m, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 5.09 (t,J= 12.5 Hz, 2H), 4.57 (t,J= 12.5 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.8 Hz, 2H), 1.57 (d,J= 7.6 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 22 F2N5O2[M+H] + : 426.2, found: 426.1. Example 82. Piperazin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone [piperazin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone] Compound 74-1 and 1-Boc-piperazine were used in the same manner as steps 1-2 of Example 1 and the method of synthesizing Example 34, respectively, to obtain the target compound 82. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.13 (d,J= 2.1 Hz, 1H), 9.02 (s, 2H), 8.56 (dd,J= 8.1, 2.2 Hz, 1H), 8.27 (s, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.87 (d,J= 8.2 Hz, 1H), 7.57 (dd,J= 8.9, 7.1 Hz, 1H), 7.35 (dd,J= 7.1, 1.4 Hz, 1H), 3.91 (d,J= 5.6 Hz, 2H), 3.78 (d,J= 6.2 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 3.21 (d,J= 6.3 Hz, 2H), 3.18-3.08 (m, 2H), 1.66 (q,J= 5.6 Hz, 2H), 1.58 (q,J= 5.5 Hz, 4H). MS (ESI, LR) Calc. for C 23 H 27 N6O2[M+H] + : 419.2, found: 419.1. Example 83. (4-methylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone [(4-methylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone] Example 84. (4-isopropylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone [(4-isopropylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone] For Examples 83 and 84, compounds corresponding to compound 74-1 were obtained by the synthetic method used in Example 49. The structural and spectral data are shown in Table 9 below. Example structure 1 H NMRMS83 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.10 (dd,J= 2.3, 0.9 Hz, 1H), 8.52 (dd,J= 8.2, 2.2 Hz, 1H), 8.27 (s, 1H), 7.94 (dd,J= 8.9, 1.4 Hz, 1H), 7.76 (dd,J= 8.2, 0.9 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.35 (dd,J= 7.0, 1.4 Hz, 1H), 3.69 (t,J= 5.1 Hz, 2H), 3.63 (t,J= 5.5 Hz, 4H), 3.47 (t,J= 4.9 Hz, 2H), 2.42 (t,J= 5.1 Hz, 2H), 2.33 (t,J= 5.0 Hz, 2H), 1.66 (q,J= 6.2 Hz, 2H), 1.57 (p,J= 5.3 Hz, 4H).MS (ESI, LR) Calc. for C 24 H 29N6O2[M+H] + : 433.2, found: 433.1.84 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.10 (dd,J= 2.2, 0.9 Hz, 1H), 8.52 (dd,J= 8.2, 2.2 Hz, 1H), 8.27 (s, 1H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.76 (dd,J= 8.2, 0.9 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.35 (dd,J= 7.1, 1.4 Hz, 1H), 3.67 (t,J= 5.0 Hz, 2H), 3.63 (t,J= 5.5 Hz, 4H), 3.45 (t,J= 4.9 Hz, 2H), 2.71 (p,J= 6.5 Hz, 1H), 2.54 (t,J= 5.1 Hz, 2H), 2.45 (t,J= 5.0 Hz, 2H), 1.65 (d,J= 4.9 Hz, 2H), 1.57 (d,J= 7.0 Hz, 4H), 0.99 (d,J= 6.5 Hz, 6H).MS (ESI, LR) Calc. for C 26 H 33 N6O2[M+H] + : 461.3, found: 461.2. Example 243. 3-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylic acid [3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylic acid] <Reaction Formula 8> Step 243-1: Using compound 1-2 and (5-fluoro-6-(methoxycarbonyl)pyridin-3-yl)boronic acid, the target compound 243-1 was obtained using the same synthetic method as step 1-3 in Example 1. Step 243-2: Compound 243-1 (19 mg, 49 μM) was dissolved in tetrahydrofuran (1 mL), 1 N sodium hydroxide (0.3 mL) was added, and the mixture was stirred at 0 °C for 2 hours. After completion of the reaction, water (3 mL) was added to the reaction solution and the mixture was washed with dichloromethane solution. The aqueous layer was acidified with 1 N hydrochloric acid to adjust the pH to 2, and then extracted with dichloromethane (5 mL x 3). The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated to obtain the target compound 243 (12 mg, 66%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 13.82 (s, 1H), 9.07 (d,J= 1.6 Hz, 1H), 8.57 (dd,J= 11.5, 1.7 Hz, 1H), 8.31 (s, 1H), 7.98 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.1 Hz, 1H), 7.46 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (q,J= 5.6 Hz, 2H), 1.57 (q,J= 5.7 Hz, 4H). MS (ESI, LR) Calc. for C 19 H 18 FN4O3[M+H] + : 369.1, found: 369.1. Example 248. [7-[6-(azetidine-1-carbonyl)-5-fluoro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[6-(azetidine-1-carbonyl)-5-fluoro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] The target compound 248 was obtained using the same synthetic method as steps 1-2 in Example 1 using compound 243 and azetidine. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.02 (t,J= 1.5 Hz, 1H), 8.53 (dd,J= 11.2, 1.7 Hz, 1H), 8.30 (s, 1H), 7.97 (dd,J= 8.9, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.1 Hz, 1H), 7.43 (dd,J= 7.0, 1.3 Hz, 1H), 4.28 (t,J= 7.7 Hz, 2H), 4.13 (t,J= 7.8 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 2.32 (p,J= 7.7 Hz, 2H), 1.66 (d,J= 5.2 Hz, 2H), 1.57 (d,J= 6.7 Hz, 4H). MS (ESI, LR) Calc. for C 22 H 23 FN5O2[M+H] + : 408.2, found: 408.1. Example 249. [7-[5-fluoro-6-(morpholine-4-carbonyl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[5-fluoro-6-(morpholine-4-carbonyl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 250. 3-Fluoro-N-methyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxamide [3-fluoro-N-methyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxamide] For Examples 249 and 250, the target compounds were obtained using the same synthetic method as steps 1 and 2 of Example 1 using the compound corresponding to compound 243. The structural and spectral data are shown in Table 10 below. Example structure 1 H NMRMS249 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.03 (t,J= 1.6 Hz, 1H), 8.56 (dd,J= 10.5, 1.7 Hz, 1H), 8.30 (s, 1H), 7.97 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.1 Hz, 1H), 7.42 (dd,J= 7.1, 1.4 Hz, 1H), 3.72 (s, 4H), 3.61 (dt,J= 13.6, 5.2 Hz, 6H), 3.35 (d,J= 4.9 Hz, 2H), 1.65 (d,J= 4.7 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 23 H 25 FN5O3[M+H] + : 438.2, found: 438.2.250 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.03 (t,J= 1.5 Hz, 1H), 8.78 (d,J= 5.1 Hz, 1H), 8.53 (dd,J= 11.7, 1.7 Hz, 1H), 8.30 (s, 1H), 7.98 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.1 Hz, 1H), 7.45 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.84 (d,J= 4.7 Hz, 3H), 1.66 (d,J= 5.7 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 20 H 21 FN5O2[M+H] + : 382.2, found: 382.1. Example 277. [7-[2-(azetidine-1-carbonyl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[2-(azetidine-1-carbonyl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] <Reaction Formula 9> Compound 277-1 was obtained using the same synthetic method as step 1-3 in Example 1 using compound 1-2 and (2-(methoxycarbonyl)pyrimidin-5-yl)boronic acid, and then target compound 277 was obtained using the same synthetic method as step 1-2 in Example 1 using azetidine. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.51 (s, 2H), 8.31 (s, 1H), 7.98 (dd,J= 8.9, 1.4 Hz, 1H), 7.58 (dd,J= 8.9, 7.0 Hz, 1H), 7.48 (dd,J= 7.1, 1.4 Hz, 1H), 4.48 (t,J= 7.7 Hz, 2H), 4.14 (t,J= 7.7 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 2.39-2.27 (m, 2H), 1.66 (d,J= 5.4 Hz, 2H), 1.57 (d,J= 6.9 Hz, 4H). MS (ESI, LR) Calc. for C 21 H 23 N6O2[M+H] + : 391.2, found: 391.1. Example 258. 3-chloro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylic acid After obtaining an intermediate by the same synthetic method as steps 1-3 in Example 1 using (5-chloro-6-(methoxycarbonyl)pyridin-3-yl)boronic acid, the target compound 258 was obtained by the same synthetic method as step 243-2 in Example 243. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 14.07 (s, 1H), 9.08 (d,J= 1.8 Hz, 1H), 8.71 (d,J= 1.9 Hz, 1H), 8.30 (s, 1H), 7.97 (dd,J= 8.9, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.1 Hz, 1H), 7.43 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.73-1.62 (m, 2H), 1.57 (d,J= 7.4 Hz, 4H). MS (ESI, LR) Calc. for C 19 H 18 ClN4O3[M+H] + : 385.1, found: 385.1. Example 262. 3-chloro-N-methyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxamide [3-chloro-N-methyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxamide] Example 286. [7-[6-(azetidine-1-carbonyl)-5-chloro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[6-(azetidine-1-carbonyl)-5-chloro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] For Examples 262 and 286, compounds 258 and the corresponding compounds were obtained using the same synthetic method as steps 1-2 in Example 1. The structural and spectral data are shown in Table 11 below. Example structure 1 H NMRMS262 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.06 (d,J= 1.8 Hz, 1H), 8.72 (d,J= 5.0 Hz, 1H), 8.67 (d,J= 1.8 Hz, 1H), 8.30 (s, 1H), 7.97 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.42 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.83 (d,J= 4.7 Hz, 3H), 1.65 (d,J= 5.3 Hz, 2H), 1.57 (d,J= 5.1 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 21 ClN5O2[M+H] + : 398.1, found: 398.1.286 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.08 (d,J= 1.8 Hz, 1H), 8.71 (d,J= 1.8 Hz, 1H), 8.31 (s, 1H), 7.97 (dd,J= 8.9, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.46-7.40 (m, 1H), 4.12 (dt,J= 22.1, 7.8 Hz, 4H), 3.63 (t,J= 5.4 Hz, 4H), 2.34 (p,J= 7.7 Hz, 2H), 1.66 (d,J= 5.8 Hz, 2H), 1.58 (d,J= 7.8 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 23 ClN5O2[M+H] +: 424.1, found: 424.1. MS (ESI, LR) Calc. for C 22 H 23 ClN5O2[M+H] + : 424.1, found: 424.1. Example 90. N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)furan-2-carboxamide [N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)furan-2-carboxamide] <Reaction Scheme 10> After obtaining compound 90-1 using compound 1-2 and methyl (5-methoxycarbonyl-2-furyl)boronic acid by the synthetic method used in Example 39, target compound 90 was obtained using 3-aminopropanenitrile by the same synthetic method as step 1-2 in Example 1. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.11 (t,J= 5.9 Hz, 1H), 8.42 (s, 1H), 8.05-7.91 (m, 3H), 7.64 (dd,J= 8.8, 7.3 Hz, 1H), 7.39 (d,J= 3.6) Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 3.56 (q,J= 6.3 Hz, 2H), 2.83 (t,J= 6.5 Hz, 2H), 1.66 (d,J= 4.9 Hz, 2H), 1.58 (d,J= 6.0 Hz, 4H). MS (ESI, LR) Calc. for C 21 H 22 N5O3[M+H] + : 392.2, found: 392.1. Example 230. (3-hydroxyiminoazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone [(3-hydroxyiminoazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone] After obtaining an intermediate using the same synthetic method as steps 1-2 in Example 1 using compound 39-1 and azetidin-3-one, the target compound 230 was obtained using the same synthetic method as step 236-2 in Example 236. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.07 (d,J= 12.6 Hz, 1H), 9.22 (d,J= 2.2 Hz, 1H), 9.00 (d,J= 2.1 Hz, 1H), 8.68 (s, 1H), 8.27 (d,J= 6.5 Hz, 1H), 7.95 (d,J= 8.9 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.37 (d,J= 7.0 Hz, 1H), 5.13 (s, 2H), 4.79 (d,J= 17.8 Hz, 2H), 3.63 (s, 4H), 1.65 (d,J= 6.1 Hz, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 22 H 23 N6O3[M+H] + : 419.2, found: 419.1. Example 91. 3-methoxy-N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)propanamide [3-methoxy-N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)propanamide] Example 93. 1-methyl-N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)piperidine-4-carboxamide [1-methyl-N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)piperidine-4-carboxamide] Example 94. N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclopropanecarboxamide [N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclopropanecarboxamide] Example 95. N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide [N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide] Example 96. N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclohexanecarboxamide [N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclohexanecarboxamide] For Examples 91, 93, 94, 95, and 96, compounds corresponding to compound 7 were obtained using the same synthetic method as steps 1-2 of Example 1. The structural and spectral data are shown in Table 12 below. Example structure 1 H NMRMS91 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.14 (s, 1H), 8.23 (s, 1H), 8.18 (t,J= 2.0 Hz, 1H), 7.88 (dd,J= 8.9, 1.4 Hz, 1H), 7.76 (d,J= 8.0 Hz, 1H), 7.57-7.45 (m, 3H), 7.12 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (dq,J= 5.6, 3.0 Hz, 6H), 3.25 (s, 3H), 2.58 (t,J= 6.1 Hz, 2H), 1.65 (d,J= 5.6 Hz, 2H), 1.57 (d,J= 7.8 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 27 N4O3[M+H] + : 407.2, found: 407.2.93 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.24 (s, 1H), 8.23 (s, 1H), 8.18 (s, 1H), 7.88 (d,J= 8.7 Hz, 1H), 7.75 (d,J= 8.0 Hz, 1H), 7.52 (dq,J= 15.8, 7.9 Hz, 3H), 7.11 (d,J= 7.0 Hz, 1H), 3.62 (s, 4H), 2.98 (s, 2H), 2.78 (s, 2H), 2.03 (s, 3H), 1.66 (s, 2H), 1.57 (s, 4H), 1.25 (s, 2H).MS (ESI, LR) Calc. for C 26 H 32 N5O2[M+H] + : 446.3, found: 446.2.94 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.39 (s, 1H), 8.23 (s, 1H), 8.16 (d,J= 2.0 Hz, 1H), 7.88 (dd,J= 8.9, 1.4 Hz, 1H), 7.74 (d,J= 8.3 Hz, 1H), 7.57-7.44 (m, 3H), 7.12 (dd,J= 7.0, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.85-1.78 (m, 1H), 1.65 (d,J= 7.7 Hz, 2H), 1.57 (s, 4H), 0.82 (d,J= 5.1 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 25 N4O2[M+H] + : 389.2, found: 389.2.95 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.64 (s, 1H), 9.14 (d,J= 2.3 Hz, 1H), 8.78 (dd,J= 4.8, 1.7 Hz, 1H), 8.39-8.28 (m, 2H), 8.25 (s, 1H), 7.92 (ddd,J= 17.9, 8.5, 1.7 Hz, 2H), 7.66 (d,J= 7.8 Hz, 1H), 7.63-7.48 (m, 3H), 7.17 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.57 (d,J= 4.8 Hz, 4H).MS (ESI, LR) Calc. for C 25 H 24 N5O2[M+H] + : 426.2, found: 426.1.96 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.99 (s, 1H), 8.23 (s, 1H), 8.18 (d,J= 2.0 Hz, 1H), 7.88 (dd,J= 9.0, 1.4 Hz, 1H), 7.75 (d,J= 8.1 Hz, 1H), 7.56-7.42 (m, 3H), 7.11 (dd,J= 7.0, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.79 (dd,J= 22.7, 12.6 Hz, 4H), 1.65 (d,J= 7.6 Hz, 2H), 1.57 (s, 4H), 1.42 (q,J= 12.0 Hz, 2H), 1.25 (dq,J= 24.3, 12.0 Hz, 4H).MS (ESI, LR) Calc. for C 26 H 31 N4O2[M+H] + : 431.2, found: 431.2. Example 92. 1-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)urea [1-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)urea] <Reaction Formula 11> Sodium cyanate (28.4 mg, 0.44 mmol) was dissolved in warm water (3 mL). Compound 7 (70 mg, 0.22 mmol) dissolved in acetic acid (0.5 mL) and water (1.5 mL) was added to the reaction solution and stirred at 50 °C for 12 hours. After completion of the reaction, the temperature was lowered using ice water and the precipitated solid was filtered to obtain it. The target compound 92 (35.6 mg, 45%) was obtained by recrystallization using boiling water. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.74 (s, 1H), 8.22 (s, 1H), 7.95 (d,J= 2.1 Hz, 1H), 7.86 (dd,J= 8.9, 1.3 Hz, 1H), 7.60-7.54 (m, 1H), 7.50 (dd,J= 8.9, 7.0 Hz, 1H), 7.42-7.37 (m, 2H), 7.11 (dd,J= 7.0, 1.4 Hz, 1H), 5.91 (s, 2H), 3.62 (t,J= 5.3 Hz, 4H), 1.65 (d,J= 7.7 Hz, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 20 H 22 N5O2[M+H] + : 364.2, found: 364.2. Example 97. N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)acetamide [N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)acetamide] Example 98. 3-methoxy-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)propanamide [3-methoxy-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)propanamide] Example 99. 1-methyl-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)piperidine-4-carboxamide [1-methyl-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)piperidine-4-carboxamide] Example 100. N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclopropanecarboxamide [N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclopropanecarboxamide] Example 101. N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide [N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide] Example 102. N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclohexanecarboxamide [N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclohexanecarboxamide] Example 274. N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-2-(pyridin-3-yl)acetamide [N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-2-(pyridin-3-yl)acetamide] For Examples 97, 98, 99, 100, 101, 102, and 274, the compounds corresponding to compound 14 were obtained by the same synthetic method as steps 1-2 of Example 1. The structural and spectral data are shown in Table 13 below. Example structure 1 H NMRMS97 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.19 (s, 1H), 8.23 (s, 1H), 7.94-7.87 (m, 2H), 7.84 (dd,J= 8.9, 1.4 Hz, 1H), 7.75 (d,J= 8.6 Hz, 2H), 7.49 (dd,J= 8.9, 7.1 Hz, 1H), 7.14 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 2.10 (s, 3H), 1.65 (d,J= 6.0 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 21 H 23 N4O2[M+H] + : 363.2, found: 363.2.98 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.20 (s, 1H), 8.23 (s, 1H), 7.93-7.88 (m, 2H), 7.84 (dd,J= 8.9, 1.4 Hz, 1H), 7.77 (d,J= 8.7 Hz, 2H), 7.49 (dd,J= 8.9, 7.1 Hz, 1H), 7.14 (dd,J= 7.1, 1.3 Hz, 1H), 3.63 (dt,J= 11.6, 5.8 Hz, 6H), 3.26 (s, 3H), 2.60 (t,J= 6.2 Hz, 2H), 1.65 (d,J= 5.9 Hz, 2H), 1.56 (s, 4H).MS (ESI, LR) Calc. for C 23 H 27 N4O3[M+H] + : 407.2, found: 407.2.99 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.46 (s, 1H), 8.23 (s, 1H), 7.92 (d,J= 8.5 Hz, 2H), 7.82 (dd,J= 15.7, 8.7 Hz, 3H), 7.49 (dd,J= 8.9, 7.1 Hz, 1H), 7.14 (d,J= 7.0 Hz, 1H), 3.62 (t,J= 5.5 Hz, 4H), 2.73 (s, 3H), 2.09 - 1.91 (m, 4H), 1.64 (t,J= 5.5 Hz, 2H), 1.56 (q,J= 5.4 Hz, 4H), 1.31-1.16 (m, 3H).MS (ESI, LR) Calc. for C 26 H 32 N5O2[M+H] + : 446.3, found: 446.4.100 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.45 (s, 1H), 8.23 (s, 1H), 7.91 (d,J= 8.6 Hz, 2H), 7.84 (dd,J= 8.9, 1.3 Hz, 1H), 7.76 (d,J= 8.7 Hz, 2H), 7.49 (dd,J= 8.9, 7.1 Hz, 1H), 7.15 (dd,J= 7.0, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.87-1.78 (m, 1H), 1.65 (d,J= 6.9 Hz, 2H), 1.57 (d,J= 7.6 Hz, 4H), 0.87-0.83 (m, 4H).MS (ESI, LR) Calc. for C 23 H 25 N4O2[M+H] + : 389.2, found: 389.2.101 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.69 (s, 1H), 9.16 (d,J= 2.2 Hz, 1H), 8.80 (dd,J= 4.8, 1.7 Hz, 1H), 8.37-8.32 (m, 1H), 8.25 (s, 1H), 8.06-7.92 (m, 4H), 7.89 - 7.84 (m, 1H), 7.61 (dd,J= 8.0, 4.8 Hz, 1H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.20 (d,J= 7.0 Hz, 1H), 3.64 (d,J= 5.9 Hz, 4H), 1.66 (s, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 25 H 24 N5O2[M+H] + : 426.2, found: 426.1.102 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.05 (s, 1H), 8.23 (s, 1H), 7.90 (d,J= 8.7 Hz, 2H), 7.84 (dd,J= 9.0, 1.3 Hz, 1H), 7.78 (d,J= 8.7 Hz, 2H), 7.49 (dd,J= 8.9, 7.1 Hz, 1H), 7.14 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.81 (dd,J= 23.4, 12.8 Hz, 4H), 1.66 (s, 2H), 1.57 (s, 4H), 1.44 (q,J= 11.9 Hz, 2H), 1.27 (dq,J= 23.5, 12.0 Hz, 4H).MS (ESI, LR) Calc. for C 26 H 31 N4O2[M+H] + : 431.2, found: 431.2.274 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.49 (s, 1H), 8.56 (d,J= 2.4 Hz, 1H), 8.52-8.43 (m, 1H), 8.23 (s, 1H), 7.93 (d,J= 8.5 Hz, 2H), 7.85 (d,J= 8.9 Hz, 1H), 7.80-7.72 (m, 3H), 7.49 (dd,J= 8.9, 7.0 Hz, 1H), 7.39 (dd,J= 7.9, 4.8 Hz, 1H), 7.15 (d,J= 7.0 Hz, 1H), 3.78 (s, 2H), 3.62 (t,J= 5.3 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 26 H 26 N5O2[M+H] + : 440.2, found: 440.1. Example 196. 2-(dimethylamino)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide [2-(dimethylamino)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide] Example 197. 3-methoxy-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)propenamide [3-methoxy-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)propenamide] Example 198. 2-oxo-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)piperidine-4-carboxamide [2-oxo-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)piperidine-4-carboxamide] Example 326. N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)nicotinamide [N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)nicotinamide] Example 327. N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(pyridin-3-yl)acetamide [N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(pyridin-3-yl)acetamide] Example 333. 1,2-dimethyl-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-1H-imidazole-5-carboxamide [1,2-dimethyl-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-1H-imidazole-5-carboxamide] Example 334. N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)pyrimidine-5-carboxamide [N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)pyrimidine-5-carboxamide] Example 335. 5-Fluoro-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)nicotinamide [5-fluoro-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)nicotinamide] Example 388. N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(6-(trifluoromethyl)pyridin-3-yl)acetamide [N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(6-(trifluoromethyl)pyridin-3-yl)acetamide] Example 389. 2-phenyl-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide [2-phenyl-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide] Example 402. 2-(5-fluoropyridin-3-yl)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide [2-(5-fluoropyridin-3-yl)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide] Example 403. N-(5-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(pyrimidin-5-yl)acetamide [N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(pyrimidin-5-yl)acetamide] Example 406. 2-(4-chlorophenoxy)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide [2-(4-chlorophenoxy)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide] For Examples 196, 197, 198, 326, 327, 333, 334, 335, 388, 389, 402, 403, and 406, the compounds corresponding to compound 9 were obtained by the same synthetic method as steps 1-2 in Example 1. The structural and spectral data are shown in Table 14 below. Example structure 1 H NMRMS196 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.18 (s, 1H), 8.99 (d,J= 2.4 Hz, 1H), 8.75 (d,J= 2.0 Hz, 1H), 8.70 (t,J= 2.2 Hz, 1H), 8.27 (s, 1H), 7.93 (dd,J= 8.9, 1.4 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.26 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.15 (s, 2H), 2.31 (s, 6H), 1.65 (d,J= 5.4 Hz, 2H), 1.57 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 27 N6O2[M+H] + : 407.2, found: 407.1.197 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.40 (s, 1H), 8.89 (d,J= 2.4 Hz, 1H), 8.72 (d,J= 2.0 Hz, 1H), 8.67 (t,J= 2.2 Hz, 1H), 8.27 (s, 1H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.26 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (q,J= 6.1 Hz, 6H), 3.26 (s, 3H), 2.63 (t,J= 6.1 Hz, 2H), 1.65 (d,J= 6.5 Hz, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 22 H 26 N5O3[M+H] + : 408.2, found: 408.1.198 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.45 (s, 1H), 8.90 (d,J= 2.4 Hz, 1H), 8.73 (d,J= 2.0 Hz, 1H), 8.68 (t,J= 2.2 Hz, 1H), 8.27 (s, 1H), 7.93 (dd,J= 8.9, 1.4 Hz, 1H), 7.58-7.51 (m, 2H), 7.26 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.26-3.13 (m, 2H), 2.98-2.89 (m, 1H), 2.36 (d,J= 7.7 Hz, 2H), 1.65 (d,J= 5.8 Hz, 2H), 1.57 (s, 4H), 1.25 (s, 2H).MS (ESI, LR) Calc. for C 24 H 27 N6O3[M+H] + : 447.2, found: 447.2.326 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.86 (s, 1H), 9.17 (d,J= 2.2 Hz, 1H), 9.08 (d,J= 1.5 Hz, 1H), 8.86-8.77 (m, 3H), 8.36 (dt,J= 8.0, 2.0 Hz, 1H), 8.27 (s, 1H), 7.94 (dd,J= 9.0, 1.3 Hz, 1H), 7.61 (dd,J= 8.0, 4.8 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.30 (dd,J= 7.1, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (q, J = 5.8 Hz, 2H), 1.61-1.47 (m, 4H).MS (ESI, LR) Calc. for C 24 H 23 N6O3[M+H] + : 427.2, found: 427.1.327 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.67 (s, 1H), 8.90 (d,J= 2.4 Hz, 1H), 8.74 (d,J= 2.0 Hz, 1H), 8.67 (t,J= 2.2 Hz, 1H), 8.55 (d,J= 2.3 Hz, 1H), 8.48 (dd,J= 4.8, 1.7 Hz, 1H), 8.25 (s, 1H), 7.92 (dd,J= 8.9, 1.4 Hz, 1H), 7.77 (dt,J= 8.0, 2.0 Hz, 1H), 7.53 (dd,J= 8.9, 7.1 Hz, 1H), 7.37 (dd,J= 7.8, 4.8 Hz, 1H), 7.26 (dd,J= 7.0, 1.4 Hz, 1H), 3.80 (s, 2H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (m, 2H), 1.57 (m, 4H).MS (ESI, LR) Calc. for C 25 H 25 N6O2[M+H] + : 441.2, found: 441.1.333 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.32 (s, 1H), 9.01 (d,J= 2.4 Hz, 1H), 8.77 (d,J= 2.0 Hz, 1H), 8.72 (t,J= 2.2 Hz, 1H), 8.27 (s, 1H), 7.94 (dd,J= 8.9, 1.4 Hz, 1H), 7.78 (s, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.28 (dd,J= 7.1, 1.4 Hz, 1H), 3.80 (s, 3H), 3.63 (t,J= 5.4 Hz, 4H), 2.37 (s, 3H), 1.66 (m, 2H), 1.58 (m, 4H).MS (ESI, LR) Calc. for C 24 H 26 N7O2[M+H] + : 444.2, found: 444.1.334 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.01 (s, 1H), 9.40 (s, 1H), 9.33 (s, 2H), 9.07 (d,J= 2.3 Hz, 1H), 8.84 (dd,J= 7.5, 2.1 Hz, 2H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.4 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.31 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (m, 2H), 1.58 (m, 4H).MS (ESI, LR) Calc. for C 23 H 22 N7O2[M+H] + : 428.2, found: 428.1.335 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.90 (s, 1H), 9.12-8.98 (m, 2H), 8.83 (dt,J= 9.0, 2.0 Hz, 3H), 8.34-8.20 (m, 2H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.30 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.71-1.59 (m, 2H), 1.60-1.46 (m, 4H).MS (ESI, LR) Calc. for C 24 H 22 FN6O2[M+H] + : 445.2, found: 445.1.388 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.75 (s, 1H), 8.90 (d,J= 2.4 Hz, 1H), 8.75 (t,J= 2.4 Hz, 2H), 8.67 (t,J= 2.3 Hz, 1H), 8.26 (s, 1H), 8.12-7.99 (m, 1H), 7.96-7.84 (m, 2H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.27 (dd,J= 7.1, 1.4 Hz, 1H), 3.97 (s, 2H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (m, 2H), 1.57 (m, 2H), 1.25 (m, 2H).MS (ESI, LR) Calc. for C 26 H 24 F3N6O2[M+H] + : 509.2, found: 509.1.389 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.62 (s, 1H), 8.90 (d,J= 2.4 Hz, 1H), 8.72 (d,J= 2.0 Hz, 1H), 8.67 (t,J= 2.2 Hz, 1H), 8.26 (s, 1H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.52 (dd,J= 8.9, 7.0 Hz, 1H), 7.42-7.16 (m, 5H), 3.73 (s, 2H), 3.62 (t,J= 5.4 Hz, 3H), 1.65 (m, 2H), 1.56 (m, 2H), 1.25 (m, 2H).MS (ESI, LR) Calc. for C 26 H 26 N5O2[M+H] + : 440.2, found: 440.1.402 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.71 (s, 1H), 8.90 (d,J= 2.4 Hz, 1H), 8.75 (d,J= 2.0 Hz, 1H), 8.67 (t,J= 2.2 Hz, 1H), 8.50 (d,J= 2.8 Hz, 1H), 8.43 (t,J= 1.8 Hz, 1H), 8.26 (s, 1H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.73 (dt,J= 10.0, 2.2 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.26 (dd,J= 7.0, 1.4 Hz, 1H), 3.88 (s, 2H), 3.62 (m, 4H), 1.65 (m, 2H), 1.56 (m, 4H).MS (ESI, LR) Calc. for C 25 H 24 FN6O2[M+H] + : 459.2, found: 459.1.403 1H NMR (400 MHz, DMSO-d6) δ(ppm): 10.75 (s, 1H), 9.10 (s, 1H), 8.89 (d,J= 2.4 Hz, 1H), 8.78 (s, 2H), 8.75 (d,J= 1.9 Hz, 1H), 8.68 (d,J= 2.2 Hz, 1H), 8.25 (s, 1H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.26 (dd,J= 7.0, 1.4 Hz, 1H), 3.87 (s, 2H), 3.62 (t,J= 5.4 Hz, 5H), 1.65 (m, 2H), 1.56 (m, 4H).MS (ESI, LR) Calc. for C 24 H 24 N7O2[M+H] + : 442.2, found: 442.2.406 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.56 (s, 1H), 8.96 (d,J= 2.4 Hz, 1H), 8.78 (d,J= 2.0 Hz, 1H), 8.70 (t,J= 2.2 Hz, 1H), 8.26 (s, 1H), 7.93 (dd,J= 8.9, 1.4 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.42-7.35 (m, 2H), 7.27 (dd,J= 7.1, 1.4 Hz, 1H), 7.12-7.02 (m, 2H), 4.81 (s, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.73-1.62 (m, 2H), 1.57 (m, 4H).MS (ESI, LR) Calc. for C 26 H 25 ClN5O3[M+H] + : 490.2, found: 490.1. Example 103. 3-methoxy-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)propanamide [3-methoxy-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)propanamide] <Reaction Formula 12> Compound 17 (50 mg, 0.16 mmol) was dissolved in N,N-dimethylformamide (5 mL), and triethylamine (64 μL, 0.47 mmol) was added. 3-Methoxypropionyl chloride (28 mg, 0.23 mmol) was added to the reaction solution, and the mixture was stirred at room temperature for 12 hours. After completion of the reaction, the reaction solution was concentrated, diluted with ethyl acetate (20 mL), and washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 103 (27.2 mg, 43%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.75 (s, 1H), 8.89 (d,J= 2.4 Hz, 1H), 8.40 (dd,J= 8.8, 2.4 Hz, 1H), 8.28 - 8.25 (m, 1H), 7.89 (dd,J= 8.8, 1.3 Hz, 1H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.27 (dd,J= 7.1, 1.4 Hz, 1H), 5.75 (s, 1H), 3.64 (dt,J= 10.7, 5.7 Hz, 6H), 3.26 (s, 3H), 2.70 (t,J= 6.2 Hz, 2H), 1.65 (d,J= 5.6 Hz, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 23 H 28 N5O3[M+H] + : 408.2, found: 408.1. Example 104. 2-(dimethylamino)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)acetamide [2-(dimethylamino)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)acetamide] <Reaction Formula 13> HOBt (21 mg, 0.16 mmol) and EDCI·HCl (71.6 mg, 0.37 mmol) were dissolved in dichloromethane (10 mL), triethylamine (64.7 μL, 0.47 mmol) was added, and the mixture was stirred for 1 hour. Compound 17 (0.1 g, 0.31 mmol) was added to the reaction solution, and the mixture was stirred for 3 hours. After the reaction was completed, the reaction solution was diluted with dichloromethane (20 mL) and washed with water. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 104 (36.3 mg, 29%). [HOBt (Hydroxybenzotriazole), EDCI (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide)] 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.17 (s, 1H), 8.88 (d,J= 2.4 Hz, 1H), 8.43 (dd,J= 8.7, 2.4 Hz, 1H), 8.30-8.22 (m, 2H), 7.89 (dd,J= 8.9, 1.4 Hz, 1H), 7.52 (dd,J= 8.9, 7.0 Hz, 1H), 7.27 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 3.20 (s, 2H), 2.33 (s, 6H), 1.65 (d,J= 7.6 Hz, 2H), 1.57 (q, J = 5.8 Hz, 4H). MS (ESI, LR) Calc. for C22 H 27 N6O2[M+H] + : 407.2, found: 407.1. Example 105. 2-oxo-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)piperidine-4-carboxamide [2-oxo-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)piperidine-4-carboxamide] <Reaction Formula 14> HOBt (42 mg, 0.31 mmol), EDCI·HCl (58 mg, 0.37 mmol), and 4-dimethylaminopyridine (19 mg, 0.15 mmol) were dissolved in dichloromethane (7 mL), and triethylamine (86 μL, 0.62 mmol) was added and stirred for 1 hour. Compound 17 (0.1 mg, 0.31 mmol) was added to the reaction solution and stirred for 3 hours. After completion of the reaction, the reaction solution was diluted with dichloromethane (20 mL) and washed with water. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 105 (29.8 mg, 22%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.87 (s, 1H), 8.90 (d,J= 2.4 Hz, 1H), 8.41 (dd,J= 8.8, 2.4 Hz, 1H), 8.26 (d,J= 7.7 Hz, 2H), 7.91-7.86 (m, 1H), 7.52 (t,J= 7.9 Hz, 2H), 7.27 (d,J= 7.0 Hz, 1H), 3.62 (t,J= 5.5 Hz, 4H), 3.24-3.00 (m, 4H), 2.35 (d,J= 7.7 Hz, 2H), 2.05-1.96 (m, 1H), 1.65 (s, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 24 H 27 N6O3[M+H] + : 447.2, found: 447.1 Example 106. N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide [N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide] The target compound 106 was obtained using the synthetic method used in Example 105 using compound 17 and 2-(3-pyridyl)acetic acid. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.10 (s, 1H), 8.91 (dd,J= 2.4, 0.9 Hz, 1H), 8.56 (d,J= 2.3 Hz, 1H), 8.48 (dd,J= 4.8, 1.7 Hz, 1H), 8.40 (dd,J= 8.7, 2.4 Hz, 1H), 8.26 (s, 1H), 8.21 (d,J= 8.7 Hz, 1H), 7.89 (dd,J= 8.8, 1.4 Hz, 1H), 7.78 (dt,J= 7.8, 2.1 Hz, 1H), 7.52 (dd,J=8.9, 7.1 Hz, 1H), 7.42-7.34 (m, 1H), 7.27 (dd,J= 7.1, 1.3 Hz, 1H), 3.85 (s, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.56 (d,J= 7.1 Hz, 4H). MS (ESI, LR) Calc. for C 25 H 25 N6O2[M+H] + : 441.2, found: 441.1 Example 407. N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl-2-pyrimidin-5-yl-acetamide [N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-2-pyrimidin-5-yl-acetamide] Example 408. N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-2-[6-(trifluoromethyl)-3-pyridyl]acetamide [N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-2-[6-(trifluoromethyl)-3-pyridyl]acetamide] Example 409. 2-(5-fluoropyridin-3-yl)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)acetamide [2-(5-fluoropyridin-3-yl)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)acetamide] Example 410. 2-(4-chlorophenoxy)-N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]acetamide [2-(4-chlorophenoxy)-N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]acetamide] For Examples 407, 408, 409, and 410, compound 17 and the corresponding compound were obtained by the same synthetic method as steps 1-2 in Example 1. The structural and spectral data are shown in Table 15 below. Example structure 1 H NMRMS407 1H NMR (400 MHz, DMSO-d6) δ(ppm): 11.15 (s, 1H), 9.11 (s, 1H), 8.95-8.90 (m, 1H), 8.79 (s, 2H), 8.41 (dd,J= 8.8, 2.4 Hz, 1H), 8.27 (s, 1H), 8.21 (d,J= 8.8 Hz, 1H), 7.89 (dd,J= 8.9, 1.3 Hz, 1H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.28 (dd,J= 7.1, 1.3 Hz, 1H), 3.93 (s, 2H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 5.8 Hz, 2H), 1.57 (s, 5H).MS (ESI, LR) Calc. for C 24 H 24 N7O2[M+H] + : 442.2, found: 442.1.408 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.17 (s, 1H), 8.96-8.87 (m, 1H), 8.75 (d,J= 2.1 Hz, 1H), 8.41 (dd,J= 8.8, 2.4 Hz, 1H), 8.27 (s, 1H), 8.21 (d,J= 8.8 Hz, 1H), 8.08 (dd,J= 8.5, 2.1 Hz, 1H), 7.94-7.84 (m, 2H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.28 (dd,J= 7.0, 1.3 Hz, 1H), 4.02 (s, 2H), 3.62 (d,J= 5.3 Hz, 4H), 1.65 (d,J= 5.9 Hz, 2H), 1.56 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 26 H 24 F3N6O2[M+H] + : 509.2, found: 509.1.409 1H NMR (400 MHz, DMSO-d6) δ(ppm): 11.11 (s, 1H), 8.92 (d,J= 2.4 Hz, 1H), 8.50 (d,J= 2.8 Hz, 1H), 8.44 (t,J= 1.9 Hz, 1H), 8.40 (dd,J= 8.8, 2.4 Hz, 1H), 8.26 (s, 1H), 8.21 (d,J= 8.7 Hz, 1H), 7.89 (dd,J= 8.9, 1.4 Hz, 1H), 7.73 (dt,J= 9.8, 2.3 Hz, 1H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.27 (dd,J= 7.1, 1.4 Hz, 1H), 3.93 (s, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.64 (d,J= 7.1 Hz, 2H), 1.57 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 25 H 24 FN6O2[M+H] + : 459.2, found: 459.2.410 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.88 (s, 1H), 8.97-8.88 (m, 1H), 8.43 (dd,J= 8.8, 2.4 Hz, 1H), 8.27 (s, 1H), 8.21 (d,J= 8.7 Hz, 1H), 7.89 (dd,J= 8.9, 1.3 Hz, 1H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.43-7.32 (m, 2H), 7.28 (dd,J= 7.1, 1.4 Hz, 1H), 7.08-6.97 (m, 2H), 4.88 (s, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.3 Hz, 2H), 1.57 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 26 H 25 ClN5O3[M+H] + : 490.2, found: 490.1. Example 278. N-(2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-2-(pyridin-3-yl)acetamide [N-(2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-2-(pyridin-3-yl)acetamide] <Reaction Formula 15> Step 278-1 [Step 278-1]: The target compound 278-1 was obtained by the same synthetic method as Step 1-2 in Example 1 using 4-bromo-2,6-difluoro-aniline and 2-(3-pyridyl)acetic acid. Step 278-1 [Step 278-2]: Using compound 278-1, target compound 278-2 was obtained using the same synthetic method as step 351-1 in Example 351. Step 278-1 [Step 278-3]: Compound 278 was obtained using the same synthetic method as Step 159-3 in Example 159 using compound 278-2. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.21 (s, 1H), 8.56 (d,J= 2.3 Hz, 1H), 8.49 (dd,J= 4.8, 1.7 Hz, 1H), 8.27 (s, 1H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.84 (d,J= 8.9 Hz, 2H), 7.82-7.72 (m, 1H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.40 (dd,J= 7.9, 4.8 Hz, 1H), 7.32 (dd,J= 7.1, 1.3 Hz, 1H), 3.82 (s, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.6 Hz, 2H), 1.56 (d,J= 6.9 Hz, 4H). MS (ESI, LR) Calc. for C 26 H24 F2N5O2[M+H] + : 476.2, found: 476.1. Example 107. (7-(6-((3-methoxypropyl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-((3-methoxypropyl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 16> To a solution of 3-methoxypropylamine (47 μL, 0.46 mmol) in N,N-dimethylformamide (6 mL) was added potassium carbonate (0.106 g, 0.77 mmol), and the mixture was stirred for 10 minutes. Compound 19 (0.1 g, 0.31 mmol) was added to the reaction solution, and the mixture was stirred at 100 °C for 12 hours. After completion of the reaction, the reaction solution was concentrated, diluted with dichloromethane (20 mL), and washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 107 (0.059 g, 49%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.55 (d,J= 2.4 Hz, 1H), 8.22 (s, 1H), 8.02 (dd,J= 8.9, 2.5 Hz, 1H), 7.78 (dd,J= 8.9, 1.4 Hz, 1H), 7.46 (dd,J= 8.9, 7.1 Hz, 1H), 7.11 (dd,J= 7.2, 1.4 Hz, 1H), 6.59 (d,J= 8.9 Hz, 1H), 3.61 (t,J= 5.4 Hz, 4H), 3.42 (t,J= 6.3 Hz, 2H), 3.38 (d,J=6.7 Hz, 2H), 3.26 (s, 3H), 1.80 (p,J= 6.6 Hz, 2H), 1.65 (d,J= 6.0 Hz, 2H), 1.56 (d,J= 7.1 Hz, 4H). MS (ESI, LR) Calc. for C 22 H 28 N5O2[M+H] + : 394.2, found: 394.2. Example 108. (7-(6-morpholinopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-morpholinopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 109. (7-(6-(isopropylamino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(isopropylamino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 110. Piperidin-1-yl(7-(6-(piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone [piperidin-1-yl(7-(6-(piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone] Example 111. (7-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 206. (7-(6-(azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 208. (7-(6-(3-fluoroazetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(3-fluoroazetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 209. (7-(6-(3,3-difluoroazetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(3,3-difluoroazetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 210. (7-(6-(3-hydroxyazetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(3-hydroxyazetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 215. (7-(6-(2-azabicyclo[2.2.1]heptan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(2-azabicyclo[2.2.1]heptan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 216. (7-(6-(2-azabicyclo[2.2.2]octan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(2-azabicyclo[2.2.2]octan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 217. (7-(6-(7-azabicyclo[2.2.1]heptan-7-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(7-azabicyclo[2.2.1]heptan-7-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 218. (7-(6-(3-(dimethylamino)azetidin-1-yl)(pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(3-(dimethylamino)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 219. Methyl 1-(5-(3-(piperidine-1-carbonyl)(pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)azetidine-3-carboxylate [methyl 1-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)azetidine-3-carboxylate] Example 220. (7-(6-(2-azaspiro[3.3]heptan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(2-azaspiro[3.3]heptan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 221. (7-(6-(3-(hydroxymethyl)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(3-(hydroxymethyl)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 222. (7-(6-(7-azaspiro[3.5]nonan-7-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(7-azaspiro[3.5]nonan-7-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 223. (7-(6-(6-azaspiro[3.4]octan-6-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(6-azaspiro[3.4]octan-6-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 332. Piperidin-1-yl(7-(6-((2-pyridin-3-yl)ethyl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone [piperidin-1-yl(7-(6-((2-(pyridin-3-yl)ethyl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone] Example 344. (7-(6-(4-amino-1H-pyrazol-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(4-amino-1H-pyrazol-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] For Examples 108, 109, 110, 111, 206, 208, 209, 210, 215, 216, 217, 218, 219, 220, 221, 222, 223, 332, and 344, the compounds corresponding to compound 19 were obtained by the synthetic method described in Example 107. The structural and spectral data are shown in Table 16 below. Example structure 1 H NMRMS108 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.70 (d,J= 2.5 Hz, 1H), 8.22 (d,J= 9.5 Hz, 2H), 7.81 (dd,J= 8.8, 1.3 Hz, 1H), 7.48 (dd,J= 8.9, 7.1 Hz, 1H), 7.18 (dd,J= 7.1, 1.3 Hz, 1H), 6.99 (d,J= 9.0 Hz, 1H), 3.74 (t,J= 4.8 Hz, 4H), 3.60 (dt,J= 9.9, 5.0 Hz, 8H), 1.65 (d,J= 5.6 Hz, 2H), 1.57 (d, J = 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 26 N5O2[M+H] + : 392.2, found: 392.2.109 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.55 (d,J= 2.5 Hz, 1H), 8.22 (s, 1H), 8.00 (dd,J= 8.9, 2.5 Hz, 1H), 7.77 (dd,J= 8.8, 1.4 Hz, 1H), 7.46 (dd,J= 8.9, 7.1 Hz, 1H), 7.11 (dd,J= 7.1, 1.4 Hz, 1H), 6.89 (d,J= 7.6 Hz, 1H), 6.57 (d,J= 8.9 Hz, 1H), 4.11 (h,J= 6.6 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.7 Hz, 2H), 1.62-1.53 (m, 4H), 1.19 (d,J= 6.5 Hz, 6H).MS (ESI, LR) Calc. for C 21 H 26 N5O [M+H] + : 364.2, found: 364.2.110 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.67 (d,J= 2.5 Hz, 1H), 8.23 (s, 1H), 8.16 (dd,J= 9.0, 2.6 Hz, 1H), 7.80 (dd,J= 8.8, 1.4 Hz, 1H), 7.47 (dd,J= 8.8, 7.1 Hz, 1H), 7.16 (dd,J= 7.2, 1.4 Hz, 1H), 6.96 (d,J= 9.1 Hz, 1H), 3.64 (dt, J= 13.9, 5.4 Hz, 8H), 1.66 (dt,J= 9.2, 5.6 Hz, 4H), 1.58 (p,J= 5.8 Hz, 8H).MS (ESI, LR) Calc. for C 23 H 28 N5O [M+H] + : 390.2, found: 390.2.111 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.68 (d,J= 2.5 Hz, 1H), 8.23 (s, 1H), 8.19 (dd,J= 9.0, 2.5 Hz, 1H), 7.81 (dd,J= 8.9, 1.3 Hz, 1H), 7.47 (dd,J= 8.8, 7.1 Hz, 1H), 7.17 (dd,J= 7.1, 1.4 Hz, 1H), 6.98 (d,J= 9.1 Hz, 1H), 3.63 (dd,J= 6.4, 3.2 Hz, 8H), 2.42 (t,J= 5.1 Hz, 4H), 2.24 (s, 3H), 1.65 (d,J= 8.5 Hz, 2H), 1.56 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 29 N6O [M+H] + : 405.2, found: 405.2.206 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.61 (d,J= 2.4 Hz, 1H), 8.22 (s, 1H), 8.15 (dd,J= 8.7, 2.4 Hz, 1H), 7.80 (dd,J= 8.8, 1.4 Hz, 1H), 7.47 (dd,J= 8.9, 7.1 Hz, 1H), 7.13 (dd,J= 7.1, 1.4 Hz, 1H), 6.48 (d,J= 8.8 Hz, 1H), 4.05 (t,J= 7.4 Hz, 4H), 3.61 (t,J= 5.4 Hz, 4H), 2.38 (p,J= 7.4 Hz, 2H), 1.65 (q,J= 5.8 Hz, 2H), 1.57 (q,J= 5.6 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 24 N5O [M+H] + : 362.2, found: 362.1.208 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.64 (d,J= 2.3 Hz, 1H), 8.23 (s, 1H), 8.19 (dd,J= 8.7, 2.4 Hz, 1H), 7.82 (dd,J= 8.9, 1.4 Hz, 1H), 7.48 (dd,J= 8.8, 7.1 Hz, 1H), 7.16 (dd,J= 7.1, 1.4 Hz, 1H), 6.61 (d,J= 8.7 Hz, 1H), 5.64-5.47 (m, 1H), 4.45-4.32 (m, 2H), 4.17-4.06 (m, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.61 (dd,J= 34.5, 6.4 Hz, 6H).MS (ESI, LR) Calc. for C 21 H 23 FN5O [M+H] + : 380.2, found: 380.1.209 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.69 (d,J= 2.3 Hz, 1H), 8.27-8.21 (m, 2H), 7.84 (dd,J= 8.8, 1.4 Hz, 1H), 7.49 (dd,J= 8.9, 7.1 Hz, 1H), 7.18 (dd,J= 7.0, 1.4 Hz, 1H), 6.74 (d,J= 8.7 Hz, 1H), 4.50 (t,J= 12.5 Hz, 4H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.0 Hz, 2H), 1.56 (d,J= 7.7 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 22 F2N5O [M+H] + : 398.2, found: 398.1.210 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.61 (d,J= 2.4 Hz, 1H), 8.22 (s, 1H), 8.15 (dd,J= 8.7, 2.4 Hz, 1H), 7.80 (dd,J= 8.9, 1.4 Hz, 1H), 7.47 (dd,J= 8.9, 7.1 Hz, 1H), 7.14 (dd,J= 7.1, 1.4 Hz, 1H), 6.52 (d,J= 8.7 Hz, 1H), 5.73 (d,J= 6.4 Hz, 1H), 4.63 (q,J= 5.4 Hz, 1H), 4.26 (dd,J= 8.9, 6.6 Hz, 2H), 3.78 (dd,J= 9.0, 4.6 Hz, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.4 Hz, 2H), 1.56 (d,J= 4.6 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 24 N5O2[M+H] + : 378.2, found: 378.1.215 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.61 (d,J= 2.4 Hz, 1H), 8.22 (s, 1H), 8.11 (dd,J= 8.9, 2.5 Hz, 1H), 7.78 (dd,J= 8.9, 1.4 Hz, 1H), 7.46 (dd,J= 8.8, 7.1 Hz, 1H), 7.12 (dd,J= 7.1, 1.4 Hz, 1H), 4.60 (s, 1H), 3.62 (t,J= 5.4 Hz, 4H), 3.45 (d,J= 9.5 Hz, 1H), 3.10 (s, 1H), 2.66 (s, 1H), 1.76-1.50 (m, 11H), 1.39 (t,J= 8.5 Hz, 1H).MS (ESI, LR) Calc. for C 24 H 28 N5O [M+H] + : 402.2, found: 402.1.216 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.62 (d,J= 2.5 Hz, 1H), 8.22 (s, 1H), 8.15 (dd,J= 9.0, 2.5 Hz, 1H), 7.78 (dd,J= 8.9, 1.3 Hz, 1H), 7.47 (dd,J= 8.9, 7.1 Hz, 1H), 7.13 (dd,J= 7.0, 1.4 Hz, 1H), 6.62 (d,J= 9.0 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 3.43 (s, 2H), 2.03 (s, 1H), 1.88-1.52 (m, 16H).MS (ESI, LR) Calc. for C 25 H 30 N5O [M+H] + : 416.2, found: 416.1.217 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.66 (d,J= 2.4 Hz, 1H), 8.23 (s, 1H), 8.17 (dd,J= 8.8, 2.5 Hz, 1H), 7.81 (dd,J= 8.8, 1.4 Hz, 1H), 7.48 (dd,J= 8.9, 7.0 Hz, 1H), 7.17 (dd,J= 7.1, 1.3 Hz, 1H), 7.01 (d,J= 8.8 Hz, 1H), 4.64-4.56 (m, 2H), 3.62 (t,J= 5.5 Hz, 4H), 1.76-1.46 (m, 14H).MS (ESI, LR) Calc. for C 24 H 28 N5O [M+H] + : 402.2, found: 402.1.218 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.62 (d,J= 2.4 Hz, 1H), 8.22 (s, 1H), 8.16 (dd,J= 8.8, 2.4 Hz, 1H), 7.80 (dd,J= 8.9, 1.4 Hz, 1H), 7.47 (dd,J= 8.8, 7.1 Hz, 1H), 7.14 (dd,J= 7.1, 1.4 Hz, 1H), 6.52 (d,J= 8.7 Hz, 1H), 4.08 (dd,J= 8.6, 6.9 Hz, 2H), 3.82 (dd,J= 8.7, 5.2 Hz, 2H), 3.61 (t,J= 5.4 Hz, 4H), 3.27-3.20 (m, 1H), 2.14 (s, 6H), 1.65 (d,J= 6.0 Hz, 2H), 1.57 (t,J= 6.7 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 29 N6O [M+H] + : 405.2, found: 405.1.219 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.63 (d,J= 2.3 Hz, 1H), 8.22 (s, 1H), 8.18 (dd,J= 8.7, 2.4 Hz, 1H), 7.81 (dd,J= 8.9, 1.4 Hz, 1H), 7.48 (dd,J= 8.9, 7.1 Hz, 1H), 7.15 (dd,J= 7.1, 1.3 Hz, 1H), 6.58 (d,J= 8.8 Hz, 1H), 4.26 (t,J= 8.6 Hz, 2H), 4.12 (dd,J= 8.3, 5.8 Hz, 2H), 3.71 (s, 4H), 3.62 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 8.2 Hz, 2H), 1.56 (d,J= 7.6 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 26 N5O3[M+H] + : 420.2, found: 420.1.220 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.61 (d,J= 2.4 Hz, 1H), 8.22 (s, 1H), 8.14 (dd,J= 8.8, 2.4 Hz, 1H), 7.80 (dd,J= 8.9, 1.4 Hz, 1H), 7.47 (dd,J= 8.9, 7.1 Hz, 1H), 7.13 (dd,J= 7.1, 1.4 Hz, 1H), 6.49 (d,J= 8.8 Hz, 1H), 4.02 (s, 4H), 3.62 (t,J= 5.4 Hz, 4H), 2.22 (t,J= 7.6 Hz, 4H), 1.84 (p,J= 7.5 Hz, 2H), 1.69-1.61 (m, 2H), 1.56 (s, 4H).MS (ESI, LR) Calc. for C 24 H 28 N5O [M+H] + : 420.2, found: 420.1.221 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.61 (d,J= 2.4 Hz, 1H), 8.22 (s, 1H), 8.14 (dd,J= 8.7, 2.4 Hz, 1H), 7.80 (dd,J= 8.9, 1.4 Hz, 1H), 7.47 (dd,J= 8.8, 7.1 Hz, 1H), 7.13 (dd,J= 7.1, 1.4 Hz, 1H), 6.49 (d,J= 8.8 Hz, 1H), 4.81 (t,J= 5.3 Hz, 1H), 4.06 (t,J= 8.2 Hz, 2H), 3.79 (dd,J= 8.3, 5.4 Hz, 2H), 3.61 (t,J= 5.8 Hz, 6H), 2.85 (ddd,J= 13.7, 7.5, 5.3 Hz, 1H), 1.61 (dd,J= 35.4, 6.3 Hz, 6H).MS (ESI, LR) Calc. for C 22 H 26 N5O2[M+H] + : 392.2, found: 392.1.222 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.66 (d,J= 2.5 Hz, 1H), 8.22 (s, 1H), 8.15 (dd,J= 9.0, 2.5 Hz, 1H), 7.79 (dd,J= 8.8, 1.4 Hz, 1H), 7.47 (dd,J= 8.8, 7.1 Hz, 1H), 7.15 (dd,J= 7.1, 1.3 Hz, 1H), 6.97 (d,J= 9.1 Hz, 1H), 3.66-3.54 (m, 8H), 1.96-1.76 (m, 6H), 1.69-1.51 (m, 10H).MS (ESI, LR) Calc. for C 26 H 32 N5O [M+H] + : 430.2, found: 430.1.223 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.64 (d,J= 2.4 Hz, 1H), 8.22 (s, 1H), 8.14 (dd,J= 8.9, 2.5 Hz, 1H), 7.78 (dd,J= 8.9, 1.4 Hz, 1H), 7.46 (dd,J= 8.8, 7.1 Hz, 1H), 7.13 (dd,J= 7.2, 1.4 Hz, 1H), 6.57 (d,J= 8.9 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 3.47 (d,J= 6.5 Hz, 4H), 2.09-1.87 (m, 8H), 1.65 (d,J= 5.6 Hz, 2H), 1.56 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 25 H 30 N5O [M+H] + : 416.2, found: 416.1.332 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.59 (d,J= 2.4 Hz, 1H), 8.50 (d,J= 2.3 Hz, 1H), 8.43 (dd,J= 4.8, 1.7 Hz, 1H), 8.22 (s, 1H), 8.03 (dd,J= 8.8, 2.5 Hz, 1H), 7.78 (dd,J= 8.9, 1.4 Hz, 1H), 7.70 (dt,J= 7.9, 2.0 Hz, 1H), 7.46 (dd,J= 8.9, 7.1 Hz, 1H), 7.34 (dd,J= 7.7, 4.8 Hz, 1H), 7.19-7.05 (m, 2H), 6.63 (d,J= 8.8 Hz, 1H), 3.71-3.54 (m, 6H), 2.92 (t,J= 7.1 Hz, 2H), 1.65 (q,J= 5.8 Hz, 2H), 1.57 (q,J= 5.8 Hz, 4H).MS (ESI, LR) Calc. for C 25 H 27 N6O [M+H] + : 427.2, found: 427.2.344 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.93 (d,J= 2.3 Hz, 1H), 8.50 (dd,J= 8.7, 2.4 Hz, 1H), 8.27 (s, 1H), 7.98-7.88 (m, 3H), 7.56-7.51 (m, 1H), 7.44 (s, 1H), 7.34-7.29 (m, 1H), 4.39 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (s, 2H), 1.58 (s, 4H).MS (ESI, LR) Calc. for C 21 H 22 N7O [M+H] + : 388.2, found: 388.1. Example 287. N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)nicotinamide [N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)nicotinamide] <Reaction Formula 17> Compound 19 (36.5 mg, 0.11 mmol), pyridine-3-carboxamide (20.6 mg, 0.17 mmol), and sodium hydride (6.8 mg, 0.17 mmol) were added to N,N-dimethylformamide (3 mL), and the mixture was stirred at 80°C for 12 hours. After completion of the reaction, the reaction solution was concentrated, diluted with dichloromethane (10 mL), and washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 287 (39.4 mg, 82%). 1H NMR (400 MHz, DMSO-d6) δ(ppm): 11.36 (s, 1H), 9.19 (d,J= 2.3 Hz, 1H), 8.98 (d,J= 2.3 Hz, 1H), 8.79 (dd,J= 4.8, 1.7 Hz, 1H), 8.50 (dd,J= 8.8, 2.4 Hz, 1H), 8.46-8.35 (m, 2H), 8.28 (s, 1H), 7.91 (dd,J= 8.8, 1.4 Hz, 1H), 7.62-7.50 (m, 2H), 7.32 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 6.0 Hz, 2H), 1.58 (d,J= 7.4 Hz, 4H). MS (ESI, LR) Calc. for C 24 H 23 N6O2[M+H] + : 427.2, found: 427.1. Example 316. 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one [3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one] Example 355. (7-(6-(4-nitro-1H-pyrazol-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(6-(4-nitro-1H-pyrazol-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] For Examples 316 and 355, the compounds corresponding to compound 19 were obtained by the synthetic method used in Example 287. The structural and spectral data are shown in Table 17 below. Example structure 1 H NMRMS316 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.92 (d,J= 2.4 Hz, 1H), 8.45 (dd,J= 8.9, 2.4 Hz, 1H), 8.25 (t,J= 4.4 Hz, 2H), 7.90 (dd,J= 8.9, 1.4 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.27 (dd,J= 7.1, 1.4 Hz, 1H), 4.52 (t,J= 8.0 Hz, 2H), 4.27 (dd,J= 8.7, 7.3 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.70-1.62 (m, 2H), 1.57 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 22 N5O3[M+H] + : 392.2, found: 392.1.355 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.55 (s, 1H), 9.13 (d,J= 2.3 Hz, 1H), 8.80-8.60 (m, 2H), 8.29 (s, 1H), 8.21 (d,J= 8.6 Hz, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.39 (dd,J= 7.2, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (m, 2H), 1.63-1.44 (m, 4H).MS (ESI, LR) Calc. for C 21 H 20 N7O3[M+H] + : 418.2, found: 418.1. Example 301. N-(3-chloro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)nicotinamide [N-(3-chloro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)nicotinamide] Example 311. N-(3-chloro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide [N-(3-chloro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide] For Examples 301 and 311, compounds corresponding to compound 289 were obtained by the synthetic method described in Example 287. The structural and spectral data are shown in Table 18 below. Example structure 1 H NMRMS301 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.19 (s, 1H), 9.19 (d,J= 2.3 Hz, 1H), 9.02-8.97 (m, 1H), 8.82 (d,J= 4.7 Hz, 1H), 8.76-8.71 (m, 1H), 8.41-8.35 (m, 1H), 8.30 (s, 1H), 7.96 (d,J= 8.8 Hz, 1H), 7.62 (dd,J= 7.9, 4.9 Hz, 1H), 7.56 (dd,J= 8.9, 7.1 Hz, 1H), 7.43 (d,J= 7.0 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (m, 3H), 1.58 (m, 4H).MS (ESI, LR) Calc. for C 24 H 22 ClN6O2[M+H] + : 461.1, found: 461.0.311 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.71 (s, 1H), 8.91 (d,J= 2.1 Hz, 1H), 8.65 (d,J= 2.1 Hz, 1H), 8.57 (d,J= 2.2 Hz, 1H), 8.49 (dd,J= 4.8, 1.7 Hz, 1H), 8.28 (s, 1H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.79 (dt,J= 7.8, 2.1 Hz, 1H), 7.54 (dd,J= 8.9, 7.1 Hz, 1H), 7.38 (ddd,J=7.2, 4.9, 3.1 Hz, 2H), 3.83 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.3 Hz, 2H), 1.58 (t,J= 6.7 Hz, 4H).MS (ESI, LR) Calc. for C 25 H 24 ClN6O2[M+H] + : 475.2, found: 475.1. Example 323. 3-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one [3-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one] Example 362. N-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide [N-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide] For Examples 323 and 362, compounds corresponding to compound 288 were obtained by the synthetic method described in Example 287. The structural and spectral data are shown in Table 19 below. 실시예구조 1 H NMRMS323 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.92-8.80 (m, 1H), 8.53 (dd,J= 11.3, 1.9 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.4 Hz, 1H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.38 (dd,J= 7.1, 1.4 Hz, 1H), 4.60 (dd,J= 8.6, 6.9 Hz, 2H), 4.25 (dd,J= 8.4, 7.0 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (m, 2H), 1.58 (m, 4H).MS (ESI, LR) Calc. for C 21 H 21 FN5O3[M+H] + : 410.2, found: 410.1.362 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 10.80 (s, 1H), 8.81 (dd,J= 1.9, 0.9 Hz, 1H), 8.56 (d,J= 2.3 Hz, 1H), 8.49 (dd,J= 4.8, 1.7 Hz, 1H), 8.44 (dd,J= 11.2, 1.9 Hz, 1H), 8.27 (s, 1H), 7.93 (dd,J= 8.9, 1.3 Hz, 1H), 7.78 (dt,J= 7.9, 2.0 Hz, 1H), 7.54 (dd,J= 8.9, 7.1 Hz, 1H), 7.43-7.31 (m, 2H), 3.85 (s, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (m, 2H), 1.57 (m, 4H).MS (ESI, LR) Calc. for C 25 H 24 FN6O2[M+H] + : 459.2, found: 459.1. Example 308. 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrimidin-2-yl)oxazolidin-2-one [3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrimidin-2-yl)oxazolidin-2-one] The target compound 308 was obtained using compound 267 and oxazolidin-2-one according to the synthetic method in Example 287. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.30 (s, 2H), 8.27 (s, 1H), 7.93 (dd,J= 8.9, 1.4 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.38 (dd,J= 7.1, 1.4 Hz, 1H), 4.48 (t,J= 7.9 Hz, 2H), 4.27 (t,J= 7.9 Hz, 2H), 3.62 (d,J= 5.3 Hz, 4H), 1.73-1.63 (m, 2H), 1.58 (d,J= 7.2 Hz, 4H). MS (ESI, LR) Calc. for C 20 H 21 N6O3[M+H] + : 393.2, found: 393.1. Example 257. (7-(2-(3-fluoroazetidin-1-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(2-(3-fluoroazetidin-1-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] An intermediate was obtained using the same synthetic method as steps 1-3 in Example 1 using compound 1-2 and (2-fluoro-4-pyridyl)boronic acid, and then target compound 257 was obtained using the synthetic method in Example 107 using azetidine. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.65 (d,J= 2.3 Hz, 1H), 8.23 (s, 1H), 8.19 (dd,J= 8.7, 2.4 Hz, 1H), 7.82 (dd,J= 8.9, 1.4 Hz, 1H), 7.48 (dd,J= 8.9, 7.1 Hz, 1H), 7.16 (dd,J= 7.1, 1.4 Hz, 1H), 6.61 (d,J= 8.8 Hz, 1H), 5.56 (ddt,J= 57.4, 5.9, 2.9 Hz, 1H), 4.39 (dddd,J= 21.3, 10.3, 5.9, 1.5 Hz, 2H), 4.12 (dddd,J= 24.5, 10.4, 3.2, 1.5 Hz, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.4 Hz, 2H), 1.56 (d,J= 7.6 Hz, 4H). MS (ESI, LR) Calc. for C 21 H 23 FN5O [M+H] + : 380.2, found: 380.1. Example 112. N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanesulfonamide [N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanesulfonamide] <Reaction Formula 18> Compound 17 (0.1 g, 0.31 mmol) and triethylamine (97 μL, 0.7 mmol) were dissolved in dichloromethane (5 mL), the temperature was lowered to 0 ℃ using ice water, and methanesulfonyl chloride (52 μL, 0.7 mmol) was added dropwise. The temperature was raised to room temperature and stirred for 12 hours. After completion of the reaction, the reaction solution was diluted with dichloromethane (20 mL) and washed with water (30 mL), saturated aqueous sodium bicarbonate solution (30 mL), and brine (30 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 112 (29 mg, 24%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.80 (d,J= 2.4 Hz, 1H), 8.33 (dd,J= 8.7, 2.4 Hz, 1H), 8.25 (s, 1H), 7.88 (dd,J= 8.9, 1.3 Hz, 1H), 7.51 (dd,J= 8.9, 7.1 Hz, 1H), 7.24 (dd,J= 7.0, 1.4 Hz, 1H), 7.12 (d,J= 8.7 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 3.36 (s, 3H), 1.65 (d,J= 7.5 Hz, 2H), 1.56 (d,J= 7.6 Hz, 4H). MS (ESI, LR) Calc. for C 20 H 22 N5O4S [M+H] + : 400.1, found: 400.0. Example 113. (7-(3-(1H-tetrazol-5-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-(1H-tetrazol-5-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 19> Compound 6 (0.1 g, 0.3 mmol) was dissolved in N,N-dimethylformamide (8 mL). Sodium azide (0.039 g, 0.61 mmol) dissolved in water (2 mL) was added, and the mixture was stirred at 140°C for 12 hours. After completion of the reaction, the reaction solution was concentrated and separated using column chromatography to obtain the target compound 113 (7 mg, 6%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.51 (t,J= 1.7 Hz, 1H), 8.25 (s, 1H), 8.12 (dt,J= 7.7, 1.4 Hz, 1H), 7.89 (dd,J= 8.9, 1.3 Hz, 1H), 7.78 (dt,J= 7.7, 1.5 Hz, 1H), 7.55 (dt,J= 10.8, 8.3 Hz, 2H), 7.20 (dd,J= 7.0, 1.3 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 7.4 Hz, 2H), 1.58 (s, 4H). MS (ESI, LR) Calc. for C 20 H 20 N7O [M+H] + : 374.2, found: 374.2. Example 114. (7-(4-(1H-tetrazol-5-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(4-(1H-tetrazol-5-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] The target compound 114 was obtained by the synthetic method in Example 113 using the compound corresponding to compound 15. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.14 (d,J= 8.1 Hz, 2H), 7.97 (d,J= 9.2 Hz, 2H), 7.90-7.83 (m, 1H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.22 (d,J= 7.0 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (s, 2H), 1.58 (s, 4H). MS (ESI, LR) Calc. for C 20 H 20 N7O [M+H] + : 374.2, found: 374.2. Example 115. 3-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one [3-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one] <Reaction Formula 20> Step 115-1: After dissolving compound 6 (0.15 g, 0.45 mmol) in ethanol (6.5 mL), hydroxyamine (47 mg, 0.68 mmol) was added and stirred at 80 °C for 16 hours. After completion of the reaction, the reaction solution was concentrated, diluted with ethyl acetate (20 mL), and washed with water (10 mL). The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated to obtain the target compound 115-1 (0.079 g, 24%). Step 115-2: Compound 115-1 (0.2 g, 0.55 mmol) was dissolved in tetrahydrofuran (20 mL) and DIPEA (0.19 mL, 1.1 mmol) was added. Triphosgene (0.065 g, 0.22 mmol) dissolved in tetrahydrofuran (5 mL) was slowly added to the reaction solution and stirred at room temperature for 30 minutes. The temperature was increased to 80 °C and stirred for 1 hour. After completion of the reaction, the reaction solution was concentrated and separated using column chromatography to obtain the target compound 115 (0.093 g, 43%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.36 (d,J= 2.0 Hz, 1H), 8.26 (s, 1H), 8.09 (d,J= 7.8 Hz, 1H), 7.94 (dd,J= 15.0, 8.4 Hz, 2H), 7.71 (t,J= 7.5 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.24 (d,J= 6.7 Hz, 1H), 6.53 (s, 1H), 3.63 (t,J= 5.4 Hz, 3H), 1.65 (s, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 21 H 20 N5O3[M+H] + : 390.2, found: 390.1. Example 116. 3-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one [3-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one] Example 117. 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-1,2,4-oxadiazol-5(4H)-one [3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-1,2,4-oxadiazol-5(4H)-one] Example 247. 3-[3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]2-pyridyl]-4H-1,2,4-oxadiazol-5-one [3-[3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-4H-1,2,4-oxadiazol-5-one] Example 275. 3-[2-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one Example 295. 3-[3-fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one [3-[3-fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one] Example 297. 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-1,2,4-oxadiazol-5-(4H)-one [3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-1,2,4-oxadiazol-5(4H)-one] Example 299. 3-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one [3-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one] Example 304. 3-[2-fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one Example 321. 3-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrimidin-2-yl]-4H-1,2,4-oxadiazol-5-one [3-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrimidin-2-yl]-4H-1,2,4-oxadiazol-5-one] Example 329. 3-(3-nitro-5-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one [3-(3-nitro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one] Example 331. 3-(2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one [3-(2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one] For Examples 116, 117, 247, 275, 295, 297, 299, 304, 321, 329, and 331, the compounds corresponding to Compound 1-2 were obtained by sequentially using the synthetic method in Steps 1-3 of Example 1 and the synthetic method of Example 115. The structural and spectral data are shown in Table 20 below. Example structure 1 H NMRMS116 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (d,J= 4.8 Hz, 1H), 8.11 (d,J= 7.9 Hz, 2H), 7.97 (d,J= 7.9 Hz, 2H), 7.91 (d,J= 8.9 Hz, 1H), 7.54 (t,J= 8.1 Hz, 1H), 7.27 (d,J= 7.1 Hz, 1H), 6.53 (s, 1H), 3.62 (d,J= 5.3 Hz, 3H), 1.65 (s, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 21 H 20 N5O3[M+H] + : 390.2, found: 390.1.117 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.27 (d,J= 2.2 Hz, 1H), 8.64 (dd,J= 8.3, 2.2 Hz, 1H), 8.28 (s, 1H), 8.17 (d,J= 8.3 Hz, 1H), 7.97 (dd,J= 8.8, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.41 (dd,J= 7.0, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (s, 2H), 1.57 (s, 4H).MS (ESI, LR) Calc. for C 20 H 19 N6O3[M+H] + : 391.1, found: 391.1.247 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 13.36 (s, 1H), 9.19 (s, 1H), 8.70 (d,J= 11.5 Hz, 1H), 8.31 (s, 1H), 8.00 (dd,J= 8.9, 1.3 Hz, 1H), 7.59 (dd,J= 8.9, 7.1 Hz, 1H), 7.50 (d,J= 7.1 Hz, 1H), 3.63 (t,J= 5.3 Hz, 4H), 1.66 (d,J= 6.0 Hz, 2H), 1.57 (q,J= 5.4 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 18 FN6O3[M+H] + : 409.1, found: 409.1.275 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 12.97 (s, 1H), 8.36 (dd,J= 6.8, 2.3 Hz, 1H), 8.33-8.24 (m, 2H), 7.93 (dd,J= 8.9, 1.3 Hz, 1H), 7.69 (dd,J= 10.4, 8.8 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.27 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.5 Hz, 4H), 1.66 (q,J= 5.7 Hz, 2H), 1.57 (q,J= 5.7 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 19 FN5O3[M+H] + : 408.1, found: 408.1.295 1H NMR (400 MHz, DMSO-d6) δ(ppm): 13.19 (s, 1H), 8.21 (s, 1H), 7.98 (dd,J= 8.9, 1.4 Hz, 1H), 7.92 (t,J= 7.5 Hz, 1H), 7.88-7.77 (m, 2H), 7.55 (dd,J= 9.0, 7.0 Hz, 1H), 7.24 (dd,J= 7.0, 1.4 Hz, 1H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.4 Hz, 2H), 1.57 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 19 FN5O3[M+H] + : 408.1, found: 408.1.297 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.14 (d,J= 2.2 Hz, 1H), 9.07 (d,J= 2.0 Hz, 1H), 8.74 (t,J= 2.1 Hz, 1H), 8.28 (s, 1H), 7.95 (dd,J= 8.9, 1.4 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.36 (dd,J= 6.9, 1.4 Hz, 1H), 3.63 (t,J= 5.5 Hz, 4H), 1.69-1.62 (m, 2H), 1.58 (d,J= 7.3 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 19 N6O3[M+H] + : 391.1, found: 391.1.299 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.28 (s, 1H), 8.23 (t,J= 1.5 Hz, 1H), 8.04-7.99 (m, 1H), 7.94 (dd,J= 9.0, 1.3 Hz, 1H), 7.74 (dd,J= 9.1, 2.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.31 (dd,J= 7.2, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.7 Hz, 2H), 1.58 (d,J= 4.6 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 19 FN5O3[M+H] + : 408.1, found: 408.1.304 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 13.01 (s, 1H), 8.28 (s, 1H), 8.15 (dd,J= 12.0, 1.6 Hz, 1H), 8.01 (dd,J= 8.2, 1.6 Hz, 1H), 7.96 (dt,J= 7.9, 3.3 Hz, 2H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.41-7.33 (m, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.71-1.62 (m, 2H), 1.58 (q,J= 5.6 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 19 FN5O3[M+H] + : 408.1, found: 408.1.321 1H NMR (400 MHz, DMSO-d6) δ(ppm): 13.43 (s, 1H), 9.62 (s, 2H), 8.32 (s, 1H), 8.01 (dd,J= 8.8, 1.4 Hz, 1H), 7.60 (dd,J= 8.9, 7.0 Hz, 1H), 7.57-7.50 (m, 1H), 3.63 (t,J= 5.3 Hz, 4H), 1.75-1.64 (m, 2H), 1.57 (d,J= 7.9 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 18 N7O3[M+H] + : 392.1, found: 392.1.329 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.09 (t,J= 1.9 Hz, 1H), 8.79 (t,J= 1.6 Hz, 1H), 8.77 (t,J= 1.8 Hz, 1H), 8.33 (s, 1H), 8.00 (dd,J= 8.9, 1.3 Hz, 1H), 7.59 (dd,J= 8.9, 7.1 Hz, 1H), 7.45 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 7.4 Hz, 2H), 1.58 (d,J= 7.3 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 19 N6O5[M+H] + : 435.1, found: 435.1.331 1H NMR (400 MHz, DMSO-d6) δ(ppm): 13.10 (s, 1H), 8.30 (s, 1H), 8.08 (d,J= 1.6 Hz, 1H), 8.06 (s, 1H), 7.98 (dd,J= 9.0, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.1 Hz, 1H), 7.43 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.7 Hz, 2H), 1.57 (d,J= 4.7 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 18 F2N5O3[M+H] + : 426.1, found: 426.1. Example 118. (7-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 21> After dissolving compound 116-1 (0.014 g, 0.038 mmol) in pyridine (2 mL), acetyl chloride (5.5 μL, 47 mg, 0.077 mmol) was added and stirred at 120 °C for 24 hours. After completion of the reaction, the reaction solution was diluted with ethyl acetate (10 mL) and washed with water (10 mL x 2) and brine (10 mL x 2). The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 118 (5.4 mg, 36%). 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.27 (s, 1H), 8.20-8.11 (m, 4H), 7.92 (dd,J= 8.8, 1.3 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.28 (d,J= 7.0 Hz, 1H), 3.63 (t,J= 5.5 Hz, 4H), 2.71 (s, 3H), 1.65 (s, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 22 H 22 N5O2[M+H] + : 388.2, found: 388.1. Example 263. [7-[5-fluoro-6-(5-methyl-1,2,4-oxadiazol-3-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[5-fluoro-6-(5-methyl-1,2,4-oxadiazol-3-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 276. [7-[4-fluoro-3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[4-fluoro-3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 296. [7-[2-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [7-[2-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 303. [7-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [7-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 317. [7-[2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 319. (7-(5-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 322. (7-(3-fluoro-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-fluoro-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 328. (7-(3,5-difluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3,5-difluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 330. (7-(3-(5-methyl-1,2,4-oxadiazol-3-yl)-5-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-(5-methyl-1,2,4-oxadiazol-3-yl)-5-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] For Examples 263, 276, 296, 303, 317, 319, 322, 328, and 330, the compounds corresponding to Compound 1-2 were used in the synthetic method in Step 159-3 of Example 159, the synthetic method in Step 115-1 of Example 115, and the synthetic method in Example 118, respectively, to obtain them. The structural and spectral data are shown in Table 21 below. Example structure 1 H NMRMS263 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.20 (t,J= 1.6 Hz, 1H), 8.70 (dd,J= 11.5, 1.8 Hz, 1H), 8.32 (s, 1H), 8.00 (dd,J= 8.9, 1.4 Hz, 1H), 7.59 (dd,J= 8.8, 7.1 Hz, 1H), 7.51 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.75 (s, 3H), 1.66 (d,J= 5.6 Hz, 2H), 1.58 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 20 FN6O2[M+H] + : 407.2, found: 407.1.276 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.62 (dd,J= 6.8, 2.4 Hz, 1H), 8.28 (s, 1H), 8.19 (ddd,J= 8.7, 4.8, 2.4 Hz, 1H), 7.92 (dd,J= 8.9, 1.3 Hz, 1H), 7.66 (dd,J= 10.5, 8.7 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.27 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.71 (s, 3H), 1.66 (d,J= 5.6 Hz, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 21 FN5O2[M+H] + : 406.2, found: 406.1.296 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.22 (s, 1H), 8.06-7.86 (m, 4H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.24 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.73 (s, 3H), 1.65 (d,J= 7.0 Hz, 2H), 1.62-1.51 (m, 4H).MS (ESI, LR) Calc. for C 22 H 21 FN5O2[M+H] + : 406.2, found: 406.1.303 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.30 (s, 1H), 8.18 (t,J= 7.8 Hz, 1H), 8.13 (d,J= 12.0 Hz, 1H), 8.01 (d,J= 8.2 Hz, 1H), 7.95 (d,J= 8.9 Hz, 1H), 7.55 (t,J= 8.0 Hz, 1H), 7.37 (d,J= 7.1 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.80-2.67 (m, 3H), 1.66 (d,J= 6.6 Hz, 2H), 1.58 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 21 FN5O2[M+H] + : 406.2, found: 406.1.317 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.53 (s, 2H), 8.11 (dd,J= 9.0, 1.3 Hz, 1H), 8.09 (s, 1H), 7.43 (dd,J= 9.0, 7.0 Hz, 1H), 7.15-7.09 (m, 1H), 3.73 (t,J= 5.3 Hz, 4H), 2.77 (s, 3H), 1.79-1.72 (m, 2H), 1.72-1.65 (m, 4H).MS (ESI, LR) Calc. for C 20 H 20 N7O2[M+H] + : 390.2, found: 390.1.319 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.27 (dd,J= 8.0, 2.1 Hz, 2H), 9.00 (t,J= 2.1 Hz, 1H), 8.30 (s, 1H), 7.97 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.43 (dd,J= 7.0, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 2.73 (s, 3H), 1.66 (d,J= 5.7 Hz, 2H), 1.63-1.55 (m, 4H).MS (ESI, LR) Calc. for C 21 H 21 N6O2[M+H] + : 389.2, found: 389.1.322 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.46 (t,J= 1.5 Hz, 1H), 8.30 (s, 1H), 8.07 (dt,J= 9.6, 2.1 Hz, 1H), 7.97-7.89 (m, 2H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.36 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 2.71 (s, 3H), 1.66 (d,J= 5.0 Hz, 2H), 1.58 (s, 4H).MS (ESI, LR) Calc. for C 22 H 21 FN5O2[M+H] + : 406.2, found: 406.1.328 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.32 (s, 1H), 8.04 (d,J= 9.6 Hz, 2H), 7.98 (dd,J= 8.9, 1.4 Hz, 1H), 7.59-7.54 (m, 1H), 7.44 (d,J= 7.0 Hz, 1H), 3.64 (d, J= 5.7 Hz, 4H), 2.75 (s, 3H), 1.66 (s, 2H), 1.58 (s, 4H).MS (ESI, LR) Calc. for C 22 H 20 F2N5O2[M+H] + : 424.2, found: 424.1.330 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.01 (t,J= 1.9 Hz, 1H), 8.98 (t,J= 1.6 Hz, 1H), 8.82 (t,J= 1.9 Hz, 1H), 8.33 (s, 1H), 7.99 (dd,J= 8.9, 1.4 Hz, 1H), 7.58 (dd,J= 8.9, 7.1 Hz, 1H), 7.48 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 2.75 (s, 3H), 1.66 (d,J= 7.3 Hz, 2H), 1.58 (s, 4H).MS (ESI, LR) Calc. for C 22 H 21 N6O4[M+H] + : 433.2, found: 433.1. Example 352. [7-[4-(1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[4-(1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] <Reaction Formula 22> Compound 116-1 was added with (50 mg, 0.14 mmol) trimethyl orthoformate (0.13 mL, 0.78 mmol) and stirred at 100 °C for 16 hours. The reaction solution was concentrated and separated using column chromatography to obtain the target compound 352 (35 mg, 65%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.78 (s, 1H), 8.27 (s, 1H), 8.22 (d,J= 8.5 Hz, 2H), 8.17 (d,J= 8.5 Hz, 2H), 7.93 (dd,J= 8.8, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.28 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.2 Hz, 2H), 1.58 (s, 4H). MS (ESI, LR) Calc. for C 21 H 20 N5O2[M+H] + : 374.2, found: 374.1. Example 341. (7-(3-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 342. (7-(3-nitro-5-(1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-nitro-5-(1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 374. (7-(5-(1,2,4-oxadiazol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(5-(1,2,4-oxadiazol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] For Examples 341, 342, and 374, the compounds corresponding to Compound 1-2 were used in the synthetic method in Step 159-3 of Example 159, the synthetic method in Step 115-1 of Example 115, and the synthetic method in Example 352, respectively, to obtain the compounds. The structural and spectral data are shown in Table 22 below. Example structure 1 H NMRMS341 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.81 (s, 1H), 8.51 (t,J= 1.5 Hz, 1H), 8.29 (s, 1H), 8.09 (dt,J= 9.8, 2.2 Hz, 1H), 7.97 (ddd,J= 9.0, 7.9, 1.8 Hz, 2H), 7.55 (dd,J= 8.9, 7.1 Hz, 1H), 7.37 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.5 Hz, 2H), 1.58 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 19 FN5O2[M+H] + : 392.1, found: 392.1.342 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.89 (s, 1H), 9.03 (p,J= 1.7 Hz, 2H), 8.86 (t,J= 1.9 Hz, 1H), 8.32 (s, 1H), 8.00 (dd,J= 8.9, 1.4 Hz, 1H), 7.59 (dd,J= 8.9, 7.0 Hz, 1H), 7.49 (dd,J= 7.1, 1.4 Hz, 1H), 3.65 (t,J= 5.4 Hz, 4H), 1.67 (d,J= 5.6 Hz, 2H), 1.58 (d,J= 7.7 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 19 N6O4[M+H] + : 419.1, found: 419.0.374 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.86 (s, 1H), 9.33 (d,J= 2.0 Hz, 1H), 9.28 (d,J= 2.2 Hz, 1H), 9.05 (t,J= 2.1 Hz, 1H), 8.30 (s, 1H), 7.97 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.1 Hz, 1H), 7.44 (dd,J= 7.0, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.5 Hz, 2H), 1.58 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 19 N6O2[M+H] + : 375.1, found: 375.1. Example 361. 1-piperidyl-[7-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]pyrazolo[1,5-a]pyridin-3-yl]methanone <Reaction Formula 23> Compound 116-1 (0.040 g, 0.11 mmol) was dissolved in tetrahydrofuran (2 mL), trifluoroacetic anhydride (15.3 μL, 23 mg, 0.11 mmol) was added, and the mixture was stirred at 80 °C for 16 hours. After completion of the reaction, the reaction solution was diluted with dichloromethane (10 mL) and washed with water (10 mL x 2) and brine (10 mL x 2). The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 361 (45 mg, 92%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.28 (s, 1H), 8.27-8.19 (m, 4H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.1 Hz, 1H), 7.31 (dd,J= 7.0, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.0 Hz, 2H), 1.62-1.51 (m, 4H). MS (ESI, LR) Calc. for C 22 H 19 F3N5O2[M+H] + : 442.1, found: 442.1. Example 359. [7-[4-(5-amino-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[4-(5-amino-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] <Reaction Formula 24> Step 359-1: The target compound 359-1 was obtained by the synthetic method in Example 361 using compound 116-1 and trichloroacetic anhydride. Step 359-2: To compound 359-1 (130 mg, 0.26 mmol), 7 N ammonia solution in methanol (1.6 mL, 11.2 mmol) was added, and the mixture was stirred at room temperature for 16 hours. The reaction solution was concentrated and separated using column chromatography to obtain the target compound 359 (92 mg, 89%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.09 (d,J= 8.6 Hz, 2H), 8.04 (d,J= 8.6 Hz, 2H), 8.01 (s, 2H), 7.91 (dd,J= 8.9, 1.3 Hz, 1H), 7.54 (dd,J= 8.9, 7.1 Hz, 1H), 7.26 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.1 Hz, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 21 H 21 N6O2[M+H] + : 389.2, found: 389.1. Example 348. [7-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] <Reaction Formula 25> Step 348-1: Compound 10 (120 mg, 0.34 mmol) was dissolved in dichloromethane (4 mL), and tertiary butyl carbazite (49.9 mg, 0.38 mmol) and EDC·HCl (72.4 mg, 0.38 mmol) were added and stirred for 1 hour. After completion of the reaction, the mixture was diluted with dichloromethane (10 mL), washed with aqueous sodium bicarbonate solution and brine, dried over anhydrous magnesium sulfate, filtered, and concentrated to obtain 348-1 (151 mg, 95%). Step 348-2: Add compound 348-1 (220 g, 0.47 mmol) to a reaction vessel, cool to 0 °C, add trifluoroacetic acid (1 mL, 13.1 mmol), and stir for 1 hour. After completion of the reaction, concentrate, dilute with diethyl ether (10 mL), recrystallize, and filter. Dissolve the filtrate in aqueous sodium bicarbonate solution and extract with dichloromethane. Dry over anhydrous magnesium sulfate, filter, and concentrate to obtain 348-2 (140 mg, 65%). Step 348-3: N,N-dimethylformamide (2 mL) was added to the reaction vessel, 4 N hydrochloric acid dissolved in 1,4-dioxin (0.1 mL, 0.41 mmol) was added, and stirred for 5 minutes. Imidazole (28.1 mg, 0.41 mmol) was added, and stirred for 30 minutes. Compound 348-2 (50 mg, 0.14 mmol) was added, and stirred at 100 °C for 16 hours. Phosphorus oxychloride (15.4 μL, 0.17 mmol) was added, and stirred for 12 hours. After completion of the reaction, the temperature was lowered to room temperature, the mixture was diluted with brine (5 mL), and extracted with dichloromethane (5 mL x 3). The combined organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, recrystallized using N,N-dimethylformamide, filtered, and dried to obtain the target compound 348 (14 mg, 26%). 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.27 (s, 1H), 8.23-8.10 (m, 4H), 7.93 (dd,J= 8.9, 1.3 Hz, 1H), 7.58-7.51 (m, 1H), 7.29 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.63 (s, 3H), 1.66 (s, 2H), 1.62-1.53 (m, 4H). MS (ESI, LR) Calc. for C 22 H 22 N5O2[M+H] + : 388.2, found: 388.1. Example 364. [7-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 379. [7-[5-fluoro-6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[5-fluoro-6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] For Examples 364 and 379, the corresponding compounds were obtained by sequentially using the same synthetic method as in Step 159-3 of Example 159 and the same synthetic method as in Example 348. The structural and spectral data are shown in Table 23 below. Example structure 1 H NMRMS364 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.32-9.27 (m, 1H), 8.68 (dd,J= 8.3, 2.2 Hz, 1H), 8.34 (dd,J= 8.2, 0.8 Hz, 1H), 8.30 (s, 1H), 7.97 (dd,J= 8.9, 1.3 Hz, 1H), 7.58 (dd,J= 8.9, 7.1 Hz, 1H), 7.42 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.66 (s, 3H), 1.66 (d,J= 5.3 Hz, 2H), 1.58 (d,J= 7.0 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 21 N6O2[M+H] + : 389.2, found: 389.1.379 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.22 (d,J= 1.6 Hz, 1H), 8.74 (dd,J= 11.6, 1.7 Hz, 1H), 8.33 (s, 1H), 8.00 (dd,J= 8.8, 1.4 Hz, 1H), 7.59 (dd,J= 8.8, 7.1 Hz, 1H), 7.51 (dd,J= 7.1, 1.5 Hz, 1H), 3.64 (t,J= 5.3 Hz, 4H), 2.68 (s, 3H), 1.66 (s, 2H), 1.58 (d,J= 7.1 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 20 FN6O2[M+H] + : 407.2, found: 407.1. Example 350. [7-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 380. [7-[5-fluoro-6-(1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[5-fluoro-6-(1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] For Examples 350 and 380, compounds 10 and 243 were used, respectively, and the same synthetic methods as in Steps 348-1 and 348-2 of Example 348 and Example 352 were used to obtain them. The structural and spectral data are shown in Table 24 below. Example structure 1 H NMRMS350 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.42 (s, 1H), 8.27 (s, 1H), 8.24-8.17 (m, 4H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.30 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.6 Hz, 2H), 1.58 (s, 4H).MS (ESI, LR) Calc. for C 21 H 20 N5O2[M+H] + : 374.2, found: 374.1.380 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.56 (s, 1H), 9.25 (t,J= 1.5 Hz, 1H), 8.77 (dd,J= 11.6, 1.7 Hz, 1H), 8.33 (s, 1H), 8.01 (dd,J= 8.8, 1.4 Hz, 1H), 7.59 (dd,J= 8.8, 7.1 Hz, 1H), 7.52 (dd,J= 7.1, 1.4 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.7 Hz, 2H), 1.58 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 18 FN6O2[M+H] + : 393.1, found: 393.1. Example 365. 1-piperidyl-[7-[6-(2-thioxo-3H-1,3,4-oxadiazol-5-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]methanone [1-piperidyl-[7-[6-(2-thioxo-3H-1,3,4-oxadiazol-5-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]methanone] <Reaction Formula 26> Step 365-1 [Step 365-1]: The target compound 365-1 was obtained using the same synthetic method as Step 1-3 in Example 1 using compound 1-2. Step 365-2 [Step 365-2]: Using compound 365-1, target compound 365-2 was obtained using the same synthetic method as step 243-1 in Example 243. Step 365-3 [Step 365-3]: Using compound 365-2, the target compound 365-3 was obtained using the same synthetic method as step 348-1 in Example 348. Step 365-4 [Step 365-4]: Using compound 365-3, the target compound 365-4 was obtained using the same synthetic method as step 348-2 in Example 348. Step 365-5: Compound 365-4 (70 mg, 0.15 mmol) was dissolved in 1,4-dioxin (2 mL), and di(imidazol-1-yl)methanethione (39.5 mg, 0.22 mmol) and DBU (88 μL, 0.59 mmol) were added, followed by stirring at 100 °C for 16 hours. After completion of the reaction, the reaction solution was concentrated and separated using column chromatography to obtain the target compound 365 (57 mg, 95%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.81 (s, 1H), 9.20 (d,J= 2.2 Hz, 1H), 8.62 (dd,J= 8.2, 2.2 Hz, 1H), 8.28 (s, 1H), 8.24 (d,J= 8.2 Hz, 1H), 7.95 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.0 Hz, 1H), 7.41 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.5 Hz, 4H), 1.65 (d,J= 5.3 Hz, 2H), 1.59 (d,J= 4.7 Hz, 4H). MS (ESI, LR) Calc. for C 20 H 19 N6O2S [M+H] + : 407.1, found: 407.1. Example 394. [7-[5-fluoro-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[5-fluoro-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] <Reaction Formula 27> Step 394-1 [Step 394-1]: Using compound 243, the target compound 394-1 was obtained using the same synthetic method as steps 348-1 and 348-2 in Example 348. Step 394-2 [Step 394-2]: Using compound 394-1, the target compound 394-2 was obtained using the same synthetic method as in Example 361. Step 394-3: Compound 394-2 (75 mg, 0.15 mmol) was dissolved in 1,4-dioxin (2 mL), phosphorus oxychloride (0.15 mL, 1.5 mmol) was added, and the mixture was stirred at 100 °C for 16 hours. After completion of the reaction, the reaction solution was concentrated, diluted with dichloromethane (5 mL), and the pH of the solution was adjusted to 9 with aqueous sodium bicarbonate solution. After extraction with dichloromethane (5 mL x 3), the combined organic solution was washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was separated using column chromatography to obtain the target compound 394 (7 mg, 9.2%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.29 (t,J= 1.5 Hz, 1H), 8.83 (dd,J= 11.6, 1.7 Hz, 1H), 8.33 (s, 1H), 8.02 (dd,J= 8.8, 1.5 Hz, 1H), 7.60 (dd,J= 8.8, 7.1 Hz, 1H), 7.57-7.52 (m, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 6.1 Hz, 2H), 1.58 (d,J= 4.6 Hz, 4H). MS (ESI, LR) Calc. for C 21 H 17 F4N6O2[M+H] + : 461.1, found: 461.1. Example 349. 5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-3H-1,3,4-oxadiazol-2-one [5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-3H-1,3,4-oxadiazol-2-one] <Reaction Formula 28> Compound 348-2 (50 mg, 0.14 mmol) was dissolved in tetrahydrofuran (2 mL), and then DIPEA (48 μL, 0.28 mmol) and triphosgene (16.3 mg, 0.05 mmol) were added and stirred at 80 °C for 1 hour. After completion of the reaction, the reaction solution was concentrated and separated using column chromatography to obtain the target compound 349 (30 mg, 53%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 12.69 (s, 1H), 8.26 (s, 1H), 8.17-8.09 (m, 2H), 8.00-7.94 (m, 2H), 7.92 (dd,J= 8.9, 1.4 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.27 (dd,J= 7.1, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (q,J= 6.2 Hz, 2H), 1.57 (q,J= 5.7 Hz, 4H). MS (ESI, LR) Calc. for C 21 H 20 N5O3[M+H] + : 390.1, found: 390.1. Example 360. 5-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-3H-1,3,4-oxadiazol-2-one [5-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-3H-1,3,4-oxadiazol-2-one] Example 373. 5-[3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-3H-1,3,4-oxadiazol-2-one [5-[3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-3H-1,3,4-oxadiazol-2-one] For Examples 360 and 373, the corresponding compounds were obtained using the same synthetic method as in Example 349. The structural and spectral data are shown in Table 25 below. Example structure 1 H NMRMS360 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 12.88 (s, 1H), 9.24 (d,J= 2.2 Hz, 1H), 8.62 (dd,J= 8.3, 2.2 Hz, 1H), 8.29 (s, 1H), 8.10 (d,J= 8.3 Hz, 1H), 7.96 (dd,J= 8.9, 1.3 Hz, 1H), 7.57 (dd,J= 8.9, 7.1 Hz, 1H), 7.39 (dd,J= 7.1, 1.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.72-1.62 (m, 2H), 1.62-1.51 (m, 4H).MS (ESI, LR) Calc. for C 20 H 19 N6O3[M+H] + : 391.1, found: 391.1.373 1H NMR (400 MHz, DMSO-d6) δ(ppm): 12.98 (s, 1H), 9.16 (t,J= 1.6 Hz, 1H), 8.67 (dd,J= 11.9, 1.7 Hz, 1H), 8.32 (s, 1H), 7.99 (dd,J= 8.9, 1.4 Hz, 1H), 7.58 (dd,J= 8.8, 7.1 Hz, 1H), 7.49 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.5 Hz, 4H), 1.71-1.63 (m, 2H), 1.58 (q,J= 5.7 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 18 FN6O3[M+H] + : 409.1, found: 409.1. Example 300. [7-[4-(2-methylpyrazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [7-[4-(2-methylpyrazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 302. [7-[4-(3-furyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] [7-[4-(3-furyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 305. 5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]pyrimidine-2-carbonitrile [5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]pyrimidine-2-carbonitrile] Example 306. [7-[4-(2-hydroxypyrimidin-5-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[4-(2-hydroxypyrimidin-5-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 307. 5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]pyrimidine-2-carboxamide [5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]pyrimidine-2-carboxamide] Example 324. [7-[4-(3,5-dimethylisoxazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[4-(3,5-dimethylisoxazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 346. 1-piperidyl-[7-[4-(1H-pyrazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]methanone Example 347. 1-piperidyl-[7-[4-(3-thienyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]methanone For Examples 300, 302, 305, 306, 307, 324, 346, and 347, the compounds corresponding to Compound 292 were obtained using the same synthetic method as Steps 1-3 in Example 1. The structural and spectral data are shown in Table 26 below. Example structure 1 H NMRMS300 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.07 (d,J= 8.0 Hz, 2H), 7.91 (dd,J= 8.9, 1.4 Hz, 1H), 7.74 (d,J= 8.1 Hz, 2H), 7.58-7.50 (m, 2H), 7.25 (d,J= 7.0 Hz, 1H), 6.53 (d,J= 1.9 Hz, 1H), 3.95 (s, 3H), 3.63 (t,J= 5.3 Hz, 4H), 1.66 (d,J= 4.9 Hz, 2H), 1.58 (d,J= 6.4 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 24 N5O [M+H] + : 386.2, found: 386.1.302 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.34-8.31 (m, 1H), 8.25 (d,J= 5.8 Hz, 1H), 8.01-7.95 (m, 2H), 7.88 (dd,J= 8.9, 1.4 Hz, 1H), 7.83-7.78 (m, 3H), 7.52 (dd,J= 8.8, 7.0 Hz, 1H), 7.21 (dd,J= 7.1, 1.4 Hz, 1H), 7.09-7.05 (m, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (s, 2H), 1.57 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 22 N3O2[M+H] + : 372.2, found: 372.1.305 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.51 (s, 2H), 8.26 (s, 1H), 8.16 (d,J= 8.4 Hz, 2H), 8.12 (d,J= 8.4 Hz, 2H), 7.92 (d,J= 8.8 Hz, 1H), 7.55 (dd,J= 8.9, 7.0 Hz, 1H), 7.28 (d,J= 7.0 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.3 Hz, 2H), 1.58 (d,J= 7.7 Hz, 4H).MS (ESI, LR) Calc. for C 24 H 21 N6O [M+H] + : 409.2, found: 409.1.306 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 12.29 (s, 1H), 8.75 (s, 2H), 8.24 (s, 1H), 8.02 (d,J= 8.4 Hz, 2H), 7.88 (d,J= 8.9 Hz, 1H), 7.83 (d,J= 8.2 Hz, 2H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.22 (d,J= 7.0 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.1 Hz, 2H), 1.57 (d,J= 7.6 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 22 N5O2[M+H] + : 400.2, found: 400.2.307 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.38 (s, 2H), 8.26 (s, 2H), 8.14 (d,J= 8.1 Hz, 2H), 8.09 (d,J= 8.2 Hz, 2H), 7.96-7.89 (m, 1H), 7.85 (s, 1H), 7.55 (dd,J= 9.0, 7.1 Hz, 1H), 7.28 (d,J= 6.9 Hz, 1H), 3.64 (t,J= 5.4 Hz, 4H), 1.66 (s, 2H), 1.58 (s, 4H).MS (ESI, LR) Calc. for C 24 H 23 N6O2[M+H] + : 427.2, found: 427.1.324 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (s, 1H), 8.04 (d,J= 8.2 Hz, 2H), 7.90 (dd,J= 8.9, 1.4 Hz, 1H), 7.59 (d,J= 8.1 Hz, 2H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.27-7.21 (m, 1H), 3.63 (t,J= 5.4 Hz, 4H), 2.49 (s, 3H), 2.31 (s, 3H), 1.66 (d,J= 7.5 Hz, 2H), 1.57 (d,J= 7.5 Hz, 4H).MS (ESI, LR) Calc. for C 24 H 25 N4O2[M+H] + : 401.2, found: 401.1.346 1H NMR (400 MHz, DMSO-d6) δ(ppm): 13.04 (s, 1H), 8.31 (s, 1H), 8.24 (s, 1H), 8.05 (s, 1H), 7.95 (d,J= 8.1 Hz, 2H), 7.87 (dd,J= 8.9, 1.4 Hz, 1H), 7.79 (d,J= 8.1 Hz, 2H), 7.51 (dd,J= 8.9, 7.0 Hz, 1H), 7.20 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (s, 2H), 1.58 (d,J= 7.4 Hz, 4H).MS (ESI, LR) Calc. for C 22 H 22 N5O [M+H] + : 372.2, found: 372.1.347 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (s, 1H), 8.06-7.97 (m, 3H), 7.94-7.86 (m, 3H), 7.71 (dd,J= 5.0, 2.8 Hz, 1H), 7.67 (dd,J= 5.0, 1.5 Hz, 1H), 7.52 (dd,J= 8.9, 7.1 Hz, 1H), 7.23 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.5 Hz, 2H), 1.58 (d,J= 7.2 Hz, 4H).MS (ESI, LR) Calc. for C 23 H 22 N3OS [M+H] + : 388.1, found: 388.1. Example 351. [7-[4-(5-methylthiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[4-(5-methylthiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] <Reaction Formula 29> Step 351-1: Compound 292 (0.370 g, 0.96 mmol) was dissolved in N,N-dimethylformamide (10 mL), and bis(pinacolato)diboron (0.366 g, 1.44 mmol), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium (0.040 g, 0.05 mmol), and potassium acetate (0.283 g, 2.89 mmol) were added. The reaction solution was bubbled with nitrogen for 10 minutes and stirred at 90 ℃ for 16 hours. After completion of the reaction, the temperature was lowered to room temperature, diluted with dichloromethane (10 mL), and palladium was removed using diatomaceous earth (Celite). The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was separated using column chromatography to obtain the target compound 351-1 (0.528 g, 57%). Step 351-2 [Step 351-2]: The target compound 351 was obtained using the same synthetic method as Step 159-3 in Example 159 using compound 351-1 and 2-bromo-5-methyl-thiazole. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.13-8.01 (m, 4H), 7.91 (dd,J= 8.8, 1.3 Hz, 1H), 7.69 (d,J= 1.5 Hz, 1H), 7.53 (dd,J= 8.9, 7.1 Hz, 1H), 7.26 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 6.8 Hz, 2H), 1.58 (d,J= 5.0 Hz, 4H). MS (ESI, LR) Calc. for C 23 H 23 N4OS [M+H] + : 403.2, found: 403.1. Example 358. [7-[4-(1,2-dimethylimidazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [7-[4-(1,2-dimethylimidazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] The target compound 358 was obtained using the same synthetic method as step 351-2 in Example 351 using compound 351-1 and 4-bromo-1,2-dimethyl-imidazole. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.07 (s, 1H), 7.93 (d,J= 8.8 Hz, 1H), 7.87 (s, 4H), 7.36 (dd,J= 8.9, 7.0 Hz, 1H), 7.17 (s, 1H), 6.97 (d,J= 7.1 Hz, 1H), 3.72 (t,J= 5.3 Hz, 4H), 3.62 (s, 3H), 2.45 (s, 3H), 1.72 (q,J= 5.6 Hz, 2H), 1.69-1.62 (m, 4H). MS (ESI, LR) Calc. for C 24 H 26 N5O [M+H] + : 400.2, found: 400.1. Example 343. (7-(3-amino-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(3-amino-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Using compound 330, the target compound 343 was obtained using the same synthetic method as in Example 7. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.24 (s, 1H), 7.88 (dd,J= 8.9, 1.3 Hz, 1H), 7.64 (t,J= 1.5 Hz, 1H), 7.50 (dd,J= 8.9, 7.0 Hz, 1H), 7.39 (t,J= 1.9 Hz, 1H), 7.25 (t,J= 1.9 Hz, 1H), 7.14 (dd,J= 7.1, 1.4 Hz, 1H), 5.64 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 2.66 (s, 3H), 1.68-1.62 (m, 2H), 1.62-1.55 (m, 4H). MS (ESI, LR) Calc. for C 22 H 23 N6O2[M+H] + : 403.2, found: 403.1. Example 119. (Z)-5-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzylidene)thiazolidine-2,4-dione [(Z)-5-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzylidene)thiazolidine-2,4-dione] <Reaction Formula 30> Step 119-1 [Step 119-1]: The target compound 119-1 was obtained using the same synthetic method as Step 1-3 in Example 1 using compound 1-2 and 3-formylphenylboronic acid. Step 119-2: Compound 119-1 and (0.15 g, 0.45 mmol) thiazolidine-2,4-dinone were dissolved in ethanol (5 mL) (0.063 g, 0.54 mmol), piperidine (35 μL, 0.36 mmol) was added, and the mixture was stirred at 80 °C for 16 hours. After completion of the reaction, the mixture was cooled to room temperature, diluted with water (5 mL), and acidified with 1 N citric acid (pH 4) to obtain a precipitated solid. The solid was filtered and washed successively with water, diethyl ether, and methyl tert-butyl ether to obtain the target compound 119 (50 mg, 25%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.09-8.04 (m, 2H), 8.01-7.83 (m, 3H), 7.67-7.64 (m, 2H), 7.45 (td,J= 8.7, 4.4 Hz, 1H), 7.06-6.96 (m, 1H), 3.76-3.72 (m, 4H), 1.76-1.69 (m, 6H). MS (ESI, LR) Calc. for C 23 H 21 N4O3S [M+H] + : 433.1, found: 433.1. Compound 253. 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzaldehyde oxime The target compound 253 was obtained by the synthetic method in step 236-2 of Example 236 using compound 119-1. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 11.35 (s, 1H), 8.16 (t,J= 1.8 Hz, 1H), 7.94-7.87 (m, 2H), 7.76 (dt,J= 7.9, 1.4 Hz, 1H), 7.66-7.48 (m, 4H), 7.20 (dd,J= 7.1, 1.4 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (q,J= 5.7 Hz, 2H), 1.57 (q,J= 7.6 Hz, 4H). MS (ESI, LR) Calc. for C 20 H 21 N4O2[M+H] + : 349.2, found: 349.1. Example 132. 2-Methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one [2-methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one] <Reaction Formula 31> Compound 131 (30 mg, 0.08 mmol) was dissolved in N,N-dimethylformamide (3 mL), the temperature was lowered to 0 °C, and sodium hydride (60%, 8 mg, 0.2 mmol) was added. The reaction solution was stirred at room temperature for 15 minutes, after which methyl iodide (7.5 μL, 0.12 mmol) was added and stirred for 1 hour. After completion of the reaction, the temperature was lowered to 0 °C, the reaction solution was diluted with water (10 mL), and then extracted with dichloromethyl (10 mL x 3). The combined organic layers were washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was purified using column chromatography to obtain the target compound 132 (13.8 mg, 44%). 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.41 (d,J= 2.0 Hz, 1H), 8.24 (s, 1H), 8.00 (dd,J= 7.9, 2.0 Hz, 1H), 7.89 (dd,J= 8.9, 1.4 Hz, 1H), 7.55-7.45 (m, 2H), 7.19 (dd,J= 7.0, 1.4 Hz, 1H), 3.63 (t,J= 5.5 Hz, 6H), 3.08 (d,J= 7.4 Hz, 5H), 1.69-1.62 (m, 2H), 1.62-1.55 (m, 4H). MS (ESI, LR) Calc. for C 23 H 25 N4O2[M+H] + : 389.2, found: 389.2. Example 199. 6-Methyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-7,8-dihydro-1,6-naphthyridin-5-(6H)-one [6-methyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-7,8-dihydro-1,6-naphthyridin-5(6H)-one] The target compound 199 was obtained by the synthetic method in Example 132 using the compound corresponding to compound 195. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.09 (d,J= 2.3 Hz, 1H), 8.78 (d,J= 2.3 Hz, 1H), 8.27 (s, 1H), 7.93 (dd,J= 8.9, 1.4 Hz, 1H), 7.54 (dd,J= 8.9, 7.1 Hz, 1H), 7.33 (dd,J= 7.1, 1.3 Hz, 1H), 3.73 (t,J= 6.8 Hz, 2H), 3.63 (t,J= 5.4 Hz, 4H), 3.24 (t,J= 6.8 Hz, 2H), 3.09 (s, 3H), 1.66 (d,J= 6.1 Hz, 2H), 1.57 (d,J= 7.3 Hz, 4H). MS (ESI, LR) Calc. for C 22 H 24 N5O2[M+H] + : 390.2, found: 390.1. Example 133. 2-Isopropyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one [2-isopropyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one] <Reaction Formula 32> The target compound 133 was obtained by the synthetic method in Example 132 using compound 131 and isopropyl iodide. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.41 (d,J= 2.0 Hz, 1H), 8.24 (s, 1H), 7.98 (dd,J= 7.9, 2.0 Hz, 1H), 7.88 (dd,J= 8.9, 1.3 Hz, 1H), 7.54-7.46 (m, 2H), 7.19 (dd,J= 7.0, 1.4 Hz, 1H), 4.89 (p,J= 6.8 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.50 (t,J= 6.5 Hz, 2H), 3.03 (t,J= 6.5 Hz, 2H), 1.65 (s, 2H), 1.57 (s, 4H), 1.17 (d,J= 6.8 Hz, 6H). MS (ESI, LR) Calc. for C 25 H 29 N4O2[M+H] + : 417.2, found: 417.1. Example 135. 2-methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one [2-methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one] The target compound 135 was obtained by the synthetic method in Example 132 using compound 134 and methyl iodide. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.80 (d,J= 1.9 Hz, 1H), 8.27 (s, 1H), 8.23 (dd,J= 8.3, 2.0 Hz, 1H), 7.91 (dd,J= 8.9, 1.3 Hz, 1H), 7.82 (d,J= 8.4 Hz, 1H), 7.60 (d,J= 7.3 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.28 (dd,J= 7.1, 1.4 Hz, 1H), 6.72 (d,J= 7.3 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 3.55 (s, 3H), 1.65 (d,J= 7.8 Hz, 2H), 1.57 (d,J= 7.7 Hz, 4H). MS (ESI, LR) Calc. for C 23 H 23 N4O2[M+H] + : 387.2, found: 387.1. Example 137. 2-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one [2-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one] The target compound 137 was obtained by the synthetic method in Example 132 using compound 136 and methyl iodide. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.04-7.99 (m, 1H), 7.93-7.86 (m, 3H), 7.52 (dd,J= 8.9, 7.0 Hz, 1H), 7.22 (dd,J= 7.1, 1.4 Hz, 1H), 3.62 (t,J= 5.5 Hz, 6H), 3.08 (s, 5H), 1.65 (q,J= 5.8 Hz, 2H), 1.57 (d,J= 6.8 Hz, 4H). MS (ESI, LR) Calc. for C 23 H 25 N4O2[M+H] + : 389.2, found: 389.1. Example 139. 2-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one [2-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one] The target compound 139 was obtained by the synthetic method in Example 132 using compound 138 and methyl iodide. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.35 (d,J= 8.4 Hz, 1H), 8.28 (s, 1H), 8.23 (d,J= 1.7 Hz, 1H), 8.01 (dd,J= 8.4, 1.8 Hz, 1H), 7.94 (dd,J= 8.9, 1.3 Hz, 1H), 7.56 (dd,J= 8.9, 7.1 Hz, 2H), 7.30 (dd,J= 7.0, 1.4 Hz, 1H), 6.72 (d,J= 7.3 Hz, 1H), 3.63 (t,J= 5.5 Hz, 4H), 3.56 (s, 3H), 1.66 (s, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 23 H 23 N4O2[M+H] + : 387.2, found: 387.1. Example 141. 2-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one [2-methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one] The target compound 141 was obtained by the synthetic method in Example 132 using compound 140 and methyl iodide. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.28-8.22 (m, 2H), 8.12 (dd,J= 7.9, 1.7 Hz, 1H), 7.91 (dd,J= 8.9, 1.3 Hz, 1H), 7.77 (d,J= 7.9 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.26 (dd,J= 7.1, 1.4 Hz, 1H), 4.58 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 3.13 (s, 3H), 1.65 (d,J= 8.0 Hz, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 22 H 23 N4O2[M+H] + : 375.2, found: 375.1. Example 142. 2-Isopropyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one [2-isopropyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one] The target compound 142 was obtained by the synthetic method in Example 132 using compound 140 and isopropyl iodide. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.29-8.21 (m, 2H), 8.11 (dd,J= 7.9, 1.7 Hz, 1H), 7.91 (dd,J= 8.9, 1.4 Hz, 1H), 7.78 (d,J= 7.9 Hz, 1H), 7.53 (dd,J= 8.9, 7.0 Hz, 1H), 7.25 (dd,J= 7.1, 1.4 Hz, 1H), 4.56 (s, 2H), 4.47 (p,J= 6.7 Hz, 1H), 3.63 (t,J= 5.4 Hz, 4H), 1.72-1.63 (m, 2H), 1.57 (d,J= 7.3 Hz, 4H), 1.28 (d,J= 6.8 Hz, 6H). MS (ESI, LR) Calc. for C 24 H 27 N4O2[M+H] + : 403.2, found: 403.1. Example 144. 2-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one [2-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one] The target compound 144 was obtained by the synthetic method in Example 132 using compound 143 and methyl iodide. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.15 (s, 1H), 8.01 (dd,J= 7.9, 1.6 Hz, 1H), 7.92 (dd,J= 9.0, 1.3 Hz, 1H), 7.83 (d,J= 7.9 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.24 (dd,J= 7.1, 1.4 Hz, 1H), 4.57 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 3.13 (s, 3H), 1.66 (d,J=5.4 Hz, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 22 H 23 N4O2[M+H] + : 375.2, found: 375.1. Example 259. [7-(3-amino-1,2-benzoxazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-(3-amino-1,2-benzoxazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] <Reaction Formula 33> Potassium tert-butyrate and (64.4 mg, 0.57 mmol) acetohydroxamic acid were dissolved in N,N-dimethylformamide (3 mL) and stirred for 20 minutes. Compound 254 (100 mg, 0.29 mmol) was added and stirred for 1 hour, then the temperature was increased to 60 °C and stirred for 1 hour. After completion of the reaction, the temperature of the reaction solution was lowered to room temperature, water was added, and filtered. The filtrate was separated using column chromatography to obtain the target compound 259 (36 mg, 33%). 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.41 (d,J= 1.9 Hz, 1H), 8.26 (s, 1H), 8.06 (dd,J= 8.8, 1.8 Hz, 1H), 7.90 (dd,J= 8.9, 1.4 Hz, 1H), 7.62 (d,J= 8.8 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.18 (dd,J= 7.1, 1.4 Hz, 1H), 6.55 (s, 2H), 3.63 (t,J= 5.5 Hz, 4H), 1.66 (d,J= 5.6 Hz, 2H), 1.62-1.50 (m, 4H). MS (ESI, LR) Calc. for C 20 H 20 N5O2[M+H] + : 362.2, found: 362.1. Example 320. [7-(3-amino-1,2-benzoxazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-(3-amino-1,2-benzoxazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] The target compound 320 was obtained using the synthetic method in Example 259 using compound 22. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 8.04 (s, 1H), 7.98 (d,J= 8.2 Hz, 1H), 7.92 (dd,J= 8.9, 1.4 Hz, 1H), 7.77 (dd,J= 8.2, 1.4 Hz, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.27 (dd,J= 7.0, 1.4 Hz, 1H), 6.54 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (s, 2H), 1.57 (d,J= 7.4 Hz, 4H). MS (ESI, LR) Calc. for C20 H 20 N5O2[M+H] + : 362.2, found: 362.1. Example 260. [7-(3-amino-1H-indazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-(3-amino-1H-indazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] <Reaction Formula 34> Compound 254 (100 mg, 0.29 mmol) was dissolved in ethanol (3 mL), hydrazine hydrate (35.9 mg, 0.57 mmol) was added, and the mixture was stirred in a microwave reactor at 150 °C for 35 minutes. The reaction solution was concentrated, diluted with water, and filtered. The filtrate was separated using column chromatography to obtain the target compound 260 (85 mg, 33%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.64 (s, 1H), 8.32-8.21 (m, 2H), 7.81 (ddd,J= 20.3, 8.8, 1.5 Hz, 2H), 7.51 (dd,J= 8.9, 7.0 Hz, 1H), 7.40-7.32 (m, 1H), 7.12 (dd,J= 7.1, 1.4 Hz, 1H), 5.51 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.3 Hz, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 20 H 21 N6O [M+H] + : 361.2, found: 361.1. Example 309. 7-(3-amino-1H-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [7-(3-amino-1H-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Compound 22 was used to obtain the target compound 309 by the synthetic method in Example 260. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.62 (s, 1H), 8.24 (d,J= 1.1 Hz, 1H), 7.90-7.85 (m, 2H), 7.83 (d,J= 8.4 Hz, 1H), 7.52 (dd,J= 8.8, 7.1 Hz, 1H), 7.40-7.34 (m, 1H), 7.22 (dd,J= 7.1, 1.4 Hz, 1H), 5.45 (s, 2H), 3.63 (t,J= 5.3 Hz, 4H), 1.66 (d,J= 6.9 Hz, 2H), 1.58 (d,J= 7.3 Hz, 4H). MS (ESI, LR) Calc. for C 20 H 21 N6O [M+H] + : 361.2, found: 361.1. Example 261. [7-(3-amino-1-methyl-indazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-(3-amino-1-methyl-indazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 310. [7-(3-amino-1-methyl-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [7-(3-amino-1-methyl-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] For Examples 261 and 310, compounds 254 and 22 were obtained using methylhydrazine according to the synthetic method described in Example 260, respectively. The structural and spectral data are shown in Table 27 below. Example structure 1 H NMRMS261 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.37 (d,J= 2.3 Hz, 1H), 8.25 (d,J= 8.9 Hz, 2H), 7.88 (dd,J= 8.8, 1.3 Hz, 1H), 7.51 (dd,J= 8.9, 7.1 Hz, 1H), 7.43 (d,J= 9.0 Hz, 1H), 7.24 (dd,J= 7.1, 1.3 Hz, 1H), 4.32 (q,J= 7.0 Hz, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.4 Hz, 2H), 1.57 (s, 4H), 1.43 (t,J= 6.9 Hz, 3H).MS (ESI, LR) Calc. for C 21 H 23 N6O [M+H] + : 375.2, found: 375.1.310 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.26 (s, 1H), 7.94 (d,J= 8.9 Hz, 1H), 7.90 (d,J= 8.1 Hz, 1H), 7.78 (d,J= 1.5 Hz, 1H), 7.67-7.62 (m, 1H), 7.54 (dd,J= 8.9, 7.0 Hz, 1H), 7.31 (d,J= 7.0 Hz, 1H), 4.29 (q,J= 7.0 Hz, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.2 Hz, 2H), 1.57 (d,J= 5.8 Hz, 4H), 1.41 (t,J= 7.0 Hz, 3H).MS (ESI, LR) Calc. for C 21 H 23 N6O [M+H]+ : 375.2, found: 375.1. Example 395. (7-(1-((1,2,4-oxadiazol-3-yl)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(1-((1,2,4-oxadiazol-3-yl)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 35> Step 395-1 [Step 395-1]: Compound 1-2 and 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]acetonitrile were used to obtain the target compound 395-1 using the synthetic method in Step 159-3 of Example 159. Step 395-2 [Step 395-2]: Compound 395-2 was obtained using the synthetic method in Step 115-1 of Example 115 using compound 395-1 and DIPEA. Step 395-3: To compound 395-2, (100 mg, 0.27 mmol) trimethyl orthoformate and (1.49 mL, 13.6 mmol) trifluoroacetic acid (8.3 μL) were added, and the mixture was stirred at 60 °C for 1 hour. After completion of the reaction, the reaction solution was diluted with dichloromethane (10 mL) and washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 395 (39 mg, 38%). 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.64 (s, 1H), 9.13 (s, 1H), 8.48 (s, 1H), 8.35 (s, 1H), 7.78 (dd,J= 8.7, 1.4 Hz, 1H), 7.58 (dd,J= 7.3, 1.4 Hz, 1H), 7.50 (dd,J= 8.7, 7.2 Hz, 1H), 5.80 (s, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.5 Hz, 2H), 1.57 (d,J= 5.6 Hz, 4H). MS (ESI, LR) Calc. for C 19 H 20 N7O2[M+H] + : 378.2, found: 378.1. Example 396. 3-((4-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-1H-pyrazol-1-yl)methyl)-1,2,4-oxadiazol-5(4H)-one [3-((4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-1H-pyrazol-1-yl)methyl)-1,2,4-oxadiazol-5(4H)-one] The target compound 396 was obtained using the synthetic method in Example 349 using compound 395-5. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.95 (s, 1H), 8.43 (s, 1H), 8.36 (s, 1H), 7.77 (d,J= 8.8 Hz, 1H), 7.56 (t,J= 6.3 Hz, 1H), 7.51-7.47 (m, 1H), 5.10 (s, 2H), 3.63 (t,J= 5.5 Hz, 4H), 1.66 (s, 2H), 1.57 (s, 4H). MS (ESI, LR) Calc. for C 19 H 20 N7O3[M+H] +: 394.2, found: 394.1. Example 397. (7-(2-(1-((1,2,4-oxadiazol-3-yl)methyl)-1H-pyrazol-4-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-(2-(1-((1,2,4-oxadiazol-3-yl)methyl)-1H-pyrazol-4-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 36> Step 397-1 [Step 397-1]: The target compound 397-1 was obtained by the synthetic method in Step 159-3 of Example 159 using compound 1-2. Step 397-2 [Step 397-2]: Compound 397-2 was obtained by the synthetic method in Step 395-1 of Example 395 using compound 397-1. Step 397-3 [Step 397-3]: The target compound 397-3 was obtained using the synthetic method in Step 395-2 of Example 395 using compound 397-2. Step 397-4 [Step 397-4]: The target compound 397 was obtained using the synthetic method in Step 395-3 of Example 395 using compound 397-3. 1H NMR (400 MHz, DMSO-d6) δ(ppm): 9.64 (s, 1H), 8.71 (d,J= 5.2 Hz, 1H), 8.56 (s, 1H), 8.29 (s, 1H), 8.21 (s, 1H), 8.15 (s, 1H), 7.97 (dd,J= 8.9, 1.4 Hz, 1H), 7.78 (dd,J= 5.2, 1.6 Hz, 1H), 7.56 (dd,J= 8.9, 7.0 Hz, 1H), 7.39 (dd,J= 7.0, 1.4 Hz, 1H), 5.69 (s, 2H), 3.63 (t,J= 5.4 Hz, 4H), 1.66 (d,J= 5.6 Hz, 2H), 1.57 (d,J= 6.7 Hz, 4H). MS (ESI, LR) Calc. for C 24 H 23 N8O2[M+H] + : 455.2, found: 455.1. Example 146. 4-((3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)amino)benzonitrile [4-((3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)amino)benzonitrile] <Reaction Formula 37> Compound 1-2 (0.05 g, 0.14 mmol), palladium acetate (1.58 mg, 0.007 mmol), BINAP (8.7 mg, 0.01 mmol), and cesium carbonate (183.4 mg, 0.56 mmol) were dissolved in 1,4-dioxin (2 mL), filled with nitrogen gas, and stirred at 100 ℃ for 16 hours. After completion of the reaction, the reaction solution was diluted with dichloromethane (10 mL) and washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 146 (16 mg, 32%). [BINAP (2,2'-bis(diphenylphosphino)-1,1'-binaphthyl)] 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.72 (s, 1H), 8.28 (s, 1H), 7.85-7.73 (m, 2H), 7.58-7.50 (m, 2H), 7.49-7.35 (m, 2H), 6.88 (dd,J= 7.1, 1.5 Hz, 1H), 3.61 (t,J= 5.4 Hz, 4H), 1.65 (d,J= 5.4 Hz, 2H), 1.57 (d,J= 7.3 Hz, 4H). MS (ESI, LR) Calc. for C 20 H 20 N5O [M+H] + : 346.2, found: 346.1. Example 147. 3-((3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)amino)pyridin-2(1H)-one [3-((3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)amino)pyridin-2(1H)-one] Example 148. Piperidin-1-yl(7-((pyrimidin-2-ylmethyl)amino)pyrazolo[1,5-a]pyridin-3-yl)methanone [piperidin-1-yl(7-((pyrimidin-2-ylmethyl)amino)pyrazolo[1,5-a]pyridin-3-yl)methanone] Example 149. Piperidin-1-yl(7-((2-(pyridin-4-yl)ethyl)amino)pyrazolo[1,5-a]pyridin-3-yl)methanone [piperidin-1-yl(7-((2-(pyridin-4-yl)ethyl)amino)pyrazolo[1,5-a]pyridin-3-yl)methanone] Example 150. (7-((1-methylpiperidin-4-yl)amino)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-((1-methylpiperidin-4-yl)amino)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] Example 211. 7-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino-3,4-dihydro-2H-isoquinolin-1-one [7-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]-3,4-dihydro-2H-isoquinolin-1-one] Example 212. 6-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]isoindolin-1-one [6-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]isoindolin-1-one] Example 238. [7-[(4-chlorophenyl)methylamino]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[(4-chlorophenyl)methylamino]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] Example 242. [7-[2-(4-chlorophenyl)ethylamino]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone [[7-[2-(4-chlorophenyl)ethylamino]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone] For Examples 147, 148, 149, 150, 211, 212, 238, and 242, compounds corresponding to compounds 1-2 were obtained by the synthetic method described in Example 146. The structural and spectral data are shown in Table 28 below. Example structure 1 H NMRMS147 1H NMR (400 MHz, DMSO-d6) δ(ppm): 12.12 (s, 1H), 9.19 (s, 1H), 8.31 (s, 1H), 7.60 (dd,J= 7.3, 1.6 Hz, 1H), 7.45 (t,J= 8.2 Hz, 1H), 7.37 (dd,J= 8.8, 1.1 Hz, 1H), 7.12 (dd,J= 6.7, 1.6 Hz, 1H), 7.00-6.87 (m, 1H), 6.33 (t,J= 6.9 Hz, 1H), 3.61 (t,J= 5.3 Hz, 4H), 1.65 (d,J= 7.8 Hz, 2H), 1.57 (d,J= 6.8 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 20 N5O2[M+H] + : 338.2, found: 338.1.148 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.84 (d,J= 4.9 Hz, 2H), 8.23 (s, 1H), 7.66 (t,J= 5.7 Hz, 1H), 7.46 (t,J= 4.9 Hz, 1H), 7.30 (t,J= 8.1 Hz, 1H), 7.13-7.04 (m, 1H), 6.09 (d,J= 7.6 Hz, 1H), 4.81 (d,J= 5.7 Hz, 2H), 3.60 (t,J= 5.4 Hz, 4H), 1.64 (d,J= 5.8 Hz, 2H), 1.56 (q,J= 5.8 Hz, 4H).MS (ESI, LR) Calc. for C 18 H 21 N6O [M+H] + : 337.2, found: 337.1.149 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.53-8.42 (m, 2H), 8.15 (s, 1H), 7.39 - 7.26 (m, 3H), 7.12 (t,J= 6.1 Hz, 1H), 7.05 (dd,J= 8.7, 1.1 Hz, 1H), 6.21 (d,J= 7.6 Hz, 1H), 3.64 (q,J= 6.8 Hz, 2H), 3.57 (t,J= 5.4 Hz, 4H), 3.01 (t,J= 7.2 Hz, 2H), 1.63 (d,J= 5.9 Hz, 2H), 1.54 (d,J= 4.9 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 24 N5O [M+H] + : 350.2, found: 350.1.150 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.15 (s, 1H), 7.31 (t,J= 8.2 Hz, 1H), 7.04 (dd,J= 8.7, 1.1 Hz, 1H), 6.63 (d,J= 8.5 Hz, 1H), 6.19 (d,J= 7.7 Hz, 1H), 3.58 (t,J= 5.4 Hz, 4H), 3.55-3.45 (m, 1H), 2.75 (d,J= 11.2 Hz, 2H), 2.19 (s, 3H), 2.13-2.02 (m, 2H), 1.98 - 1.88 (m, 2H), 1.72 (td,J= 10.9, 2.8 Hz, 2H), 1.64 (dt,J= 11.0, 4.7 Hz, 2H), 1.54 (p,J= 5.6 Hz, 4H).MS (ESI, LR) Calc. for C 19 H 28 N5O [M+H] + : 342.2, found: 342.2.211 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.09 (d,J= 1.5 Hz, 2H), 7.91 (s, 1H), 7.42 (dd,J= 8.1, 2.5 Hz, 1H), 7.37 (dd,J= 8.8, 1.2 Hz, 1H), 7.29-7.24 (m, 2H), 6.57 (dd,J= 7.7, 1.2 Hz, 1H), 6.07 (s, 1H), 3.71 (t,J= 5.3 Hz, 4H), 3.61 (td,J= 6.6, 2.8 Hz, 2H), 3.02 (t,J= 6.6 Hz, 2H), 1.78-1.64 (m, 6H).MS (ESI, LR) Calc. for C 22 H 24 N5O2[M+H] + : 390.2, found: 390.1.212 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.11 (s, 1H), 8.00 (s, 1H), 7.90 (d,J= 1.6 Hz, 1H), 7.52 (d,J= 1.4 Hz, 2H), 7.45-7.36 (m, 1H), 7.29 (d,J= 8.0 Hz, 1H), 6.78 (s, 1H), 6.62 (d,J= 7.5 Hz, 1H), 4.49 (s, 2H), 3.71 (t,J= 5.3 Hz, 4H), 1.78-1.66 (m, 6H).MS (ESI, LR) Calc. for C 21 H 22 N5O2[M+H] + : 376.2, found: 376.1.238 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.20 (s, 1H), 7.90 (t,J= 6.5 Hz, 1H), 7.47-7.35 (m, 4H), 7.23 (t, J = 8.1 Hz, 1H), 7.03 (dd,J= 8.7, 1.2 Hz, 1H), 5.95 (dd,J= 7.7, 1.1 Hz, 1H), 4.59 (d,J= 6.5 Hz, 2H), 3.58 (t,J= 5.4 Hz, 4H), 1.64 (d,J= 5.3 Hz, 2H), 1.54 (t,J= 5.9 Hz, 4H).MS (ESI, LR) Calc. for C 20 H 22 ClN4O [M+H] + : 369.1, found: 369.1.242 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.15 (s, 1H), 7.40-7.27 (m, 5H), 7.10-7.01 (m, 2H), 6.19 (dd,J= 7.8, 1.2 Hz, 1H), 3.67-3.52 (m, 6H), 2.98 (t,J= 7.3 Hz, 2H), 1.68-1.59 (m, 2H), 1.55 (q,J= 5.7 Hz, 4H).MS (ESI, LR) Calc. for C 21 H 24 ClN4O [M+H] + : 383.2, found: 383.1. Example 194. (7-((3-methoxyphenyl)thio)(pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone [(7-((3-methoxyphenyl)thio)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone] <Reaction Formula 38> Compound 1-2 (0.06 g, 0.17 mmol), tris(dibenzylidenethacetone)dipalladium(0) (3.86 mg, 0.025 mmol), Xantphos (4.88 mg, 0.05 mmol), DIPEA (43.6 mg, 0.34 mmol), and 3-methoxybenzenethiol (71.05 mg, 0.51 mmol) were dissolved in 1,4-dioxin (2 mL), filled with nitrogen gas, and stirred at 100 °C for 1 hour. After completion of the reaction, the reaction solution was diluted with dichloromethane (10 mL) and washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, concentrated, and separated using column chromatography to obtain the target compound 194 (61 mg, 98%). 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 8.32 (s, 1H), 7.68 (dd,J= 8.8, 1.2 Hz, 1H), 7.50 (t,J= 8.2 Hz, 1H), 7.32 (dd,J= 8.8, 7.4 Hz, 1H), 7.29-7.22 (m, 2H), 7.20-7.14 (m, 1H), 6.34 (dd,J= 7.3, 1.2 Hz, 1H), 3.81 (s, 3H), 3.60 (t,J= 5.4 Hz, 4H), 1.72-1.60 (m, 2H), 1.60-1.48 (m, 4H). MS (ESI, LR) Calc. for C 20 H 22 N3O2S [M+H] + : 368.1, found: 368.1. Example 235. 4-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]-1H-pyrimidin-6-one [4-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]-1H-pyrimidin-6-one] Compound 1-2, palladium acetate, and the corresponding compound were used to obtain the target compound 235 by the synthetic method in Example 194. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 12.24 (s, 1H), 9.77 (s, 1H), 8.27 (s, 1H), 8.15 (s, 1H), 7.58-7.39 (m, 3H), 6.07 (s, 1H), 3.61 (t,J= 5.4 Hz, 4H), 1.71-1.61 (m, 2H), 1.56 (d, J = 7.9 Hz, 4H). MS (ESI, LR) Calc. for C 17 H 19 N6O2[M+H] + : 339.1, found: 339.1. Example 236. 3-methyl-6-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]pyrimidin-4-one [3-methyl-6-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]pyrimidin-4-one] <Reaction Formula 39> Step 236-1 [Step 236-1]: Compound 236-1 was obtained using the synthetic method in Example 146 using compound 1-2 and diphenylmethanimine. Step 236-2: Compound 236-1 (2 g, 4.89 mmol), hydroxylamine hydrochloride (0.68 g, 9.79 mmol), and sodium acetate (1 g, 12.24 mmol) were dissolved in methanol (48 mL) and stirred at room temperature for 16 hours. The reaction solution was concentrated, and the residue was separated using column chromatography to obtain the target compound 236-2 (845 mg, 69%). Step 236-3: The target compound 236 was obtained using the synthetic method in Example 235 using compound 236-2 and 6-bromo-3-methyl-pyrimidin-4-one. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.79 (s, 1H), 8.43 (s, 1H), 8.27 (s, 1H), 7.56-7.40 (m, 3H), 6.16 (s, 1H), 3.61 (t,J= 5.4 Hz, 4H), 3.38 (s, 3H), 1.65 (q,J= 5.7 Hz, 2H), 1.57 (q,J= 5.8 Hz, 4H). MS (ESI, LR) Calc. for C 18 H 21 N6O2[M+H] + : 353.2, found: 353.1. Example 239. 4-chloro-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzamide [4-chloro-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzamide] <Reaction Formula 40> Compound 236-2 (70 mg, 0.28 mmol) was dissolved in pyridine (2.6 mL), dimethylaminopyridine (17.5 mg, 0.14 mmol), and 4-chlorophenzoyl chloride (75.2 mg) were added, and the mixture was stirred at room temperature for 16 hours. After concentrating the reaction solution, the residue was separated using column chromatography to obtain the target compound 239 (60 mg, 53%). 1H NMR (400 MHz, DMSO-d6) δ(ppm): 8.25 (d,J=8.2 Hz, 1H), 8.11-8.04 (m, 1H), 7.91-7.86 (m, 1H), 7.84-7.77 (m, 2H), 7.66-7.61 (m, 1H), 7.46-7.39 (m, 2H), 3.81-3.69 (m, 4H), 1.82-1.74 (m, 2H), 1.69-1.67 (m, 4H). MS (ESI, LR) Calc. for C 20 H 20 ClN4O2[M+H] + : 383.1, found: 383.1. Example 240. 1,3,5-Trimethyl-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrazolo-4-sulfonamide [1,3,5-trimethyl-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrazole-4-sulfonamide] Example 241. 5-fluoro-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide [5-fluoro-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide] For Examples 240 and 241, compounds corresponding to compound 236-2 were obtained by the synthetic method in Example 239. The structural and spectral data are shown in Table 29 below. Example structure 1 H NMRMS240 1H NMR (400 MHz, DMSO-d6) δ(ppm): 11.01 (s, 1H), 8.19 (s, 1H), 7.59 (d,J= 8.8 Hz, 1H), 7.38 (dd,J= 8.9, 7.4 Hz, 1H), 6.88 (d,J= 7.4 Hz, 1H), 3.60(s,3H), 3.57(t,J=5.4Hz,4H),2.35(s,3H),2.18(s,3H),1.63(d,J=6.5Hz,2H), 1.55(q,J=5.7Hz,4H).MS(ESI,LR) Calc. for C 19 H 25 N6O3S [M+H] + : 417.2, found: 417.1.241 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 11.13(s,1H), 9.06(t,J=1.7Hz,1H), 8.88(d,J=2.8Hz,1H), 8.32(s,1H), 8.29(ddd,J=9.3, 2.8, 1.7). Hz, 1H), 7.74 (dd,J= 7.8, 2.4 Hz, 1H), 7.58-7.50 (m, 2H), 3.62 (t,J= 5.4 Hz, 4H), 1.65 (q,J= 5.8 Hz, 2H), 1.57 (p,J= 5.6 Hz, 4H). LR) Calc. for C 19 H 19 FN5O2[M+H] + : 368.1, found: 368.1. Figure 151. 1-(7-(protein-3-일)protein[1,5-a]protein-3-protein)protein-1-p [1-(7-(quinolin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)pentan-1-one] <Figure 41> Step 151-1: The target compound 151-1 was obtained using the same synthetic method as Step 1-2 of Example 1 using pyrazolo[1,5-a]pyridine-3-carboxylic acid. Step 151-2: Compound 151-1 (1 g, 4.36 mmol) was dissolved in tetrahydrofuran (15 mL), and the temperature was lowered to -78 ℃. n-Butyllithium (2.5 M solution, 2.44 mL, 6.1 mmol) was slowly added. After the reaction solution was stirred for 30 minutes, 1,2-iodoethane (1.47 g, 5.23 mmol) dissolved in tetrahydrofuran (9 mL) was added. After the reaction solution was stirred for 3 hours, the temperature was raised to room temperature and diluted with saturated sodium bicarbonate aqueous solution (20 mL) and dichloromethane (20 mL). The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was purified using column chromatography to obtain the target compound 151-2 (151 mg, 11%). Step 151-3: Compound 151-2 was synthesized using the same method as Step 1-3 in Example 1 to obtain the target compound 151. 1 H NMR (400 MHz, DMSO-d6) δ(ppm): 9.35 (d,J= 2.2 Hz, 1H), 8.78 (d,J= 2.2 Hz, 1H), 8.54 (dd,J= 8.8, 1.4 Hz, 1H), 8.41 (s, 1H), 8.20 (d,J= 8.5 Hz, 1H), 7.95 (d,J= 8.1 Hz, 1H), 7.82 (ddd,J= 8.4, 6.9, 1.5 Hz, 1H), 7.70-7.56 (m, 2H), 7.23 (dd,J= 7.1, 1.4 Hz, 1H), 2.93 (t,J= 7.5 Hz, 2H), 1.79 (p,J= 7.6 Hz, 2H), 1.46 (h,J= 7.4 Hz, 2H), 0.98 (t,J= 7.3 Hz, 3H). MS (ESI, LR) Calc. for C21 H 20 N3O [M+H] + : 330.2, found: 330.2. Example 152. 4-(3-acetylpyrazolo[1,5-a]pyridin-7-yl)benzonitrile <Reaction Formula 42> Step 152-1 [Step 152-1]: The target compound 152-1 was obtained using the same synthetic method as Step 1-3 in Example 1 using pyrazolo[1,5-a]pyridine-3-carboxylic acid and 4-cyanophenylboronic acid. Step 152-2 [Step 152-2]: The target compound 152-2 was obtained using the same synthetic method as Step 1-2 ...
Claims
1. A heterocyclic compound represented by the following chemical formula 1, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof: <Chemical Formula 1> In the above formula, A fused ring is formed by fusing two rings, A ring and B ring. X1, Y1, Y2, Y3 and Y4 are independently CH or N, X2 is CH, N or NH, Z1 and Z2 are C or N, At least one of X1, X2, Y1, Y2, Y3, Y4, Z1 and Z2 is N or NH, R a is H, R a-1 C replaced by 1-6 Straight or branched chain alkyl, or C(O)R a-1 And, Above R a-1 is C 1-6 Straight or branched chain alkyl, C 3-8 Cycloalkyl, hydroxy, R s , or R u And, the above R a-1 is a singular or plural independent R a-2 Is replaced or not replaced by, Above R a-2 is C 1-6 Straight or branched chain alkyl, halogen, C 1-4 It is haloalkyl, The above X1 is R b is substituted or not substituted, and the above R b is amino, or C(O)R s And, The above Y1 is R 1 is substituted or not substituted with R 1 Silver R f And, The above Y2 is R 2 Is replaced or not replaced by, Above R 2 is C 1-6 Straight or branched chain alkyl, halogen, C 5-12 Aryl of one or two rings, R u , or R f And, the above R 2 is a singular or plural independent R 2-1 Is replaced or not replaced by, Above R 2-1 is C 1-4 Alkoxy, halogen or hydroxy, The above Y3 is R 3 Is replaced or not replaced by, Above R 3 is C 5-7 Aryl, R u , or R f And, the above R 3 is a singular or plural independent R 3-1 Is replaced or not replaced by, Above R 3-1 Silver C 1-4 alkoxy, halogen, hydroxy or cyano, The above Y4 is R 4 or -LR 4 Is replaced or not replaced by, The above L is -NH(CH2) m -, -NHC(O)-, -NHSO2- or -S-, and m is an integer from 0 to 3, Above R 4 is C 5-12 Aryl of one or two rings, R u , R s , or R f And, the above R 4 is substituted or not substituted by singular or plural independent Q, The above Q is C 1-6 Straight or branched chain alkyl, halogen, hydroxy, C 1-4 Haloalkyl, C 1-4 Alkoxy, Nitro, Cyano, Amino, Carboxylate, Carboxylic Acid, CHR 5 , CH2R 5 , NR 5 R 6 , C(O)R 5 , C(O)OR 5 , C(O)NR 5 R 6 , NHC(O)(CH2) p R 5 , NHC(O)CH2OR 5 , NHC(O)CH2NR 5 R 6 , NHCH2CH2R 5 , NR 5 C(O)R 6 , R u , or R s , and p is an integer from 0 to 3, and Q is one or more independent R 7 Is replaced or not replaced by, Above R 5 and R 6 is independently H, C 1-6 Straight or branched chain alkyl, C 3-8 Cycloalkyl, C 1-4 Alkoxy, amino, sulfonyl, C 5-7 Aryl, arylalkyl, R u , or R s And, Above R 7 Silver C 1-6 Straight or branched chain alkyl, C 3-8 Cycloalkyl, halogen, C 1-4 Haloalkyl, hydroxy, C 1-4 Alkoxy, Hydroxyalkyl, Cyano, Amino, Alkylamino, C 1-6 Alkyl carboxylate, nitro, R u , R u C replaced by 1-4 Alkyl, or R s and the above Q and R 7 The bond between the two is either a single bond or a double bond, Above R s is a saturated heterocycloalkyl ring of 1 or 2 rings, 4 to 10 members, containing 1 to 3 heteroatoms selected from N, O and S, Above R u is a 5- to 7-membered unsaturated heterocycloalkyl ring containing 1 to 4 heteroatoms selected from N, O and S, Above R f is a fused ring of two rings, wherein a 5- to 7-membered saturated or unsaturated heterocycloalkyl ring containing 1 to 2 heteroatoms selected from N, O and S and an aryl ring or a 5- to 7-membered heteroaryl ring containing 1 to 2 N are fused, Above R s , R u and R f is independently substituted or unsubstituted with one or two oxo (O) or thioxo (S).
2. A compound according to claim 1, characterized in that the A ring is pyrrole, pyrazole, imidazole, or triazole, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.
3. A compound according to claim 1, characterized in that the B ring is benzene, pyridine, pyrimidine, or triazine, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.
4. A compound, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, characterized in that the fused ring of the two rings in which the A ring and the B ring are fused is indole, indazole, pyrrolopyridine, pyrrolopyrimidine, pyrrolotriazine, pyrazolopyridine, imidazopyridine, or triazolopyridine in the first paragraph.
5. A compound characterized in that the fused ring of the two rings in which the A ring and the B ring are fused is one selected from the group consisting of the following chemical formulas, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof in the first paragraph: , , , , , , , , , , and .
6. In paragraph 1, Above R a Ga H, Profile, C(O)R a-1 And, Above R a-1 This methyl, butyl, cyclohexyl, hydroxy, piperidinyl, azaspiroheptanyl, azaspiroctanyl, azaspirononanyl, azabicycloheptanyl, azabicyclooctanyl, azabicyclononanyl or tetrahydropyridinyl, Above R a-2 A compound, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, characterized in that the compound is methyl, ethyl, propyl, isopropyl, fluoro, or trifluoromethyl.
7. In the first paragraph, the R b A compound characterized in that it is amino or piperidinyl-carbonyl, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof.
8. In the first paragraph, the R 1 A compound characterized by being benzodioxolyl, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof.
9. In paragraph 1, Above R 2 is methyl, fluoro, phenyl, naphthyl (naphthalenyl), furanyl, pyridinyl, isoindolinone, benzodioxolyl, dihydrobenzodioxinyl, benzofuranyl or indazolyl, Above R 2-1 A compound characterized by being methoxy, chloro, fluoro or hydroxy, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof.
10. In paragraph 1, Above R 3 is phenyl, pyridinyl or benzodioxolyl, Above R 3-1 A compound characterized by being methoxy, chloro, hydroxy or cyano, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof.
11. A compound, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, characterized in that in claim 1, L is -NH-, -NHCH2-, -NH(CH2)2-, -NHC(O)-, -NHSO2- or -S-.
12. In the first paragraph, the R 4 A compound, characterized in that it is phenyl, naphthyl(naphthalenyl), furanyl, pyrazolyl, dihydropyridinyl, pyridinyl, pyrimidinyl, pyridinone, pyrimidinone, isoxazolyl, piperidinyl, benzodioxolyl, isoindolinone, dihydroisoquinolinone, benzofuranyl, benzothiophenyl, indolyl, indazolyl, quinolinyl, quinolinone, isoquinolinone, dihydropyrrolopyridinone, benzoisoxazolone, dihydronaphthyridinone, benzoxazolyl, benzoisoxazolyl, triazolopyridinone, phthalazinone, quinazolinone, or pyridopyrimidinone, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof.
13. In paragraph 1, The above Q is methyl, propyl, isopropyl, fluoro, chloro, bromo, hydroxy, trifluoromethyl, methoxy, nitro, cyano, amino, carboxylate, carboxylic acid, CHR 5 , CH2R 5 , NR 5 R 6 , C(O)R 5 , C(O)OR 5 , C(O)NR 5 R 6 , NHC(O)R 5 , NHC(O)CH2R 5 , NHC(O)(CH2)2R 5 , NHC(O)CH2OR 5 , NHC(O)CH2NR 5 R 6 , NHCH2CH2R 5 , NR 5 C(O)R 6 , tetrazolyl, oxadiazolyl, oxadiazolone, furyl, thienyl, imidazolyl, pyrazolyl, isoxazolyl, thiazolyl, oxo-thiadiazolyl, thioxo-oxadiazolyl, pyridinyl, pyrimidinyl, azetidinyl, oxazolidinone, piperidinyl, piperazinyl, morpholino, azaspiroheptanyl, azaspiroctanyl, azaspirononanyl, azabicycloheptanyl, or azabicyclooctanyl, Above R 5 wherein said H, methyl, ethyl, butyl, cyclopropyl, cyclohexane, methoxy, amino, phenyl, benzyl, imidazolyl, oxadiazolyl, oxadiazolone, pyridinyl, pyrimidinyl, azetidinyl, piperidinyl, piperidinone, piperazinyl, morpholino, thiazolidinedione, piperazinone, piperazine-dione, azaspiroheptanyl, or azaspirononanyl, Above R 6 A compound, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, characterized in that the compound is H, methyl, ethyl, propyl, isopropyl, sulfonyl, pyrazolyl, pyridinyl, pyridazinyl, azetidinyl or piperidinyl.
14. In the first paragraph, the R 7 A compound, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, characterized in that the compound is selected from the group consisting of methyl, propyl, isopropyl, cyclopropyl, fluoro, chloro, difluoromethyl, trifluoromethyl, hydroxy, methoxy, hydroxymethyl, cyano, amino, dimethylamino, methylcarboxylate, tert-butylcarboxylate, nitro, isoxazolyl, thiazolyl, pyridinyl, or oxadiazolylmethyl.
15. A compound characterized in that the compound represented by the chemical formula 1 in paragraph 1 is any one selected from the group consisting of the following compounds, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof: [1] 7-phenylpyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [2] (7-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [3] Methyl 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoate, [4] (7-(3-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [5] (7-(3-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [6] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [7] (7-(3-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [8] (7-(2-chloropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [9] (7-(5-aminopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [10] 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoic acid, [11] Methyl 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoate, [12] (7-(4-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [13] (7-(4-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [14] (7-(4-aminophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [15] 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [16] (7-(6-nitropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [17] (7-(6-aminopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [18] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinonitrile, [19] (7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [20] (7-(4-methoxy-3-(trifluoromethyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [21] (7-(3-chloro-4-hydroxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [22] 2-Fluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [23] 2-(dimethylamino)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [24] (7-(3,4-dimethoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [25] (7-(1-methyl-1H-pyrazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [26] (7-(3-(morpholine-4-carbonyl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [27]N-Methyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [28]N-isopropyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [29] Azetidin-1-yl(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone, [30]N-(2-methoxyethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [31]N-(2-(dimethylamino)ethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [32]N-(cyclopropylmethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [33]N-(1-methylpiperidin-4-yl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [34] Piperazin-1-yl(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone, [35]tert-butyl 4-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzoyl)piperazine-1-carboxylate, [36]N-(2-cyanoethyl)-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [37] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)benzamide, [38] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)benzamide, [39] (7-(5-(morpholine-4-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [40]N-methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide, [41] Azetidin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone, [42] (3-hydroxyazetidine-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone, [43] (7-(5-(2-azaspiro[3.3]heptane-2-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [44] (3,3-difluoroazetidin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone, [45]N-(2-methoxyethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide, [46]N-(cyclopropylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide, [47]N-(1-methylpiperidin-4-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide, [48] Piperazin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone, [49] (4-methylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone, [50] (4-isopropylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone, [51]N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide, [52]N-(cyanomethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide, [53] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)nicotinamide, [54] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)nicotinamide, [55]N-(isoxazol-3-ylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide, [56] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridazin-4-yl)nicotinamide, [57] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(thiazol-5-ylmethyl)nicotinamide, [58]N-Methyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [59]N,N-dimethyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [60]N-isopropyl-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [61] Azetidin-1-yl(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone, [62]N-(2-methoxyethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [63]N-(2-(dimethylamino)ethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [64]N-(cyclopropylmethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [65]N-(1-methylpiperidin-4-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [66] Piperazin-1-yl(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone, [67] (4-methylpiperazin-1-yl)(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone, [68] (4-isopropylpiperazin-1-yl)(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)methanone, [69]N-(2-cyanoethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [70]N-(cyanomethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [71] 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)benzamide, [72] 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)benzamide, [73]N-(isoxazol-3-ylmethyl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzamide, [74] (7-(6-(morpholine-4-carbonyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [75]N-Methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide, [76]N-isopropyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide, [77] Azetidin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone, [78]N-(2-methoxyethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide, [79]N-(2-(dimethylamino)ethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide, [80]N-(cyclopropylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide, [81]N-(1-methylpiperidin-4-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide, [82] Piperazin-1-yl(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone, [83] (4-methylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone, [84] (4-isopropylpiperazin-1-yl)(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanone, [85]N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide, [86]N-(cyanomethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide, [87] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-3-yl)picolinamide, [88] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-N-(pyridin-4-yl)picolinamide, [89]N-(isoxazol-3-ylmethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)picolinamide, [90]N-(2-cyanoethyl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)furan-2-carboxamide, [91] 3-methoxy-N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)propanamide, [92] 1-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)urea, [93] 1-Methyl-N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)piperidine-4-carboxamide, [94]N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclopropanecarboxamide, [95]N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide, [96]N-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclohexanecarboxamide, [97]N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)acetamide, [98] 3-methoxy-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)propanamide, [99] 1-Methyl-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)piperidine-4-carboxamide, [100]N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclopropanecarboxamide, [101]N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide, [102]N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)cyclohexanecarboxamide, [103] 3-methoxy-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)propanamide, [104] 2-(dimethylamino)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)acetamide, [105] 2-oxo-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)piperidine-4-carboxamide, [106]N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide, [107] (7-(6-((3-methoxypropyl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [108] (7-(6-morpholinopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [109] (7-(6-(isopropylamino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [110] Piperidin-1-yl(7-(6-(piperidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone, [111] (7-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [112]N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)methanesulfonamide, [113] (7-(3-(1H-tetrazol-5-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [114] (7-(4-(1H-tetrazol-5-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [115] 3-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one, [116] 3-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one, [117] 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-1,2,4-oxadiazol-5(4H)-one, [118] (7-(4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [119] (Z)-5-(3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzylidene)thiazolidine-2,4-dione, [120]tert-butyl 4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,6-dihydropyridine-1(2H)-carboxylate, [121] (7-(benzo[d][1,3]dioxol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [122] (7-(benzofuran-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [123] (7-(benzofuran-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [124] (7-(benzo[b]thiophen-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [125] (7-(1H-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [126] (7-(1H-Indol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [127] (7-(benzofuran-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [128] (7-(naphthalen-1-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [129] (7-(naphthalen-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [130] Piperidin-1-yl(7-(quinolin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone, [131] 7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one, [132] 2-Methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one, [133] 2-Isopropyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one, [134] 7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one, [135] 2-Methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one, [136] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one, [137] 2-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one, [138] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one, [139] 2-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoquinolin-1(2H)-one, [140] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [141] 2-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [142] 2-Isopropyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [143] 5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [144] 2-Methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [145] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinolin-2(1H)-one, [146] 4-((3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)amino)benzonitrile, [147] 3-((3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)amino)pyridin-2(1H)-one, [148] piperidin-1-yl(7-((pyrimidin-2-ylmethyl)amino)pyrazolo[1,5-a]pyridin-3-yl)methanone, [149] piperidin-1-yl(7-((2-(pyridin-4-yl)ethyl)amino)pyrazolo[1,5-a]pyridin-3-yl)methanone, [150] (7-((1-methylpiperidin-4-yl)amino)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [151] 1-(7-(quinolin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)pentan-1-one, [152] 4-(3-acetylpyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [153] 4-(3-(2-hydroxypropan-2-yl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [154] 7-(3-(4-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one, [155] 6-(3-(4-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [156] 4-(3-(4-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [157] (4-fluoropiperidin-1-yl)(7-(4-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)methanone, [158] Cyclohexyl(7-phenylpyrazolo[1,5-a]pyridin-3-yl)methanone, [159] 7-(2-Amino-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-3,4-dihydroisoquinolin-1(2H)-one, [160] 7-(2-Amino-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-2-methyl-3,4-dihydroisoquinolin-1(2H)-one, [161] (7-(3-chlorophenyl)-1H-indazol-3-yl)(piperidin-1-yl)methanone, [162] (8-(3-chlorophenyl)imidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone, [163] (8-(4-nitrophenyl)imidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone, [164] (8-(4-aminophenyl)imidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone, [165] (8-(3-chlorophenyl)-6-methylimidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone, [166] (8-(2-chloropyridin-4-yl)-6-methylimidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone, [167] (8-(3-chlorophenyl)-6-fluoroimidazo[1,2-a]pyridin-3-yl)(piperidin-1-yl)methanone, [168] (7-(4-methoxyphenyl)-[1,2,3]triazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [169] (7-(3-chlorophenyl)-1H-indol-3-yl)(piperidin-1-yl)methanone, [170] (6-(3-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [171] (6-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [172] (6-(benzo[d][1,3]dioxol-5-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [173] (5-(benzo[d][1,3]dioxol-5-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [174] (4-(benzo[d][1,3]dioxol-5-yl)-1H-pyrrolo[3,2-c]pyridin-2-yl)(piperidin-1-yl)methanone, [175] (4-(benzo[d][1,3]dioxol-5-yl)-1H-pyrrolo[2,3-c]pyridin-2-yl)(piperidin-1-yl)methanone, [176] (4-(benzo[d][1,3]dioxol-5-yl)pyrrolo[2,1-f][1,2,4]triazin-6-yl)(piperidin-1-yl)methanone, [177] (4-(benzo[d][1,3]dioxol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(piperidin-1-yl)methanone, [178] (5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [179] (5-(4-methoxyphenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [180] (5-(4-chlorophenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [181] (5-(3,4-dimethoxyphenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [182] (5-(4-fluorophenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [183] (5-(furan-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [184] Piperidin-1-yl(5-(pyridin-4-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)methanone, [185] (5-(3-chlorophenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [186] (5-(3-chloro-4-hydroxyphenyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [187] (2-(benzo[d][1,3]dioxol-5-yl)-5H-pyrrolo[3,2-d]pyrimidin-6-yl)(piperidin-1-yl)methanone, [188] (5-(benzofuran-3-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [189] (5-(naphthalen-2-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [190] (5-(1H-indazol-6-yl)-1H-pyrrolo[3,2-b]pyridin-2-yl)(piperidin-1-yl)methanone, [191] 2-(2-(piperidine-1-carbonyl)-1H-pyrrolo[3,2-b]pyridin-5-yl)isoindolin-1-one, [192] (3-fluoroacetidine-1-yl)(5-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)methanone, [193]N-(1-methyl-1H-pyrazol-3-yl)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinamide, [194] (7-((3-methoxyphenyl)thio)(pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [195] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-7,8-dihydro-1,6-naphthyridin-5-(6H)-one, [196] 2-(dimethylamino)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide, [197] 3-methoxy-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)propenamide, [198] 2-oxo-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)piperidine-4-carboxamide, [199] 6-Methyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-7,8-dihydro-1,6-naphthyridin-5-(6H)-one, [200]N-(azetidin-3-yl)-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]nicotinamide, [201]N-Methylsulfonyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide, [202]N-(1-methylazetidin-3-yl)-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide, [203] 4-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carbonyl]piperazin-2-one, [204] 4-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carbonyl]piperazine-2,6-dione, [205] 3-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carbonitrile, [206] (7-(6-(azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [207] 3-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrimidin-4(3H)-one, [208] (7-(6-(3-fluoroazetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [209] (7-(6-(3,3-difluoroazetiin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [210] (7-(6-(3-hydroxyazetiin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [211] 7-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino-3,4-dihydro-2H-isoquinolin-1-one, [212] 6-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]isoindolin-1-one, [213] (3-fluoroazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone, [214] 2-Azaspiro[3,3]heptan-2-yl-[5-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone, [215] (7-(6-(2-azabicyclo[2.2.1]heptan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [216] (7-(6-(2-azabicyclo[2.2.2]octan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [217] (7-(6-(7-azabicyclo[2.2.1]heptan-7-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [218] (7-(6-(3-(dimethylamino)azetidin-1-yl)(pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [219] Methyl 1-(5-(3-(piperidine-1-carbonyl)(pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)azetidine-3-carboxylate, [220] (7-(6-(2-azaspiro[3.3]heptan-2-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [221] (7-(6-(3-(hydroxymethyl)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [222] (7-(6-(7-azaspiro[3.5]nonan-7-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [223] (7-(6-(6-azaspiro[3.4]octan-6-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [224] 7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phthalazin-1-(2H)-one, [225] (6-Hydroxy-2-azaspiro[3.3]heptan-2-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone, [226] 2-Oxa-7-azaspiro[3.5]nonan-7-yl-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone, [227] (2-azabicyclo[2.2.1]heptan-2-yl)(7-phenylpyrazolo[1,5-a]pyridin-3-yl)methanone, [228] (2-azabicyclo[2.2.2]octan-2-yl)(7-phenylpyrazolo[1,5-a]pyridin-3-yl)methanone, [229] (7-azabicyclo[2.2.1]heptan-7-yl)(7-phenylpyrazolo[1,5-a]pyridin-3-yl)methanone, [230] (3-hydroxyiminoazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-3-pyridyl]methanone, [231] 6-(3-(4-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-2-methylisoindolin-1-one, [232] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one, [233] 6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phthalazin-1(2H)-one, [234] 6-(3-(4,4-difluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [235] 4-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]-1H-pyrimidin-6-one, [236] 3-Methyl-6-[[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]amino]pyrimidin-4-one, [237] (3,3-difluoroazetidin-1-yl)-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]methanone, [238] [7-[(4-chlorophenyl)methylamino]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [239] 4-chloro-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzamide, [240] 1,3,5-Trimethyl-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrazolo-4-sulfonamide, [241] 5-Fluoro-N-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-3-carboxamide, [242] [7-[2-(4-chlorophenyl)ethylamino]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [243] 3-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylic acid, [244] Methyl 3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylate, [245] 3-Methyl-6-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinazolin-4(3H)-one, [246] 2-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one, [247] 3-[3-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]2-pyridyl]-4H-1,2,4-oxadiazol-5-one, [248] [7-[6-(azetidine-1-carbonyl)-5-fluoro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [249] [7-[5-fluoro-6-(morpholine-4-carbonyl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [250] 3-Fluoro-N-methyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxamide, [251] 3-Methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)quinazolin-4(3H)-one, [252] 2-Methyl-7-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one, [253] 3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzaldehyde oxime, [254] 2-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzonitrile, [255] 3-Methyl-6-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrido[2,3-d]pyrimidin-4(3H)-one, [256] 3-Methyl-7-3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrido[3,2-d]pyrimidin-4(3H)-one, [257] (7-(2-(3-fluoroazetidin-1-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [258] 3-chloro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxylic acid, [259] [7-(3-amino-1,2-benzoxazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [260] [7-(3-amino-1H-indazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [261] [7-(3-amino-1-methyl-indazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [262] 3-chloro-N-methyl-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyridine-2-carboxamide, [263] [7-[5-fluoro-6-(5-methyl-1,2,4-oxadiazol-3-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [264] (7-(2-chlorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [265] (7-(5-bromo-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [266] (7-(2,6-difluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [267] (7-(2-chloropyrimidin-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [268] 2-Methyl-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzo[d]isoxazol-3(2H)-one, [269] (7-(3-methoxybenzo[d]isoxazol-5-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [270] 2-(dimethylamino)-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)nicotinonitrile, [271] (7-(6-fluoropyridin-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [272] (7-(2-chloro-6-(trifluoromethyl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [273] (7-(2,6-difluoropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [274]N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-2-(pyridin-3-yl)acetamide, [275] 3-[2-fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one, [276] [7-[4-fluoro-3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [277] [7-[2-(azetidine-1-carbonyl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [278]N-(2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-2-(pyridin-3-yl)acetamide, [279] (7-(3-chloro-5-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [280] 5,6-dimethyl-3-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-5,6-dihydro-7H-pyrrolo[3,4-b]pyridin-7-one, [281] (7-(6-chloro-5-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [282] (7-(2,6-dichloropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [283] (7-(5-chloro-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [284] (7-(5-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [285] 3-Fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]benzonitrile, [286] [7-[6-(azetidine-1-carbonyl)-5-chloro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [287]N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)nicotinamide, [288] (7-(5,6-difluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl](piperidin-1-yl)methanone, [289] (7-(5-chloro-6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [290] 2,6-Difluoro-4-(3-(piperidine-1-carbonyl(pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [291] 3-Fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [292] (7-(4-bromophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [293] 5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrimidine-2-carbonitrile, [294] [7-(2-hydroxypyrimidin-5-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [295] 3-[3-fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one, [296] [7-[2-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [297] 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-1,2,4-oxadiazol-5-(4H)-one, [298] (7-(5-chloro-2-fluoropyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [299] 3-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one, [300] [7-[4-(2-methylpyrazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [301]N-(3-chloro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)nicotinamide, [302] [7-[4-(3-furyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone], [303] [7-[3-fluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [304] 3-[2-fluoro-4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-4H-1,2,4-oxadiazol-5-one, [305] 5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]pyrimidine-2-carbonitrile, [306] [7-[4-(2-hydroxypyrimidin-5-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [307] 5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]pyrimidine-2-carboxamide, [308] 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyrimidin-2-yl)oxazolidin-2-one, [309] 7-(3-amino-1H-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [310] [7-(3-amino-1-methyl-indazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [311]N-(3-chloro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide, [312] 3-nitro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)benzonitrile, [313] (7-(6-bromopyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [314] (7-(6-chloropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [315] (7-(6-chloro-2-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [316] 3-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [317] [7-[2-(5-methyl-1,2,4-oxadiazol-3-yl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [318] (7-(5-nitropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [319] (7-(5-(5-methyl-1,2,4-oxadiazol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [320] [7-(3-amino-1,2-benzoxazol-6-yl)pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [321] 3-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]pyrimidin-2-yl]-4H-1,2,4-oxadiazol-5-one, [322] (7-(3-fluoro-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [323] 3-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [324] [7-[4-(3,5-dimethylisoxazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [325] (7-(2-fluoro-5-(1-methyl-1H-pyrazol-5-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [326]N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)nicotinamide, [327]N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(pyridin-3-yl)acetamide, [328] (7-(3,5-difluoro-4-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [329] 3-(3-nitro-5-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one, [330] (7-(3-(5-methyl-1,2,4-oxadiazol-3-yl)-5-nitrophenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [331] 3-(2,6-difluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)-1,2,4-oxadiazol-5(4H)-one, [332] piperidin-1-yl(7-(6-((2-pyridin-3-yl)ethyl)amino)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone, [333] 1,2-Dimethyl-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-1H-imidazole-5-carboxamide, [334]N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)pyrimidine-5-carboxamide, [335] 5-Fluoro-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)nicotinamide, [336] (7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(3-methylpiperidin-1-yl)methanone, [337] (3-ethylpiperidin-1-yl)(7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)methanone, [338] (7-(6-fluoropyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(3-(trifluoromethyl)piperidin-1-yl)methanone, [339] 3-(5-(3-(3-(trifluoromethyl)piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [340]N-(2-nitrobenzyl)-N-(4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)phenyl)nicotinamide, [341] (7-(3-fluoro-5-(1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [342] (7-(3-nitro-5-(1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [343] (7-(3-amino-5-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [344] (7-(6-(4-amino-1H-pyrazol-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [345] (7-(3-(3-hydroxyazetidine-1-yl)-5-(isoxazol-4-yl)phenyl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [346] 1-piperidyl-[7-[4-(1H-pyrazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]methanone, [347] 1-piperidyl-[7-[4-(3-thienyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]methanone, [348] [7-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [349] 5-[4-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]phenyl]-3H-1,3,4-oxadiazol-2-one, [350] [7-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [351] [7-[4-(5-methylthiazol-2-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [352] [7-[4-(1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [353] 3-(5-(3-(3-methylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [354] 3-(5-(3-(3-ethylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [355] (7-(6-(4-nitro-1H-pyrazol-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [356] (7-(2-(4-amino-1H-pyrazol-1-yl)-6-bromopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [357] (7-(2-(3-hydroxyazetidine-1-yl)-6-(1-methyl-1H-pyrazol-5-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [358] [7-[4-(1,2-dimethylimidazol-4-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [359] [7-[4-(5-amino-1,2,4-oxadiazol-3-yl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [360] 5-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-3H-1,3,4-oxadiazol-2-one, [361] 1-piperidyl-[7-[4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenyl]pyrazolo[1,5-a]pyridin-3-yl]methanone, [362]N-(3-fluoro-5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)-2-(pyridin-3-yl)acetamide, [363] (7-(5-bromo-2-(3-(hydroxymethyl)azetidin-1-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [364] [7-[6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [365] 1-Piperidyl-[7-[6-(2-thioxo-3H-1,3,4-oxadiazol-5-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]methanone, [366] (7-(2-(isoxazol-4-yl)-6-morpholinopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [367] 3-(6-(1-methyl-1H-pyrazol-5-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [368] 3-(6-(3,5-dimethylisoxazol-4-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [369] (7-(2-(1-methyl-1H-pyrazol-5-yl)-6-morpholinopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [370] 3-(5'-fluoro-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-[2,3'-bipyridin]-6-yl)oxazolidin-2-one, [371] (7-(2-(3,5-dimethylisoxazol-4-yl)-6-morpholinopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [372] 3-(6-(2-methylpyrimidin-5-yl)-4-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [373] 5-[3-Fluoro-5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-3H-1,3,4-oxadiazol-2-one, [374] (7-(5-(1,2,4-oxadiazol-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [375] (7-(6-(3-(dimethylamino)azetidin-1-yl)-5'-fluoro-[2,3'-bipyridin]-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [376] (7-(5'-fluoro-6-morpholino-[2,3'-bipyridin]-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [377] (7-(2-(2-methylpyrimidin-5-yl)-6-morpholinopyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [378] 6-(3-(3-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [379] [7-[5-fluoro-6-(5-methyl-1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [380] [7-[5-fluoro-6-(1,3,4-oxadiazol-2-yl)-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [381] [7-[6-(3,5-dimethylisoxazol-4-yl)-5-fluoro-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [382] 6-(3-(3,3-difluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [383] 3-(5-(3-(3-fluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [384] 3-(5-(3-(3,3,-difluoropiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)oxazolidin-2-one, [385] (R)-6-(3-(3-methylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [386] (S)-6-(3-(3-methylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [387] 6-(3-(3-methylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [388]N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(6-(trifluoromethyl)pyridin-3-yl)acetamide, [389] 2-Phenyl-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide, [390] 6-(3-(2-azaspiro[3.3]heptane-2-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [391] 6-(3-(6-azaspiro[3.4]octane-6-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [392] 6-(3-(7-azaspiro[3.5]nonane-7-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [393] 6-(3-(3-ethylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [394] [7-[5-fluoro-6-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]-3-pyridyl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [395] (7-(1-((1,2,4-oxadiazol-3-yl)methyl)-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [396] 3-((4-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)-1H-pyrazol-1-yl)methyl)-1,2,4-oxadiazol-5(4H)-one, [397] (7-(2-(1-((1,2,4-oxadiazol-3-yl)methyl)-1H-pyrazol-4-yl)pyridin-4-yl)pyrazolo[1,5-a]pyridin-3-yl)(piperidin-1-yl)methanone, [398] 6-(3-(3-(trifluoromethyl)piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [399] [7-[2-(3,5-dimethylisoxazol-4-yl)pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone, [400] 6-(3-(3-isopropylpiperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [401] 6-(3-(1,2,3,6-tetrahydropyridine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [402] 2-(5-fluoropyridin-3-yl)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide, [403]N-(5-(3-piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)-2-(pyrimidin-5-yl)acetamide, [404] [7-[2-[5-(difluoromethyl)-1-oxo-1,3,4-thiadiazol-2-yl]pyrimidin-5-yl]pyrazolo[1,5-a]pyridin-3-yl]-(1-piperidyl)methanone], [405] 6-(3-(6-azaspiro[3.5]nonane-6-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [406] 2-(4-chlorophenoxy)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-3-yl)acetamide, [407]N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl-2-pyrimidin-5-yl-acetamide, [408]N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]-2-[6-(trifluoromethyl)-3-pyridyl]acetamide, [409] 2-(5-fluoropyridin-3-yl)-N-(5-(3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)pyridin-2-yl)acetamide, [410] 2-(4-chlorophenoxy)-N-[5-[3-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-7-yl]-2-pyridyl]acetamide, [411] 6-(3-(6-fluoro-2-azaspiro[3.3]heptane-2-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, [412] 6-(3-(6,6-difluoro-2-azaspiro[3.3]heptane-2-carbonyl)pyrazolo[1,5-a]pyridin-7-yl)isoindolin-1-one, and [413] 3-Hydro-5-[2-(piperidine-1-carbonyl)pyrazolo[1,5-a]pyridin-6-yl]pyridine-2-carbonitrile.
16. A pharmaceutical composition for preventing or treating a 15-PGDH-related disease, comprising a heterocyclic compound of any one of claims 1 to 15, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
17. In the 16th paragraph, the 15-PGDH related disease is an inflammatory disease (inflammatory bowel disease (ulcerative colitis, Crohn's disease), chronic obstructive pulmonary disease (COPD), Behcet's disease, acute liver injury, acute kidney injury, acute lung injury, sepsis, worsening of asthma and lung disease, peptic ulcer (ulcer caused by NSAIDs), vasculitis syndrome, non-alcoholic fatty liver disease (NASH), atopic dermatitis, psoriasis, interstitial cystitis, prostatitis syndrome), fibrosis (pulmonary fibrosis (idiopathic pulmonary fibrosis), renal fibrosis (glomerulosclerosis), cardiac fibrosis (myocardial fibrosis), oral fibrosis, triangular fibrosis, liver fibrosis, myelofibrosis, scleroderma), autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, autoimmune hepatitis, severe combined immunodeficiency syndrome (SCID)), ophthalmic disease (dry eye, Conjunctivitis, keratitis), thrombocytopenia (drug-induced thrombocytopenia, autoimmune thrombocytopenia, idiopathic thrombocytopenia, thrombocytopenia due to viral infection), myopathy (muscular dystrophy, muscle damage, muscular dystrophy), anemia (aplastic anemia, anemia of chronic disease, Fanconi anemia, beta-thalassemia or anemia of unknown cause), circulatory disease (cardiac disease (angina pectoris, heart failure, myocardial infarction), kidney disease (chronic kidney disease, renal failure), stroke, pulmonary hypertension, peripheral circulatory disorder), nerve cell death (psychiatric disorders, neurodegenerative diseases, nerve injuries), cytopenia (immune cytopenia, neutropenia, lymphopenia), osteoporosis, fracture, leukemia (acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML)), lymphoma (Hodgkin's lymphoma, non-Hodgkin's lymphoma), radiation exposure toxicity, 15-PGDH expressing cancer, multiple myeloma, paroxysmal nocturnal hemoglobinuria (PNH), pure red cell aplasia, megakaryocytosis, Wiskott-Aldrich syndrome, sickle cell disease, Hurler syndrome, adrenoleukodystrophy, metachromatic leukodystrophy, myelodysplasia, Duchenne muscular dystrophy, solid tumors, chronic granulomatous disease, systemic sclerosis, scars, wounds, otologic diseases (vertigo, tinnitus, balance disorders), hair loss, skin aging, periodontal disease, diabetes,A pharmaceutical composition characterized by at least one selected from the group consisting of stem cell and bone marrow transplantation or organ transplantation, cervical ripening, Alzheimer's disease, and Parkinson's disease.
18. A pharmaceutical composition comprising a heterocyclic compound according to any one of claims 1 to 15, a hydrate thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive.
